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Abstract.
Anti-neuronal antibodies have been conclusively shown to be pathogenic in a handful of 
neurological disorders but their value in diagnosis is undeniable Nevertheless, there are 
instances where diseases thought have an immunological component do not have clear 
antibody responses associated with them
This thesis aimed to identify anti-neuronal antibodies and characterise their antigens in 
paraneoplastic and .post-infectious neurological disorders With regard to the latter, 
interest in the occurrence o f anti-neuronal responses in post-streptococcal neurological 
disorders has culminated in the identification of four candidate auto-antigens 
Recombinant forms o f these proteins were produced and the frequency’ of an antibody 
response in patients determined. In addition, the antigen recognised by antibodies in the 
serum of patients with post-infectious opsoclonus-myoclonus was characterised using 
protein purification techniques and the frequency of an antibody response determined. 
Finally, a bacteriophage expression libraiy was employed to study a novel antibody in a 
patient w ith paraneoplastic disease.
Our findings were unable to provide support for an antibody response against the 
candidate auto-antigens in post-streptococcal disease. However we were able to 
characterise two target antigens, one in post-streptococcal opsoclonus-myoclonus and 
one in paraneoplastic neurological disease. Both antigens are thought to have specific 
roles in the nervous system and have provided interesting opportunities for further 
research into there roles in neuronal, and in the case of paraneoplastic disease, tumour 
biology . Further investigation is required to determine the importance of the antibody 
response in both post-infectious and paraneoplastic disease.
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I Chapter I: Introduction.
1.1 Paraneoplastic Syndromes.
The paraneoplastic SNTidromes are a group of pathological conditions that are associated 
with the presence of an underlying malignancy but that are not a result of either local 
infiltration or metastatic spread of the cancer Paraneoplastic syndromes are estimated to 
occur in 5% of cancer patients, but their incidaice v aries depaiding upon the tumour 
tvpe. stage and diagnostic criteria (Smith and de Boer, 2002).
Paraneoplastic svmdromes are of importance because they provide an insight into 
disease activitv and prognosis and their treatment may improv e the qualitv o f life of the 
patient. In addition they are of diagnostic importance because they are commonly the 
presenting feature of an underlving malignancy. Importantly, research into the 
pathological mechanisms of paraneoplastic svndromes may improve our understanding 
o f tumour biologv and point towards rational strategies for therap^tic interv ention.
To be classified as a paraneoplastic svmdrome four criteria have been proposed (Smith 
and de Boer, 2002);
I : There must be a direct association between the syndrome and the presence of 
a tumour
2: An agent i.e. a hormone or antibody should be detectable in the tumour, 
circulation and affected organ.
3: Treatment o f the tumour should result in a reduction of the lev els o f the agent. 
4: The tumour cells should produce the agent in vivo.
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The final criterion may not be applicable to all paraneoplastic syndromes. For example, 
when the agent is an antibody produced as a result of the immune response to malignant 
tissue the agent itself is not produced by the tumour.
1.1.1 Pathological Mechanisms.
In many instances the causes of paraneoplastic syndromes are not fully understood and 
\ar> according to the t>pe of tumour. However two broad pathological mechanisms 
ha\ e been proposed.
The first mechanism is the inappropriate secretion o f hormones or other biologically 
active molecules from the normal source ( eutopic secretion) or the tumour tissue 
('ectopic' secretion). Paraneoplastic syndromes resulting from inappropriate secretion 
include Cushing's sxndrome and h\percalcaemia of malignancy.
The second pathological mechanism is proposed to be an auto-immune mechanism in 
wiiich effector cells or antibodies directed against malignant cells cross-react with 
healthy tissue. This mechanism is thought to account for some paraneoplastic diseases 
affecting the nervous, haematological. musculoskeletal and renal systems.
1.1.2 Classification o f  Paraneoplastic Disease by System.
Paraneoplastic syndromes can be classified according to the target tissue. Systemic 
effects o f malignant disease include fever, fatigue and cachexia and have been reported 
to occur in as many as 80 % of patients with cancer (Albrecht and Canada, 1996: 
Vogelzang et al. 1997). A list of target tissues and paraneoplastic svndromes is given in 
Table 1-1. A more detailed table of the w ell-defined paraneoplastic disorders o f the
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nervous system is provided in Table 1-2
Table 1-1: Paraneoplastic Diseases in Human Classified by System.
Syatem Tmrget Tissue PuraueopUutic Syndrome
Systemic Systemic Fever
Cachexia
Fatigue
Connccti\-e tissue SLE
Sjogren's syndrome 
Scleroderma
Articular Arthritis
Haematological Red cells Aneamia of chronic disease 
Haemolytic anaemia 
Red cell aplasia
White cells Neutrophilia' 
Neutropenia^ 
Eosinophil ia
Platelets Thrombocytosi s '
Thr ombocytopeni * 
Thromboembolic disease
Rena! Glomerular disorders Membranous nephropathy
Tubular disorders Tubular nephropathy
Skin Melanocytes Acanthosis nigricans 
Sweet's syndrome
Dermis Bullous pemphigoid 
Dermatitis herpetiformis 
Dermatomyositis'
Neutrophilia/ ihrombocNtosis may result from growth factor secretion from malignant tissue 
Neutropenia/ thrombocytopenia may occur following activation of an autoimmune mechanism. 
Dermatom\ocMosis also affects muscle tissue.
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Table 1-2: Paraneoplastic neurological diseases, associated symptoms and
tumours.
PSD Symptomis JHemn Age o f  
Onset
Male:
Female
Tumour AssodatioH
PEM SSN SSN. LE, PCD. brainstem 
dusfunction
60 3:1 SCLC
PCD
.Anti-Yo Nystagmus occular disturbance. 54-61 Ovarian, breast, uterus
HD .Aya.xia, Dysarthria 44 6:1 HD
LE Subacute amnesic syndrome, affccth’e 
disorders, seizures, hallucinations, 
paranoid delusions.
55 1.2:1 Testicular tumours
OM
Adult Chaotic eye movements, myoclonus. 66 6:1 Breast and SCLC (Adult)
Pcdi^ric atxxia. 6-36 months Neuroblastoma (Pediatric)
LEMS Limb weakness, ptosis, autonomic 
disturbance.
62 4.3:1 SCLC
PEM: paraneoplastic encephalomyelitis, SSN: subacute sensor> neuronopathy, LEMS: Lambert Eaton 
myasthenic sxudrome, OM: opsoclonus/ myoclonus, LE: limbic encephalitis, PCD: paraneoplastic 
cerebeller degeneration, HD: Hodgkin s disease, SCLC: Small cell lung cancer.
1.2 Paraneoplastic Neurological Disorders.
Paraneoplastic neurological disorders (PND) encompass a wide range of disorders 
affecting any part o f the central or peripheral ner\ous system. The widely referenced 
work o f Henson and Urich (1982) describes a number of clinico-pathological entities 
associated with tumours. These include aicephalomyelitis, cortical cerebellar 
degeneration, penpheral neuropathy, muscular and neuromuscular disorders, and a 
miscellaneous group including opsoclonus-myoclonus and optic neuntis Today a 
greater number o f neurological diseases are thought to be paraneoplastic.
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The frequency with which PND occurs is largely dependent on the methods employed 
in the detection of a neurological deficit and the definition of the disease. Elrington et al 
(1991) conducted a systematic examination o f 150 patients with small cell lung cancer 
(SCLC) and found evidoice o f autonomic dysfunction in 44 % of patients while Lipton 
et al found deficits in peripheral nerve function in 43% of patiaits using quantitative 
thermal threshold testing (Lipton et al. 1987). Proximal weakness with one or more 
diminished deep tendon reflexes has been reported in association with lung cancer in 16 
% of patients (Croft and Wilkinson, 1965).
In many cases muscle weakness and peripheral neuropathy could be secondary to the 
weight loss and nutritional disturbances frequaitly experienced by cancer patients 
(Haw ley et al. 1980). As a result it is unclear w hat percentage of these disorders are 
truly paraneoplastic.
With the exceptions of Lambert-Eaton myasthenic syndrome (LEMS), which affects 3 
% o f patients with SCLC (Elrington et al. 1991) and my asthenia gravis (MG), which 
affects 15 % o f patients with thymoma (Levy et al. 1998), distinct PND rather than mild 
generalised peripheral and autonomic neuropathy are rare. Reports on the estimated 
incidence vary. For example, paraneoplastic cerebellar degeneration (PCD) has a 
reported incidence ranging from 0.6 % (Croft & Wilkinson, 1965) to 26 % of patiaits 
(Wessel & Smith, 1988). These figures are derived from studies involving patients with 
clearly defined tumours. More reçoit reports suggest that the occurrence of clinically 
significant PND in patients with any cancer is approximately 0.01 % (Darnell and 
Posner, 2003).
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In his book, Posner (1995) described some common characteristics shared by PND:
1 : In many cases the onset of the neurological disorder is sub-acute.
2: The neurological disease precedes the identification of the underlying
tumour
3: When a tumour is discovered it is frequently small, non-metastatic and
indolently growing.
The potaitial reasons for these findings will be discussed What follows is an 
introduction to specific PNDs, the common underlying tumours and, where appropriate 
the association with anti-neuronal antibodies
1.2.1 Paraneoplastic Encephalomyelitis Sub -acute Sensory Neuronopathy.
Henson originally described ‘encephalomyelitis with carcinoma' in patients with 
clinical signs o f dysfunction of the nervous system who at autopsy had inflammatory 
involvement of the brain, brainstem, spinal cord, and dorsal root ganglia (DRG) 
(Henson et ah 1965). Today the term aicephalomyelitis with carcinoma' has beai 
replaced by paraneoplastic encephalomyelitis/ sub-acute sensory neuronopathy 
(PEM/SSN). This definition is used to encompass a number of discrete clinical entities 
such as paraneoplastic cerebellar degeneration, limbic encephalitis, brainstem 
dysfunction and autonomic neuropathy
SCLC is the commonest tumour associated with PEM occurring in 74-83 % of patients
(Dalmau et a i  1992: Graus et a i  2001). The disease is rare affecting less than 1 % of
patients with SCLC (Elrington et a i  1991; Henson & Urich H 1982). Its incidence
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peaks around 60 years of age reflecting the epidemiology o f the underlying malignancy. 
In most cases the onset of neurological disease will prompt the search for an underlying
cancer
The commonest presenting feature of PEM/SSN is SSN, which is also the predominant 
neurological symptom during the course of the disease (Dalmau et aL 1992: Chalk et al, 
1992). Graus described sensory neuropathy as the m ^or neurological feature in 200 
patients with PEM (Graus et al, 2001). Early symptoms include a patchy numbness 
often involving the face, trunk or proximal limbs, which progresses to involve all limbs, 
dysesthesia and severe aching or lancinating pain.
Despite the predominance of a single syndrome, the clinical picture commonly evolves 
as inflammation spreads to involve different areas o f the nervous system. In the series of 
71 patients studied by Dalmau et al only 27 % had uni-focal involvement o f the nervous 
sy stem throughout the course of the disease (20% sensory syndrome, 1% brainstem 
dysfunction, 6% limbic encephalitis) (Dalmau et al, 1992).
Microscopic examination of the nervous system o f patients with PEM demonstrates
neuronal degeneration and gliosis in multiple areas o f the nerv ous system The neuronal
degeneration is frequently accompanied by a perivascular and parenchymal
inflammatory infiltrate composed mainly o f mononuclear cells (Scaravilli et al, 1999).
Immunohistochemical analysis has shown that the parenchymal infiltrates are composed
largely o f CDS positive T cells (Jean et al, 1994: Graus et al, 1990). Aggregation of B
cells has not been positively demonstrated, but direct immuno-fluorescence to detect
immunoglobulin has found ev idence o f IgG deposition in areas of inflammation. The
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inflammatory infiltrate in the perivascular space is composed of B cells, macrophages 
and CD4 but not CDS T cells.
The inflammatory infiltrates found within the DRG are different. They are composed of 
both CD4 and CDS T cells, with B cells found in the stroma and surrounding the DRG 
neurones. Proliferation o f satellite cells results in the formation of Nageotte nodules, 
wtiich later predominate as the inflammation subsides (Wanschitz et al, 1997). IgG 
deposition is also found in the neurones o f the DRG particularly at the peripheries close 
to satellite cells, but also showing staining of the nucleus and cytoplasm (Graus et al, 
1990).
The prognosis o f patients with PEM is poor, the median survival time being 11.8 
months (Graus et al, 2001). Studies of tumours from affected patients have highlighted 
the limited spread o f the underlying malignant disease impKing that the death is most 
commonly a result o f neurological complications such as respiratory failure or 
autonomic dysfunction leading to cardiac arrest.
1.2.2 Paraneoplastic Cerebellar Degeneration.
The occurrence o f PCD, presaiting as ocular disturbance, ataxia and dysarthria, and its 
association with malignant disease was first recognised in 1951. The condition is rare 
affecting less than 1 % of patients with cancer (Croft & Wilkinson, 1965) but has been 
reported in association with a range of tumours. The most common of these are SCLC. 
gynaecological cancers and Hodgkin's disease (HD). These malignancies underlie 90 % 
o f cases.
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PCD can occur as a as part of PEM. Neuronal loss and gliosis may be found in all areas 
o f the cerebellar tissue and is often accompanied by patchy inflammatory change in 
other areas o f the nervous system. However PCD also stands as an individual syndrome 
distinct from PEM with different pathological changes. Macroscopic examination of the 
nervous system of patients w ith non-PEM PCD may reveal a diffuse cerebellar atrophy 
(Scaravilli et aL 1999). however the most striking change is found on microscopic 
examination o f the cerebellum which reveals complete loss o f Purkinje cells (Posner, 
1995: Verschuuren et aL 1996). Mild inflammatory change has been shown to 
accompany Purkinje cell loss in a few cases, but is thought to represent the active 
process o f Purkinje cell damage which regresses once the Purkinje cells have been 
destroyed. In addition non-PEM PCD shows sparing of the deep cerebellar nuclei 
(Henson & Urich, 1982). The pathological picture described above is consistent 
betw een tw o subtypes of non-PEM PCD ie PCD associated with anti-Yo antibodies and 
PCD associated with HD.
1.2.2.1 PCD associated with anti-Yo antibodies.
PCD can be subclassified according to the detection of anti-Yo antibodies in the patients 
serum (See section 1.4.2). Anti-Yo positive patients are predominantly female aged 
between 54 and 61 years with an underlying cancer o f the breast, ovarian or other 
gynaecological tissue (Peterson et aL 1992). The onset of the cerebellar symptoms is 
acute or sub-acute, with truncal and gait ataxia appearing over a course of day’s to weeks 
(Anderson et aL 1988) and preceding the diagnosis of the underlying tumour in 61-77 % 
o f patients The neurological deficit progresses over the following weeks before 
stabilising, often leaving the patient with severe disability
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Despite the lasting neurological deficit, progression of the underlying cancer is the 
commonest cause of death in these patients (Rojas et al, 2000). Although the primary 
tumours are usually smaller in patients suffering from PCD compared to neurologically 
intact cancer controls the tumours have generally infiltrated local lymph nodes or 
extended to involve adjacent tissues at the time of presentation Such metastasis or local 
invasion drastically decreases the possibility of tumour control (Hetzel et al, 1990). In 
addition there is a striking difference between the median survival time of patients with 
PCD associated with breast and gynaecological tumours being 100 and 22 months for 
each tumour respectively (Rojas et ah 2000).
Although the development of anti-Yo PCD is almost exclusively restricted to women, 
male cases do occuf To date there have been four reported cases of men with anti-Yo 
PCD who after investigation were found to have malignant disease. Adenocarcinomas 
o f the parotid gland, oesophagus and stomach were identified in three patients after the 
onset o f  neurological disease prompted intensive investigation. In a fourth, 
adenocarcinoma in a single lymph node was identified but the primary tumour eluded 
detection (Barnett et al, 2001: Krakauer et al, 1996: Meglic et al, 2001: Felician et al, 
1995)
1.2.2.2 Paraneoplastic Cerebellar Degeneration and Hodgkin 's Disease.
Although cases of PCD associated w ith HD are rare they can be considered to represent 
a second useful sub-classification. The pathological picture in these cases is identical to 
that described in the anti-Yo positive patients However, the study by Hammack et al 
( 1992) o f the largest cohort of HD associated PCD has highlighted some differences
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between this group and the anti-Yo positive patients. PCD associated with HD was 
found to occur more frequaitly in men and affected patients o f a younger age than those 
with anti-Yo positive PCD. In addition, the diagnosis of IvTnphoma preceded the onset 
o f PCD in 80 % of patients. The differences betweai HD and anti-Yo associated PCD 
are most probably a consequoice of the differences in the underlying malignancies, with 
the sex and age bias reflecting the demographics of the tumour. The diagnosis of the 
underlying malignancy in advance of the onset of PCD is likely to be a result of the 
overt nature o f HD. Stabilisation and even recovery from HD associated PCD has been 
reported.
1.2.3 Paraneoplastic Limbic encephalitis.
Just as PCD can be a manifestation of the multi-focal inflammatory changes of PEM or 
the result o f distinct pathological changes, so too can paraneoplastic limbic encephalitis 
(PLE). PLE affects both men and women equally most commonly in the fifth decade of 
life, but has been reported in patients ranging from 11 to 75 years of agen (Gultekin et 
al. 2000). A number of tumour associations have been described (Dropcho. 1998) the 
most common being SCLC (50%). testicular (20%) and breast (8%) cancers (Gultekin, 
et al. 2000). The nature of these tumours accounts for the wide range in the ages o f 
people affected. PLE commonly presents prior to the identification of the underlying 
malignancy with a sub-acute amnesic syndrome, an affective disorders composed of 
dqjression. anxiety and personality changes, seizures hallucinations or paranoid 
delusions
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Neuropathological changes typical of those described in PEM are found most 
consistently in the amygdala and hippocampus while involvement of other areas such as 
the cingulate gyrus or insular cortex may occur
In the cohort studied by Gultekin et al (2000) PLE was associated with a poor 
neurological outcome particularly if the disease was associated with anti-Hu or anti- 
M ai antibodies (see sections 1.4.land 1.4.3). It was also observed that while 
improvement in the neurological symptoms was uncommon the chances o f it occurring 
w ere increased b\ the use of therapies directed against the underlying tumour.
1.2.4 Paraneoplastic Movement Disorders.
Paraneoplastic chorea is rare but has beai documented in association with SCLC (Albin 
et aL 1988), Hodgkin's (Batchelor et aL 1998) and non-Hodgkin's lymphoma (Nuti et 
aL 2000) among others.
One o f the best-described paraneoplastic movement disorders is opsoclonus-myoclonus 
(OM). This disorder is characterised by involuntaiy saccades o f the e\ es in all directions 
usually associated with myoclonus affecting the trunk, limbs and head. The disorder can 
be conveniently subdivided into adult and paediatric OM.
Adult OM may be the presenting feature of an occult malignancy (paraneoplastic 
opsoclonus-myoclonus, POM), usually SCLC, but may also occur in the absence of 
identified malignancy or following infection (post-infectious OM (PIOM), see section 
111)  (Verma anf Brozman, 2002: Imtiaz and Vora, 1999). One review of 58 patiaits 
with OM suggested that only II (19 %) were paraneoplastic (Digre, 1986).
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In another series of 14 patients with clearly defined POM the mean age of onset was 66 
years (range 53-75) with a striking male predominance (M: F, 6:1). As with other PND 
the onset o f neurological disease frequently presents prior to the discovery of the 
underlying tumour (Dataller et al, 2001). The prognosis for paraneoplastic OM is poor. 
7/11 o f the cases reviewed by Digre (1986) died shortly after the onset of the 
neurological disease with the longest survival being 8 months. In the remainder the 
svTidrome stabilised but never completely resolved. In most cases death was thought to 
be caused by the progression of the underlying tumour.
Paediatric POM commonly occurs between 6 and 36 months with females affected more 
frequently than males (Sakai et a i  1990). The disease is associated with an underlying 
neuroblastoma in 50 % of cases (Caviness et al, 1995), however since neuroblastoma 
has a tendency for spontaneous regression the frequency o f paediatric POM can not be 
determined. As with adult OM some case are thought to be post-infectious in nature. In 
common with other PND, the neurological syndrome frequently precedes the detection 
o f the underlying malignancy, which is often limited to the thoracic cavity. The 
neurological smdrome may show improvement with the initiation of 
immunomodulator) and surgical intervention but as many as 63 % of patients will be 
left with significant neurological deficit (Rudnick et a i  2001).
Pathological investigations of the nervous system in OM are interesting due to the
conflicting nature of the reports. CT and MRl scans are frequently normal and are
consistent w ith the lack of pathological change detected within the nervous system It
was once thought that the omnipause neurones were disrupted in OM, but pathological
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specimens often show no change, while animal models with lesions to the omnipause 
neurons do not have OM (Posner, 1995a). Distinct areas o f inflammation are oftm not 
present but when they do occur the areas of the nervous system involved vary. A few 
reports suggest changes affecting the Purkinje cells similar to those observed in cases of 
PCD however this is not a consistent finding.
Well-defined anti-neuronal antibodies including anti-Hu (Hersh et al, 1994) and anti-Ri 
(Prestigiacomo et al, 2001) have beai associated with adult OM. More recent reports 
suggest a heterogeneous immune response occurs in which antibodies are directed 
against various antigens within the nervous system (Dataller etaL  2003).
Similarly anti-Hu antibodies have been detected in 16 % of patiaits with paediatric 
POM (Antunes et aL 2000) but are by no means the rule. Pranzatelli et al (2002) found 
no evidoice o f anti-Hu. Yo or Ri activity in 18 (jiildrm with paraneoplastic POM. 
Connolly et al (1997) found anti-neuronal antibodies in nine patients with POM and 
described binding to the 210 kDa subunit o f neurofilament among other antigens. 
Plioplys et al (1989) described cerd)ellar specific reactivity with 27. 35 and 62 kDa 
antigens. It is clear that a specific serological marker of adult or paediatric POM has not 
been described.
Reports regarding the benefit of immunomodulatory therapies to treat adult POM are
inconsistent. Protein A column therapy has been reported to be beneficial in one case
(Nitschke and Dropcho. 1995). In Datallers report 4/10 patients with breast cancer who
did not receive surgical intervention died in spite o f immunomodulatory therapies
(plasmapherisis. IVIG, steroids). However such intervention may have the effect of
dampemng anti-tumour immunity The lack of consistent pathological findings
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indicating an immune mediated process and the lack of consistent detection of anti- 
neuronal antibodies means that there is no clear cause for this disorder.
1.2.5 Lambert Eaton Myesthenic Syndrome.
Lambert Eaton Myesthenic Syndrome is the most frequently occurring paraneoplastic 
neurological syndrome affecting 2-3 % patients with SCLC (Elrington et aL 1991) and 
is one o f the few PND in which the associated antibodies have beoi proven to have 
pathological effect (see below). 60 % of patients who present with the syndrome are 
found to have an underlying malignancy on investigation which is almost always SCLC 
(O'Neill et aL 1988). The syndrome is characterised by proximal lower limb weakness, 
depression of deep, tendon reflexes (which may be augmented following sustained 
contraction), autonomic disturbance (dry mouth, impotence, constipation) and ptosis.
Neuro transmission at the neuromuscular junction requires an influx o f Calcium ions 
into the pre-synaptic neurone th ro u ^  voltage gated calcium diannels (VGCC). The 
clinical picture described in LEMS is a consequaice o f impaired calcium flux due to the 
presence o f anti-VGCC antibodies. It is though that in paraneoplastic LEMS the 
stimulus for this antibody production is the expression o f VGCC on the surface of 
SCLC cells
LEMS is debilitating but rarely fatal. In contrast to PND affecting the central nervous 
system (CNS), LEMS is responsive to treatment. Plasmapheresis or immunosuppression 
to lower the titre o f circulating antibodies, mobilisation of calcium using guanidine 
hydrochloride or targeting potassium channels may be beneficial. In some cases
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removal of the underlying tumour may reduce symptoms presumably because the 
antigenic stimulus for antibody production has beai removed.
13  Antibodies and the Inunune Response to Malignant Disease.
In humans the natural history of malignant disease represents a balance between an 
effective anti-tumour immune response and its evasion by tumour tissue. Evidence for 
this immune response is provided by the histological examination of tumours which 
commonly allows the identification o f infiltrating lymphocytes, macrophages and NK 
cells. In addition tumour specific cytotoxic lymphocytes can be isolated from the 
peripheral blood of patients with various types o f cancer.
The evidence for the role o f B cell activity in the anti-tumour immune response is less 
compelling than that reported for the cellular response. In fact in some cases the 
occurrence o f an active antibody response to the tumour may be associated with a poor 
prognosis indicating a failure of the immune system to control the malignant disease 
(Taylor and Gercel-Tayior, 1998).
Since tumours represent a heterogeneous population of cells it is not surprising that 
pah a its  display a variety of responses against various tumour anhgens. Probing cellular 
homogenates of cancer cell lines with antibodies from pahents' sera reveals the 
diversity o f the immune response. Using this approach Bazhin et al (Bazhin et al. 2003) 
demonstrated that a variety of antigens w ere commonly recognised by antibodies in the 
sera o f pahents with SCLC.
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One method employed to asses B cell responses to malignancy is that of the SEREX 
technique (serological identification of antigens by recombinant expression cloning). 
This approadi, which involves the construction of cDNA libraries from tumour tissue, 
has lead to the identification of a multitude of tumour-associated antigens (Krebs et al, 
2003. While B cell responses occur, care must be taken to distinguish those responses 
that are a direct result o f anti-tumour immunity and those that are part of the normal’ 
antibody response to self antigens (Avrameas and Temynck, 1995).
While the antibody response to tumour antigens is diverse, certain responses are 
common and may provide a means to define clinical phenotypes, diagnose underlying 
disease and act as prognostic indicators. For example anti-p53 antibodies are detected 
with a frequency of 9 % in patients with breast cancer (Crawford et aL 1982), and 2 % 
o f patients with cancer of the prostate (Brandt-Rauf, 1997).
As has been alluded to, some anti-tumour responses result in the production of 
antibodies which cross-react with tumour and neuronal tissue Applying the SEREX 
technique to the screening of libraries constructed from neuronal tissue allows a way to 
track back from the neuronal tissue to allow the idmtification of potentially interesting 
antigens expressed by tumour tissue Such an approach reduces the numbo" of 
antibodies with the potential to react with antigens in the library since anti-neuronal 
responses are rare
1.4 Anti-Neuronal Antibodies.
Since Wilkinson and Zeromski first documented the existence of ‘antibodies against
neurones in sensory carcinomatous neuropathy' in 1965 (Wilkinson and Zeromski) a
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number of anti-neuronal antibodies have been identified and shown to occur in the 
serum and cerebrospinal fluid (CSF) of patimts affected by PND (Table 1-3). The role 
o f these antibodies in the pathogenesis o f PND has been proven in only a few diseases, 
wiiile in others their .pathological significance remains a matter of debate.
Despite this, the association between antibody, PND and underlying tumour provides a 
useful diagnostic tool. Once anti-neuronal antibodies have been detected the search for 
an underlying tumour can be concentrated into a few defined areas.
Characterisation of the target antigen by ^plication of the SEREX technique has in 
some cases identified previously unrecognised proteins, allowing speculation into their 
roles in normal tissue while providing valuable insights into tumour biology and anti­
tumour immunity An introduction to the common anti-neuronal antibodies is presented 
in Table 1-3.
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Table 1-3: Well-described anti-neuronal antibodies found in assoication with PND.
Antibody Associated PND ItmmMHohistockemiOry ImutumoUotting Antigen and Junction
Hu PEM SSN Neuronal nuclei. 38-40 kDa band Hu: Neuron specific RNA or DNA
Nucleolus spared. binding protein. Role in RNA
processing in neurones.
Yo PCD Purkinje cell cytoplasm 34 and 62 kD band from CDR34 and CDR62: Involved in
and axons. Coarse extracts of breast and ovary DNA binding and gene transcription.
granular staining. tumours.
M ai CD B D  MW subnuclear elements of 37 and 40 kDa Unknown function
neurones
Ma2 LE Nucleus, perkarion 40 kD Unknown functicm
Ri Œ 1 All nuclei of CNS 55 kDa Ri: RNA binding protein.
CV2 CD SMK Cytoplasm of 66 kDa LILIP/ CRMP: Uncertain
UN-eitis ol igodendroc ytes
VGCC LEMS Presynaptic Not detectable VGCC : ACh release
Tr PCD Purkinje ceil cytoplasm. Negative inununblot Not known
molecular layer
CD; ccr^>ellar dysfunctioa. BD: brainstem dysfimction. NfW: motor weakness, SNIN: Sensorimotor neuropathy. PEM: 
paraneoplastic encephalomyelitis. SSN: subacute sensory neuronopathy, LEMS: Lambert Eaton myasthenic syndrome. LE: limbic 
encephalitis. PCD: paraneoplastic cerebeller degeneration
1.4.1 Anti-Hu Antibodies.
The antibodies first described by Wilkinson and Zeromski were probably the same as 
those idmtified in four patients with both SSN and SCLC by Graus et al (Graus et aL 
1986). Using a combination of immunohistochemistry and immunoblotting techniques 
this antibody has been well characterised, and designated anti-Hu after the patient in 
which the antibodv was first described
Immunohistochemical staining of neuronal tissue with anti-Hu positive sera produces
strong staining o f all CNS and peripheral nervous system (PNS) neuronal nuclei with a
striking sparing of the nucleolus, and a faint granular staining of the cytoplasm.
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Incubation of sera containing anti-Hu antibodies with systemic tissue does not produce a 
reaction Immunoblotting of nuclear or crude neuronal extracts reveals the antibody 
reacts with series of proteins between 35 to 40 kDa. By eluting reactive antibodies from 
this region of the immunoblot Graus et al (Graus et al, 1986) were able to show that this 
anti-neuronal antibody cross-reacted with the patient’s tumour
The anti-Hu antibody is a highly specific marker of PEM/ SSN. Molinuevo quoted a 
specificitv’ and sensitivity o f 99 % and 82 % respectively for the anit-Hu antibody as a 
marker of SSN (Molinuevo et al, 1998). In addition the anti-Hu antibody is a useful 
marker o f underlying malignancy. Approximately 78 % of patients with paraneoplastic 
disease and demonstrable anti-Hu antibodies have SCLC as the underlying tumour 
(Molinuevo et al, 1998: Dalmau et al, 1992). Only rarely is a tumour not found (Dalmau 
et al, 1992). Initially it was th o u ^ t that the anti-Hu antibody did not occur in 
neurologically normal SCLC patients (Anderson et al, 1988). It has since been shown 
that anti-Hu antibodies can be detected in 16-25.5 % of neurologically intact patients 
with SCLC, although at a lower titre than in those patients with PEM/SSN (Dalmau et 
al, 1990: Monstad et al, 2004).
To date there are few reports o f false positive' patients. In these cases it is thought that 
a tumour was present, but small and easily missed at autopsy. In addition Sjogren's 
syndrome may be complicated by a sub-acute sensory neuropathy clinically 
indistinguishable from paraneoplastic SSN with antibodies against a 38 to 40 kDa 
protein from neuronal tissue (Sillevis-Smitt et al, 1996: Moll et al. 1994). These false 
positives can be avoided either by routinely testing for anti-neuronal antibodies by both
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histochemical and immunoblotting methods or by screening patients against 
recombinant antigen.
Cloning o f the Hu antigen was achieved by Szabo et ai m 1991. Using anti-Hu sera this 
group successfully screened a cerebellar Lambda ZAP cDNA expression library to 
identify two different but related genes that were subsequently designated HuD and 
HuC. These genes encode members o f a highly conserved family of RNA binding 
proteins which has been expanded to include Hel-N 1 and HuR (Nabors et al, 1998). The 
proteins are homologous to the embryonic lethal abnormal vision (ELAV) protein of 
Drosophilia, a protein required for the development and maintenance of the fly nervous 
system however its precise role in the human nerv ous system or tumour tissue remains 
unknown.
1.4.2 Anti-Yo Antibodies.
As described previously (see section 1.2.2.1). a subgroup of patients with PCD has been 
found to have anti-neuronal antibodies in their sera. Greenlee and Brashear (1983) and 
later Jaeckle et al (1985) described the presence of an antibody directed against the 
cvloplasm of Purkinje cells in patients with ovarian cancer. The anti-Purkinje cell 
antibodies stain the cvloplasm and proximal dendrites of the Purkinje cell layer with 
faint staining of the neurones of the molecular and granular layers, but do not stain 
neurones from other areas of the nervous sv stem Immunoblots of Purkinje cell extracts 
reveals that anti-Yo sera reacts consistently with a two antigens with a molecular weight 
o f 34 kDa and 62 kDa.
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Anti-Yo PCD sera has been used to clone DNA encoding the cerebellar degeneration 
related (Cdr) proteins. Cdrl the gene that encodes the 34 kDa protein has beai cloned 
(Dropcho et al, 1987) and mapped to the long arm of the X chromosome (Chen et al, 
1990). The predicted amino acid sequence of this protein reveals an unusual structure 
composed of hex^eptide rqjeats making up 91 % of the total protein. As yet the 
function o f this protein is unknown. Using cDNA expression libraries the 62 kDa 
antigen (subsequently designated cdr2) was cloned simultaneously by Sakai (Sakai et al, 
1990) and Fathallah-Shaykh (1991) and mapped to chromosome 16. The encoded 
protein was shown to contain a leucine zipper and zinc finger motif and is speculated to 
play a role in gene expression. Corradi et al (1997) demonstrated that cdr2 mRNA is 
widely expressed in multiple systemic tissues, but its expression, regulated by a post- 
transcriptional mechanism, is restricted solely to the testis and the brain, both classically 
regarded as immunoprivileged sites.
Early reports suggested that cdr2 w as only expressed by the tumours of those patients 
with anti-Yo associated PCD (Fumeaux et al. 1990). However, more recently 
expression of cdr2 has been confirmed in a significant number o f gynaecological 
tumours from neurologically normal patients (Darnel 1 et al. 2000).
J.4.3 Anti-Ma Antibodies.
Dalmau et al (Dalmau et al. 1999) first described anti-Mai antibodies in the sera of
patients with suspected PND. The antibodies were found in patients with brainstem and
cerebellar dysfunction or motor weakness. Underlying tumours of the parotid gland,
breast, lung or colon were found. These findings were obtained from a small group of
patiaits, however it is though that anti-Mai antibodies are reliable markers of PND
44
involving the brainstem or cerebellum The use of these antibodies in predicting the 
underlying malignancy is more uncertain. Each patient from the original paper suffered 
from different malignant disease. More recent studies have failed to highlight an 
overwhelming tumour association (Rosenfeld et al, 2001).
Staining o f human tissue sections with anti-Ma sera reveals exclusive reactivity with 
subnuclear elements of neurones and testicular germ cells. Probing immunoblots of 
neuronal extracts shows that the antibodies react with 37 and 40 kDa bands and also 
react with the associated malignancy. As with other anti-neuronal antibodies, the 37 
kDa target antigen (M ai) has been cloned from a bacteriophage expression library. The 
function o f this proton, the expression of which is restricted to brain and testicular 
tissue, is unknown, and there is no homology shown between known proteins or 
sequence motifs.
Serum from some patients with PLE, accompanied in some cases by brainstem or 
cerebellar dysfunction, and testicular tumours was found to contain anti-neuronal 
antibodies against a 40 kDa protein. The antigenic target was found to share significant 
homolog) with M ai, the antibodies and antigen were therefore designated anti-Ma2 and 
Ma2 respectively. Immunohistochemical staining of neuronal sections shows reactivity 
with subnuclear and cytoplasmic structures in all neurones. Normal expression of Ma2 
is limited only to brain and testicular tumours. As with Mai the function of this protein 
is unknown.
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1.4.4 Anti-Ri Antibodies.
The anti-Ri antibody was first described in a patient with breast cancer and opsoclonus- 
myoclonus (Budde-Steffen et aL 1988). The antibody provides an identical 
histochemical picture to that produced by anti-Hu serum with the exception that anti-Ri 
serum does not react with nervous tissue from the PNS. Immunoblots of extracts of 
cortical neurones show that the antibody reacts with two proteins, one of 55 kDa and 
one o f  80 kD a The antibodies eluted from these regions react specifically with 
neoplastic tissue taken fi’om the patients but not fi-om neurologically normal tumour 
controls (Luque et aL 1991).
The gene encoding the antigen has been cloned and designated Nova-1. Normal 
expression o f this protein is limited to the brain, however alternatively spliced forms are 
found in malignant tissue (Buckanovich et al, 1993). Nova-1 is an RNA binding protein 
th o u ^ t  to play a role in alternative splicing of mRNA. the activity o f which can be 
interrupted in-vivo by anti-Ri sera (Buckanovich eta l, 1996).
1.4.5 Anti-CV2' CRMP-5 Antibodies.
Honnorat et al (Honnorat et al, 1996) first described anti-CV2 antibodies in patients 
with cerebellar degeneration, uveitis and peripheral neuropathy in 1996. These 
antibodies stained a subpopulation of oligodoidrocvtes in adult rat brain and reacted 
with a 66 kDa protein belonging to the Ulip/CRMP family of proteins. The commonest 
underlying malignancy associated with anit-CV2 antibodies is SCLC (77 %) followed 
by thymoma (6 %). Comparison of patients with anti-Hu and anti-CV2 associated 
peripheral neuropathy showed that the former tended to suffer from a pure sensory
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neuropathy as opposed to a mixed sensorimotor neuropathy associated with the 
presence o f anti-CV2 antibodies (Antoine eta l, 2001).
Tani et al (Tani et al, 2000) and Croteau et al (2001) have described cases of 
paraneoplastic chorea in-patients with an underlying SCLC whose sera contained 
antibodies directed against a 68 kDa and 79 kDa protein in each case respectively. The 
identity o f these proteins was not documented. Later Yu and collègues (Yu er al, 2001) 
described antibodies against CRMP5 in patients with PND which is thought to 
correspond to the previously described auto antigens. It has more recaitly been 
suggested that anti-CV2 and anti-CRMP5 antibodies are directed against the same 
antigen (Posner and Dalmau, 2001 ; Honnorat et al, 2002).
In a study o f 116 anti-CRMP-5 positive patients cerebellar ataxia dementia cranial 
neuropathy, chorea loss of taste/smell and optic neuritis were among the most frequent 
manifestations of neurological dysfunction. Further reports described 16 anti-CRMP5- 
IgG positive patients with underlying malignancy and chorea normally as part of a 
multifocal neurological disorder (Vemino et al. 2002). Chorea has rarely been described 
in anti-Hu positive patients with PEM (Heckmann et al, 1997), however. anti-Hu 
antibodies are often detected concurroitly with the presence of anti-CRMP-5 IgG and 
chorea may thus represent a discrete syndrome that occurs in combination with 
PEM/SSN. The findings to date suggest that anti-CRMP-5 is the most frequently 
occurring marker of paraneoplastic chorea
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1.4.6 What Are We Missing?
Posner and Dalmau's editorial ‘Yet another paraneoplastic antibody’ (Posner and 
Dalmau, 2000) implies efforts to identify novel anti-neuronal antibodies are becoming 
exhausted. As has been described, even the more common anti-neuronal antibodies 
occur infrequently, so what are the chances of finding novel antibody associations? In 
their study o f 50 patients with limbic encephalitis Gultekin et al (Gultekin et aL 2000) 
found that 40 % of the patients were antibody negative Similarly, Antoine et aïs' study 
o f paraneoplastic peripheral neuropathies showed 73 % of patients had no evidaice for 
anti-neuronal antibodies (1999). In both studies the association of neurological and 
neoplastic disease was considered enough to consider the disease to be paraneoplastic. 
Our own investigations have shown that 23 % of patients with paraneoplastic disease 
have no anti-neuronal antibodies, a figure likely to be lower than the actual figure as the 
method for data collection was biased for antibody positive cases of PND (See 
Appendix 3). It is clearly possible that in some patients anti-neuronal antibodies simply 
do not occur. In^propriate secretion o f neurotoxic compounds or c\tokines could 
feasibly trigger distant neurological dysfunction. Similarly a T cell mediated response 
could result in inflammation w ithin the nervous system in the absence of B cell activity. 
However investigations conducted in a routine laborator> frequently detect anti­
neuronal activity in patients with neurological disease and cancer that do not conform to 
the classical antibodies described in the preceding text.
Since antibodies associations are rare a large library of samples are required to
demonstrate novel antibody associations. Uncommon immune responses may be
dismissed as unique simply due to the infrequency with which samples arrive.
GephyTin, one o f the latest target antigen described in the literature was characterised on
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the basis of results obtained from investigation with the serum from one patient (Butler 
et al, 2000).
It must also be remembered that the detection of a single well-characterised anti­
neuronal antibody may not be the complete story. We have already described how a 
number o f tumour antigens can be recognised by antibodies in the serum of a single 
cancer patient (Anti-Hu and anti-CRMP-5 antibodies See section 1.4.5). It is probable 
that patients have antibodies against numerous neuronal antigens at the same time. 
Dataller et al (Dataller et al, 2004) have recently described an antibody response to 
Zic4. a zinc finger protein in 27 % of serum samples with anti-Hu and CRMP5 
antibodies. In a different study coexisting anti-neuronal antibodies were found in 31 % 
o f 553 samples contained multiple antibodies (Pittock et al, 2004). It is possible that the 
phenotvpe o f a disease may be the result o f multiple immune responses against various 
antigens, some of wfrich may remain unidentified.
To date most proteins identified as targets for anti-neuronal antibodies have been 
characterised by the screening o f bacteriophage expression libraries. Antigen 
identification using this technique may not be universally applicable. For example, 
carbohydrate antigens and conformational epitopes may not be detectable. It may be for 
this reason that efforts to screen expression libraries with anti-Tr positive sera have not 
yielded a candidate antigen. As a result alternative techniques may be required in order 
to characterise as yet undetected antigens associated with PND. The benefit of 
characterising novel target antigens lies not just in the potential to develop diagnostic 
tests, but in broadening the understanding of the pathological mechanisms involved in 
PND and so developing effective therapeutic strategies.
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1.5 Pathogenesis of Paraneoplastic Neurological Disease.
The T and B cells which form the ad^ tive  arm of the immune system are capable of 
orchestrating an immune response against tumour cells which, as discussed, is 
evidenced by the presaice of inflammatory infiltrates in tumour tissue and the presence 
o f anti-tumour antibodies.
Normally an immune response will occur without any immune attack against normal 
healthy tissue Autoimmunity is prevented by the deletion o f self-reactive cells during 
their development. T cells, which react with self-antigens, are deleted during 
development in the thymus following recognition of self-antigen. Since not all antigens 
can be presented to T cells by the thymus some potentially reactive cells may reach the 
periphery In this instance these cells are rendered either anergic due to incorrect 
presentation o f the self-antigen, deleted because the antigen is in too low a 
concentration or remain inactive as the antigen is sequestered in sudi a way as to 
prevent T cell interaction. B cells also undergo selection in the bone marrow during 
development. However, since B cells undergo receptor editing during maturation the 
potential for B cells to become self-reactive is greater than for T cells.
The pathogenesis of most PND is still unknown however immunological abnormalities 
such as the presence of neuronal autoantibodies and presence of inflammatory change 
points towards an autoimmune mechanism. It is believed that expression of normally 
sequestered neuronal antigens by tumour cells results in the production of a cross­
reactive immune response betweoi the tumour and neuronal tissue. It is probable that T
and B cells capable o f recognising the antigenic targets of anti-neuronal antibodies are
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activated as part of the wider immune response to tumour tissue. The presence o f the 
anti-neuronal antibodies alone is not sufficient evidence to say that these syndromes are 
antibody mediated For a disease to be classified as antibody mediated it is generally 
accepted that four criteria must be satisfied;
1 : The antibodies should react with the correct tissue type to produce the
clinical phenotype.
2: The passive transfer o f antibodies from a patient into experimental
animals should replicate the disease.
3: Immunisation o f an experimental animal with purified antigen should
induce the clinical phenotype.
4: Immunotherapy that reduces antibody titres must result in clinical
improvement
The circulating antibodies found in LEMS meet these criteria. In contrast only the first 
o f the four postulates has been satisfied for the antibodies directed against intracellular 
targets. Further evidence o f pathogenicity in these cases is far more circumstantial. The 
deposition of antibodies in neurones of patients with PND has been demonstrated and 
anti-Yo antibodies are taken up by cultured rat neurones (Greailee et aL 1995). The 
medianism by which antibodies penetrate the cell is unclear but may involve 
endocvlosis. Such a mechanism would not allow antibodies to reach their nuclear 
antigens to allow them to exert a pathogenic effect. Epitope mapping of Hu (Kumagai et 
aL 1999) and Yo (Fathallah-Shaykh et aL 1991) shows that the antibodies are directed 
against the functional domains of these proteins. However in only a single report have
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anti-Hu antibodies been reported to be directly pathogenic (Schafer et al, 2000). 
Transfer o f antibodies (Tanaka K et at, 1999) or immunisation of experimental animals 
(Tanaka et aL 1994) has failed to replicate the disease despite the finding of high titres 
o f anti-neuronal antibodies. Finally, treatments that aim to reduce the titre of anti­
neuronal antibodies are consistently unsuccessful (Blaes, 2002). Therefore most 
investigators now believe that anti-neuronal antibodies associated with PND are an 
epiphenomenon, acting as markers of a disease mediated by a different process.
The failure to provide evidence for an antibody-mediated medianism has led to the
examination of the role of cell mediated immunity in PND. Analysis of the paraichymal
inflammatory infiltrate has shown that the lymphocytes in situ are recruited, and
activated folloi\ing interaction with a specific antigen. Sub-classification of the CD4 T
cells demonstrates that they are of the Thl subtvpe and as such could be involved in cell
mediated injury. Studies regarding the association between Human Leukocyte Antigen
(Involved in antigen presentation) and PND in anti-Hu positive patients have failed to
identify any h^lotype implicated in the development of anti-Hu associated syndromes
(Voltz et al, 1998). Stronger evidence exists for the role of cytotoxic T-cell lymphocytes
in anti-Yo associated PCD. One study has identified cdr2 specific cytotoxic
lymphocytes in 3/3 patients who were HLA A2.1 positive (Albert et aL 1998), wiiile
investigation of a Japanese cohorts of anti-Yo positive patients has demonstrated an
association with HLA A24 (Tanaka and Tanaka, 1996). Restricted pqjtide epitopes
from cdr2 that contain the appropriate anchor residues for these HLA molecules can
stimulate cytotoxic effects (Tanaka et aL 2001). One of the most recent and convincing
experiments regarding the need for a T-cell mediated immune response has recently
been described. By transferring Mai activated CD4 Thl lymphocytes betweoi mice
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investigators have been able to induce pathological changes in nervous tissue 
synonymous to those seen in PND (Pellkofer et al, 2004).
1.6 Anti-tumour immunity in PND
The immune response associated with PND seems to have considerable anti-tumour 
activit) which results in the restriction of tumour growth and metastatic spread. There 
was initially some doubt as to whether this was a result o f the neurological symptoms 
prompting investigation for a tumour early in the natural history. However, 16 to 25.5 % 
o f neurologically normal patioits with SCLC harbour low titres of serum anti-Hu 
antibodies (See section 1.4.1). These patients are more likely to have limited stage 
disease, a better response to treatment and improved survival when compared with 
antibody negative SCLC patients (Graus. et a i  1997). It remains to be determined 
w-hether the anti-tumour effects are a direct result of anti-tumour activity directed 
specifically against Hu, or whether the antibodies are a marker a more aggressive 
generalised activation o f the immune system (Dalmau etal, 1990).
Analysis of SCLC cells has demonstrated that Hu is expressed at the surface of all cells 
and is therefore an accessible target to an immune response, but it is unclear why only a 
proportion of patients develop an immune response to this protein. Analysis of tumours 
o f SCLC patients with neurological disease reveals MHC 1 expression to be more 
prevalent than on tumours from neurologically normal patients suggesting that these 
tumour cells are more immunogenic and more likely to elicit cell mediated immunity 
(Manley et al, 1995). Additional evidmce for an anti-tumour effect comes from animal 
models. Vaccination of murine models of SCLC with a plasmid encoding Hu elicits
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anti-tumour activity (Ohwada et al, 1999) and studies examining the lymphocytic 
infiltrate into murine neuroblastoma found a higher CDS CD4 ratio in the tumours of 
Hu vaccinated animals (Carpentier et al, 1998).
1.7 Post-Infectious Neurological Diseases.
1.7.1 Paraneoplastic and Post-infectious Disease.
PND and some post-infectious neurological disorders share similarities in that diey are 
both associated with the production of anti-neuronal antibodies and an immune response 
capable of cross-reacting with components of normal nervous tissue (Figure 1-1). The 
main difference is that in the case of paraneoplastic disease auto-immunity is thought to 
be triggered by the aberrant expression of normal self-antigen while post-infectious 
auto-immunity is thought to be initiated by an immune response to an exogenous 
antigen carried by a pathogenic agent. Methods employed in the identification of 
antigenic targets in post-infectious neurological disease can be utilised and applied to 
the detection o f antigens in paraneoplastic disease and vice versa. The following 
sections provide an introduction into the principles bdiind post-infectious autoimmunity 
with some examples of post-infectious neurological diseases.
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( A )
Periphery Blood brain barrier CNS
Pathogen 
(exogenous antigen)
( B )
Tumour cell 
(endogenous antigen)
Cross reactive antigen on 
neuronal tissue
Figure 1-1: Production of cross-reactive anti-neuronal antibodies in post-infectious 
and paraneoplastic disease.
1.7.2 Breakdown o f Tolerance and Molecular Mimicry.
As with paraneoplastic disease post-infectious autoimmune disease may be the 
consequence of an inappropriate immune response against self-antigens, which results 
in the damzige and dysfunction of the target tissue. One explanation for the breakdown 
o f tolerance and the initiation of a post-infectious autoimmune response is suggested by 
the theory of ‘molecular mimicry’. This states that the infection of a susceptible host by 
a pathogen bearing antigens similar to those on host tissue but with sufficient variation 
provokes an immune response that then cross-reacts with normal tissue. In order for a 
disease to be the result o f molecular mimicry it is generally accepted that four criteria 
must be satisfied (Rose and Bona, 1993; Benoist and Mathis, 2001). In the case of 
antibody mediated disease the criteria outlined in section 1.5 should also be kept in 
mind.
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The criteria for molecular mimicry are as follows:
1 : There must be an epidemiological link between the infectious agent and
the immune-mediated disease.
2: Patients must mount a T cell or antibody response against self-antigen.
3: An antigenic mimic of the antigen must be identified from the pathogen.
4: The disease must be produced in an animal model.
1.7.3 Evidence for MolecularMimicry as a Cause o f  Neurological Disease. 
Gullain-Barré syndrome (GBS) is a monophasic illness characterised by inflammation 
and degeneration of the peripheral nerves. Miller-Fisher syndrome (MFS) is considered 
a variant of GBS characterised by ataxia, areflexia, and ophthalamoplegia The 
s\Tidromes usually occur as a consequence of various bacterial or viral infections. 
Epidemiological studies have highlighted a clear association with Campylobacter jejuni 
(Rees et al, 1995). This bacterium carries lipopolysaccharides in the cell wall against 
wiiich antibodies are produced with the capacity to cross-react with gangliosides presait 
on the surface o f peripheral nerves. Antibodies against the ganglioside GQlb are 
detected in >90 % of patients with MFS while antibodies to GMl and other 
gangliosides can be detected in 20 to 40 % of patients with in GBS. Passive transfer of 
antibodies from GBS patients to mice has the capacity to produce GBS symptoms (van 
den Berg et al. 1994). The findings of an epidemiological link with an infectious agent 
the existence of a molecular mimic, the presence of cross-reactive antibodies and the 
capacity o f the antibodies to transfer disease means GBS is considered by many to be 
the best example o f a disease caused by molecular mimicry
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More recently, evidence for molecular mimicry causing HTLV-1 associated 
myelopathy/ tropical spastic paraparesis (HAM/TSP) following human T-lymphotropic 
virus type 1 (HTLV-1) infection has been presented. Levin et al (2002) have identified 
an antibody response against the neuronal protein hnRNP-Al which cross-reacts with 
the tax protein of HTLV-1. These antibodies were able to completely abolish neuronal 
firing in patch clamp experiments. While all the criteria for molecular mimicry have yet 
to be satisfied for HTLV-1 induced HAM/TSP the evidence presented thus far suggests 
that HAM/TSP may be an excellent example of molecular mimicry resulting in 
neurological disease.
1.8 Post-Streptococcal Diseases of the CNS.
There is considerable interest in diseases of the CNS associated with recent infection 
with group A (3 haemolytic streptococcus (GABHS). The term post-streptococcal 
neurological disorders includes diseases such as Sydenham’s chorea (SC) (Church etal,
2O02), acute disseminated encephalomyelitis (ADEM) (Dale et al, 2001), paediatric 
autoimmune neuropsychiatrie disorder associated with streptococcal infection 
(PANDAS) (Swedo et al, 1998), encephalitis lethargica (EL) (Dale et al, 2003) and 
Tourette’s syndrome (TS) (Church et al, 2003). It has been postulated that these 
disorders may involve the process o f ‘molecular mimicry’ described above. Indeed anti­
neuronal antibodies have been described and the putative antigens characterised. An 
introduction to the clinical phenotype of a number of post-streptococcal neurological 
disorders is provided below. Table 1-4 summarises the main clinical, streptococcal and 
immunological findings for each disease. The evidence for the presence of anti-neuronal 
antibodies and the putative antigens are described (see section 1.9 and 1.10 
respectively).
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Table 1-4: Clinical findings, streptococcal association and anti-neuronal antibodies in proposed post streptococcal neuropsychiatrie diseases.
Syndrome Symptoms Evidence for association with Evidence for anti-neuronal antibodies Outcome
Streptococcus Histochemistry ImmunoUot
Sydenham's Chorea, (X!D, anxiety, Yes. Raised in 63% (Ayoub Cytoplasmic staining of caudate and Antibodies to neuronal tissue but no specific bands Complete remission in 50% by
Chorea ADHD ,depres8ion. and wanna maker 1966) subthalmis neurones (Husby et al, 1976). described (Morshed et al, 2001).. Antibodies against 2 years.
.Systemic signs associated Anti-neural antibodies (Morshed et al. BG enriched proteins of 40, 45 and 60kDa (Church et
with RF. 2001). al, 2002).
PANDAS Motor Tics, (X'D. ADHD Yes. Required by definition Staining pattern similar to Sydenham's Antibodies against 40, 45 and 60kDa BG proteins Relapses associated with re­
(Swedo 1998) chorea. (Church 2004) infection. Final outcome
(Pavonc 2004) remains unclear.
Tourette’s Motor and vocal tics Evidence for ele\ ated An anti-neuronal response. Nuclear Patients with Raised ASOT frequently have antibodies ‘waxing and waning’. Often
Syndrome OCD, ADHD streptococcal serology in a staining occasionally with sparing of against 40, 45 and 60 kDa proteins (Church et al. resolves in adulthood.
subgroup of patients nucleolus (Morshed e/a/, 2001). 2003).
Encephalitis Sleep disturbances. Yes. 65% have elevated ASOT ('ytoplasmic binding of antibodies to BG Antibodies against neuronal 40, 45, 60 and 98kDa Often relapsing course.
Lethargica lethargy, movement (Dale et al, 2003). neurones (10/10 patients) (Dale et al. neuronal proteins (Dale et al. 2003). Possibly fatal. 75% will have
disorders 2003). persistent neurological disease
ADEM Various depending on site Yes: Patients with raised Immunoflouresccnt staining of large Binding to basal ganglia enriched proteins (MW = 60, Occasional relapse but
of lesion. ASOT and preceeding striatal neurones (Dale et al, 2001) 62, 67, 80kDa) (Dale et a/,1990). frequently resolution of
infection have been reported. neurological symptoms.
ADEM; Acute disseminated encephalomyelitis. ADHD: Attention deficit hyperactivity disorder. BG: Basal ganglia. OCD: Obsessive compulsive disporder.
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1.8.1 Sydenham's Chorea.
Rheumatic fever (RF) is a systemic disease precipitated by GABHS infection. The most 
common symptoms include fever, arthritis and carditis. SC, characterised by the r^ id  
onset o f bilateral chorea, often accompanied by behavioural changes is considered to be 
a late manifestation of RF. The disorder is more common in females with the peak 
incidence at 8.4 years (Cardoso et al, 1997). Medical intervention in western societies 
has resulted in the reduction o f the number of cases of RF and thus SC. However RF 
remains endemic in developing countries.
In contrast to RF which typically occurs within 21 days o f GABHS infection, SC often 
has a delayed onset ranging from 1 to 6 months (Murphy et al, 2000). This delayed 
period of onset presents problems for the diagnosis of SC as the presence of acute phase 
proteins and titers of anti-streptococcal antibodies have often subsided at the time of 
presentation, however the epidemiological association of GABHS and SC has been 
demonstrated (Ayoub and Wannamaker, 1966).
Since SC is rarely fatal only a limited number o f pathological studies involving post­
mortem tissue are available but consistently show inflammatory changes in the basal 
ganglia concentrated mainly to the caudate and putamen Neuronal loss is an uncommon 
finding and may be misleading, being related to the increased severity of the disease 
process in patients with fatal SC. More commonly patients experience persistence of 
chorea which extends beyond two years in 50 % of cases. Patients may also experience 
later relapses associated with re-infection or around the time of pregnancy.
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1.8.2 Paediatric Autoimmune Neurophsychiatric Disorders Associated With 
Streptococcal infection (PANDAS).
An apparent temporal association betweai an outbreak of GABHS and a 10 fold 
increase in the incidence o f motor tics was recognised in the 1980’s (Kiessling et al, 
1993). In 1998 Swedo et al (1998) published an in-dq)th description of 50 patients with 
neuropsychiatrie disease associated with recent infection with GABHS, and coined the 
term "paediatric autoimmune neuropsychiatrie disorders associated with streptococcal 
infections (PANDAS)’.
To conform with a diagnosis of PANDAS, Swedo et al defined a number of criteria one 
o f wiiich stated that the neuropsychiatrie disorder must occur in a pre-pubital patient, 
follow an episodic course and have evidence of GABHS infection. Since the 
phaiomenon of PANDAS is fairly new there is limited information pertaining to the 
demographics and pathological basis of the illness. The Swedo p ^ e r  describes a series 
o f predominately male patients (2.6:1 ) with a mean age of onset of 6.3 and 7.4 years for 
tics and OCD respectively (Swedo et al, 1998). There are no published rqjorts in which 
in-depth post-mortem analysis o f brain tissue has been conducted. MRI scanning 
suggests a pathology localised to the basal ganglia since patients frequently have an 
ailarged caudate and putamen when compared to healthy controls (Giedd et al, 2000). 
The association with GABHS implies that PANDAS may be an immune-mediated post- 
infectious disorder. Indeed there is some evidence to suggest the existence o f anti­
neuronal antibodies in the serum and CSF o f patients with PANDAS (see below) wfiile 
the use of immunomodulatory therapies such as IVIG and plasma exchange have been 
shown to decrease symptoms (Perlmutter et al,. 1999). The disease by definition
follows a saw-tooth’ pattern with exacerbation’s linked with recurrmt GABHS
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infection, however the natural history of the disease is unknown but is thought to be 
similar to the natural course of SC.
1.8.3 Acute Disseminated Encephalomyelitis (ADEM)
Acute disseminated encephalomyelitis is a monophasic inflammatory disease of the 
white matter which is commonly post-infectious but may also occur as a consequence of 
vaccination with killed or attenuated virus or bacteria. Cases of ADEM following 
infection with mycoplasma, influenza, enterovirus, Epstein-Barr virus and varicella 
have also been described. The clinical findings vary as a consequence of the anatomical 
localisation of the lesions. Among the more common findings are pyramidal signs, 
encephalopathy and bilateral optic neuritis. The disease is rare making the exact 
incidence difhcult to determine. ADEM following mumps has an occurrence o f 1:1000, 
while ADEM following rubella has an incidence of 1:20,000.
Pathological investigation reveals a perivenular inflammatory myelinopathy composed 
o f lymphocytes and macrophages. Demyelination occurs in the absence of axonal 
damage. The pathological findings are consistent independent of the precipitating 
pathogen or vaccine. Investigation of the CSF and brain tissue for the presence of 
infection agents is consistently unsuccessfiil and has led to the suggestion that the 
disorder may be immune mediated. This is supported by the apparent benefits of 
immunomodulatory therapies in the treatment of the disease, some of which have been 
reported to have dramatic effects.
A ith o u ^  rare (6 % o f ADEM patioits). Streptococcal infection has been associated
with ADEM. Dale et al presented a series of 10 patients with ADEM all o f whom had
61
serological evidaice for GABHS infection. This cohort were unusual in that 50 % of 
patiaits had a dystonie extrapyramidal movement disorders, an uncommon clinical 
finding in ADEM patients (Dale et al, 2001). The authors described an increased 
incidence of lesions in the basal ganglia (80 % compared to 18 % in non-streptococcal 
ADEM) and concluded that post-streptococcal ADEM represented a new post­
streptococcal neurological disease.
1.8.4 Tourette 's Syndrome
Tourettes syndrome is defined as a neuropsychiatrie disease characterised by chronic 
motor tics with one or more vocal tics associated with psychiatric symptoms such as 
OCD, attention deficit hyperactivitv’ disorder, anxiety and depression. The disorder 
affects 5:10,000, has a male predominance (M: F = 3:1) and is prepubital in onset (mean 
age = 7 years). The symptoms are typically described as ‘waxing and waning’ often 
with complete resolution by adulthood although some patients develop chronic disease. 
Excellent reviews can be found in (Jankovic, 2001; Leckman, 2002 and Robertson, 
2000).
The underlying aeitology of TS is unclear. Undoubtedly, genetic and environmental 
factors play a role. Studies of the relatives o f patients with TS suggest an autosomal 
dominant inheritance but no specific genetic markers have yet been described (Pauls,
2003). Imaging studies suggest the basal ganglia are often affected (Peterson et al, 
1993).
Like SC and PANDAS some patients with TS have positive streptococcal serology
compared to controls suggesting TS may in some cases be post-infectious in nature.
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While the use o f IVIG in TS has not been shown to have an effect some investigators 
have claimed the existence o f anti-neuronal antibodies in patients with TS (see below).
1.8.5 Encephalitis Lethargica.
Encephalitis lethargica is a severe neuropsychiatrie disease characterised by sleep 
disturbance (hypersomnolence, insomnia and sleep inversion), lethargy and 
extrapvTamidal movement disorders (Parkinsonism and dyskinesia). The majority of 
survivors are left with significant neuropsychiatrie deficits such as oculog>Tic crisis, 
opthalamoplegia, obsessive compulsive disorder (OCD), depression, apathy and 
mutism.
The first reported cases of EL formed an epidemic between 1916 and 1927 coinciding 
with the influenza pandemic of 1918. At that time EL was thought to be the result of 
direct infiltration of the brain parencyma by influmza virus (Ravenholt and Foege, 
1982) but examination of acchived brain tissue from these EL cases for the presaice of 
influenza virus failed to demonstrate its presence (McCall et al, 2001; Lo et al 2003).
Histochemical examination of brain tissue from the first epidemic and from sporadic 
cases demonstrates perivascular lymphocytic cuffing of vessels situated in the mid brain 
and basal ganglia which have more recently been identified as IgG producing plasma 
cells. These findings coupled with the presence of oligoclonal bands and the reportedly 
steroid responsive nature of the disease has lead to the suggestion that EL may be 
immune mediated.
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In 2004 Dale et al reported a series of 20 patients with EL which were frequently 
preceded by an upper respiratory tract infection or tonsillitis (Dale et al, 2003). The 
association of basal ganglia and midbrain dysfunction and the post-infectious 
presentation of the disease led the investigators to question whether these cases o f EL 
were post-streptococcal in nature. The groups were able to culture group A P- 
haemolvtic streptococcus from the throats of 2 patients while 65 % of patients had a 
significantly elevated anti-streptolysin O titres (ASOT). In addition anti-neuronal 
antibodies were detected in 95% of patioits.
1.9 Anti-Neuronal Antibodies in Post-Streptococcal Diseases of the CNS
The post-Streptococcal neurological diseases described above have all been postulated 
to be diseases in which the phenomenon of molecular mimicry may play a role in the 
pathogenesis. Epidemiological studies have demonstrated a relationship betweai 
GABHS in all the neurological diseases described above thus fulfilling the first criterion 
for molecular mimicry (see section 1.7.3). In addition circumstantial evidence for the 
involvement of an aberrant immune response in the pathogenesis of SC, PANDAS, TS, 
EL and ADEM can be inferred from the apparent therapeutic benefit of 
immunomodulatory therapies such as the use of IVIG, Plasmapheresis and 
immunosuppression. Finally, two independent studies have been able to produce 
stereotypical movements in rats after infusion of serum from patients with TS 
suggesting the presence of a serum soluble factor capable of inducing disease (Taylor et 
aL2002: Ballet et al, 2000).
More compelling evidence for an autoimmune response has been provided by studies
that have detected anti-neuronal antibodies in the serum and CSF of patients with post-
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streptococcal neurological disorders. The first evidence for anti-neuronal antibodies was 
provided in 1976 by Husby et al (1976). Immunoflourescent staining of the cytoplasm 
of neurones in the caudate and thalamus was found in 46 % of SC patients compared to 
14 % of patients with RF. In addition a correlation between antibody titre and clinical 
status was described. The existence of anti-neuronal antibodies associated with SC has 
been confirmed by a number of subsequent studies one of which (Morshed et al, 2001) 
described a similar cytoplasmic staining of neurones to that described by Husby et al. 
However, probing immunoblots of rat brain with patients’ serum failed to demonstrate a 
consistent anti-neuronal response.
In 1998, Singer et al demonstrated the existence of anti-neuronal antibodies in the 
serum of patients with TS. Using both an enzyme linked immunosorbent assay (ELISA) 
and immunoblot of human caudate and putamen tissue a more frequent anti-neuronal 
response was demonstrated in TS patients compared to controls. The immunoblots 
demonstrated a frequent antibody response against 83, 67 and 60 kDa antigens. 
Attempts to refine the detection methods using a neuroblastoma cells line proved 
disappointing. The association of antibodies against proteins of a specific molecular 
weight was lost unless powerful statistical tests were applied to the immunoblots 
(Singer era/, 1998).
Church et al re-examined the existence of anti-neuronal antibodies in patients with SC
using both an ELISA and immunoblot of human basal ganglia tissue. The results
broadly concurred with previous findings. Anti-neuronal antibodies were detected in
95% (ELISA) and 100% (Immunoblotting) of patients with acute SC (Church et al,
2002). In addition, immunoflourscence detected staining of neuronal tracts in the
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caudate, although a detailed description of the staining pattern was not provided. The 
most important finding of this paper was the description of anti-neuronal antibodies 
directed against a discrete set of proteins with molecular weights of 40, 45 and 60 kDa. 
Following the successful demonstration of anti-neuronal antibodies in SC the group 
looked at other post-streptococcal neurological disorders. Antibodies against a similar 
set of proteins to those described in SC were also detected in the serum of patients with 
PANDAS (40, 45 and 60 kDa) (Church et al, 2004) while immunoflourescent studies 
replicated the staining pattern of basal ganglia neurones (Church et al, 2003). In 
addition antibodies against the 40, 45 and 60 kDa antigens were detected in patients 
with post streptococcal EL (Dale et al, 2003) and antibodies against a 60 kDa protein 
were also detected in the serum of patients with post-streptococcal ADEM (Dale et al, 
2001).
1.10 Putative Antigens in Post-streptococcal Diseases of the CNS
Given the close association between streptococcus and the neurological and psychiatric 
symptoms in these disorders it is reasonable to suggest that the antibodies may 
recognise common antigenic targets. Thus, serum was used in combination with various 
protein purification techniques to characterise the target antigens. Thus far, four 
potential antigenic targets have been identified. These are a  and y enolase, aldolase C 
and pyruvate kinase (PYK).
First discovered in 1934, a-Enolase is a 47 kDa glycolytic enzyme that catalyses the
dehydration of 2-phospho-D-glycerate to phosphoenolpyruvate in the forward direction
of the second half of the Emden Myerhoff-Pamas glycolytic pathway. The reaction
occurs in the reverse direction during gluconeogenesis. The enzyme is classed as a
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metalloenzyme due to the requirement o f divalent cations (naturally Mg^^) as a cofactor 
for its function.
Enolase exists as three isoenzymes: a-Enolase is found in a variety of tissues, p-Enolase 
is restricted almost entirely to muscle tissue and y-Enolase is restricted to neuronal and 
neuroectodermal tissue. Enolase is one of the most abundant cytosolic proteins but has 
also been demonstrated to exist on the surface of a variety of eukaryotic cells. In 
addition, a-Enolase has been reported to occur as a surface protein on GABHS making 
it an interesting candidate in the molecular mimicry hypothesis of immune mediated 
disorders. a-Enolase has been shown to bind other glycolytic enzymes with a high 
affinity, one of which, pyruvate kinase (PYK) has been implicated as a potential antigen 
in post-streptococcal immune mediated diseases of the central nervous system.
a-Enolase has been implicated in a number of diseases. Levels of a-Enolase are 
increased in association with neuroblastoma and small cell lung cancer while antibodies 
to the protein have been implicated in cancer-associated retinopathy (CAR) and have 
been detected in a wide variety of autoimmune diseases ranging from SEE, ulcerative 
colitis and autoimmune hepatitis. Interestingly, anti-a-Enolase antibodies have 
previously been hypothesised to have an important role in the development of post­
streptococcal movement disorders (Fontan et al, 2000). It is unclear why an antibody to 
a ubiquitous enzyme should result in unassociated autoimmune disorders. One 
explanation may be that the epitope recognised by the antibodies is different between 
diseases. An epitope study into CAR sera revealed that it was only pathogenic when it 
recognised a certain epitope (Adamus et al, 1998). It is possible that a reaction to a 
distinct epitope could result in a given pathology.
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Aldolase C is one o f  the three forms o f  the enzyme fructose-1, 6-bisphosphate aldolase 
found in mammals. Aldolase A and B have similar enzymatic activities as Aldolase C 
on the substrates fhictose-1, 6-bisphosphate and fructose-1-phosphate but act with 
differing affinities. Aldolase A is essentially ubiquitously expressed in all tissues acting 
as a key enzyme in the glycolytic pathway. Aldolase B expression is restricted to the 
liver. Expression o f Aldolase C is enriched within the cerebellum distributed in stripes 
in the Purkinje cell layer o f  the cerebellum as well as in the inferior olives and sensory 
neurones o f  the posterior horn o f the spinal cord. This distribution has lead to the 
hypothesis that the protein has functions beyond that o f glycolysis within the nervous 
system (Buono et al, 2001). As with a-Enolase the aldolases are a conserved group o f 
molecules. Forms exist in GABHS thus making aldolaise a potential molecular mimic. 
The occurrence o f an antibody response against the C isoform o f  the protein is 
compatible with the production o f  a neurological disease.
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1.11 Post-Infectious Opsoclonus-myoclonus.
As discussed in section 1.2.4 OM may have a paraneoplastic or post-infectious cause. 
The incidence of PIOM is difficult to estimate for a number of reasons:
1 : OM is rare.
2: Many case reports document the absence of a tumour but do not thoroughly 
investigate the patient for an identifiable causative agent. Often tumour 
negative OM cases will be labelled as ‘Idiopathic’.
3: Neuroblastoma, commonly associated with OM may undergo spontaneous 
remission.
Despite these limitations Digre’s (Digre, 1986) review of 58 case reports of OM was 
able to attribute a paraneoplastic cause to only 19 % of cases. In the remaining 34 cases 
an infectious aetiology was implied in 26 and a pathogen positively identified in 8 
cases. The study may have carried a selection bias for infectious cases or been 
conducted before the development of high resolution scanning techniques capable of 
detecting small tumours but it implies that infection is a common cause of adult OM. 
The finding that patients with post-infectious illness were often younger than 40 years 
old is broadly supported by the investigations of Bataller et al. Indeed there were a 
number of common findings between Datallers and Digre’s findings (Table 1-5).
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Table 1-5: Comparison of two cohorts of post-infectious OM.
Finding Digre et al Batailers et al
Total number of cases. 58 24
Number o f ‘Idiopathic’ cases 38 10
Mean age onset, years (range) 35(19-73) 40 (24-80)
Male: Female 0.8:1 1:1
Clinical features.
Opsoclonus 100% 100%
Myoclonus 47% 70%
Ataxia 64% 100%
Outcome,
Complete remission 79% 60%
Mild neurological deficit 9% 40%
Severe neurological deficit 0% 0%
Death 6% 0%
Unknown 6% 0%
Identified infectious agents in OM include Psittacosis, Rickettsia, Coxsakie virus (B3 
and B2) and Salmonella. More recent reports have suggested that the onset o f OM may 
follow infection with Epstein-Barr virus (Delreux, et a/, 1989; Verma and Brozman,
2002) and Enterovirus (Imtiaz and Vora, 1999;Wiest et a/, 1997).
The underlying pathological mechanism for PIOM is unclear. Post-mortem studies
described similar changes to those seen in POM. There is limited evidence for a
consistent anti-neuronal response, although there is evidence for the benefit of
immunomodulatory therapies. Plasmapheresis (Yiu et al, 2001) and IVIG (Glatz, et al,
2003) have both been associated with improvement in the clinical syndrome. In
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Batailers adult cohort eight patients had complete recovery which was hastened by 
steroid therapy. In two patients the OM followed a relapsing course which was 
effectively treated with IVIG.
Perhaps the most interesting point regarding PIOM is the frequency with which 
recovery occurs. Between 60 and 79 % o f  patients are reported to have complete 
resolution o f neurological symptoms. This is in stark contrast to findings in adult 
paraneoplastic disease in which the average survival is nine months, and paediatric 
POM  in which 50 % o f  patients will continue to experience significant neurological 
deficit.
1.12 Summary and Aims
W ith respect to this thesis the B cell response to antigens in the nervous system 
represents an interesting phenomenon for a number o f reasons. These include the 
identification o f  novel insights into the biology o f tumours and the nervous system 
while providing antigenic targets which may later be utilised in diagnostic test. To date 
a num ber o f anti-neuronal antibodies have been described, however there is reason to 
believe from our own experience and recent research that as yet uncharacterised 
antibodies remain undetected. There is significant overlap between the pathology o f 
paraneoplastic and post-infectious neurological disease. Methods that apply to antigen 
identification can be applied to antibodies associated with both paraneoplastic and post- 
infectious neurological disease.
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I propose to use a range o f  approaches involving molecular biology and proteomic 
techmques to detect as yet unrecognised anti-neuronal antibodies and identify the 
autoantigens. The broad aims o f  the thesis are:
1: The cloning and production o f  recombinant forms o f the putative
antigens recognised by antibodies in the serum o f patients with post­
streptococcal neurological disease in order to substantiate previous 
observations and develop the techniques for application to as yet 
undefined antigens associated with paraneoplastic and post-infectious 
disease.
2: The identification o f  patient(s) with as yet undescribed anti-neuronal
antibodies in paraneoplastic and post-infectious neurological disease.
3: The characterisation o f  putative antigens by the application o f  established
protein purification techniques or bacteriophage library screening.
4: The development o f  recombinant forms o f  putative antigens for the
substantiation o f  findings and screening o f larger patient populations.
The methods used and an overview o f  the principles used in the following chapters are 
detailed therein. In addition, a methods section detaling common protocols is provided 
in chapter 8 and will be refered to at the relevant points throughout the chapters.
72
2 Chapter 2: Production of putative antigens recognised by antibodies of patients 
with post-infectious neurological disease,
2.1 Introduction.
As described in the opening chapter an increeising number o f neuropsychiatrie disorders 
are thought to be immune mediated. Evidence to support this theory comes from the 
apparent success o f immunomodulatory therapies and the detection o f  antibodies 
directed against neuronal tissue. Four potential auto-antigens recognised by antibodies 
in the sera o f  patients with post-streptococcal neuropsychiatrie disease have been 
described. These are PYK, aldolase C and a  and y-enolase. Recombinant forms o f these 
proteins were required in order to:
1: Confirm that these proteins were indeed the targets o f  an antibody
response.
2: Determine the frequency with which antibodies against these proteins
occur in patient and control groups.
An introduction to the principles o f the techniques used in this chapter is provided 
below. A summary o f the experiments is provided on the following flow chart.
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Purification of recombinant proteins (Section 2.3.5).
Cloning and expression of pyruvate kinase and y-enolase from 
commercial cDNA plasmid (Sections 2.3.3 -  2.3.4).
Determination of antibody frequency against the recombinant 
proteins in patients with PANDAS. OCD/ TS neurological controls 
and healthy controls (Section 2.3 .6).
Cloning and expression of a-enolase and aldolase by RT-PCR from 
mRNA isolated from lymphocytes and cerebellum respectively 
(Sections 2 .3 .1 -  2.3.2).
2.1.1 Cloning cDNA.
The polymerase chain reaction (PCR) is the most convenient way to amplify a specific 
sequence o f  DNA. The reaction requires the use o f two oligonucleotide primers 
complementary to sequences at either end o f  the DNA sequence to be amplified, 
orientated in such a way as to allow the polymerase to proceed through the region 
between the two primers. Following dénaturation o f the DNA template the primers bind 
their target sequence. This allows bases complementary to the rest o f the DNA template 
to be added to the 3 ’ end o f  the primer by the enzyme taq polymerase. This reaction 
produces a new template which can be denatured and hybridised by the primers. 
Repeated cycles o f dénaturation, hybridisation and extension result in the exponential 
accumulation o f PCR product.
Reverse transcription followed by PCR (RT-PCR) is a method by which RNA isolated 
from a suitable source can be converted into cDNA. The major attraction o f  this method 
with respect to the production o f  recombinant proteins is that the cDNA produced
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represents a ‘mature’ form of gene expression in which the introns have been removed 
to leave the exons in a continuous stretch of coding sequence. The downstream primer 
necessary for first strand synthesis can take the form of random hexamers or oligo-dT 
primers designed to hybridise the polyA sequences at the 3’ end of mature mRNA. If 
the sequence of the desired product is known then primers can be designed to target that 
specific sequence of RNA in first strand synthesis resulting in the increased specificity 
o f the amplification process. In the experiments conducted below RT-PCR reactions 
were conducted using the Superscript one-step RT-PCR kit (Invitrogen).
2.1.2 Primer Design.
Knowledge of the sequence to be amplified in the RT-PCR procedure and the vector 
into which the resulting cDNA is to be ligated allows the investigator to design primers 
that amplify the desired sequence and introduce appropriate restriction sites into the 
cDNA. By incorporating a different restriction site at each end of the amplified 
sequence cloned products can be directionally inserted into an appropriate vector. This 
is achieved by extending the 5’ sequence of the oligonucleotide primers used in the RT- 
PCR or PCR to introduce the appropriate restriction enzyme recognition sequence.
2.1.3 Bacterial Expression Vectors.
A number of bacterial expression vectors are available for recombinant protein
production. Such vectors usually incorporate a multiple cloning site (MCS) into which
DNA sequences coding the desired protein can be inserted. The vectors allow cloning of
the insert into the correct reading frame either through the use of restriction sites or
through the provision of 3 independent vectors covering all three reading frames. In
many vectors an affinity tag will be situated at the 3’- or 5’- end of the MCS in order to
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allow the purification o f  a  fusion protein product. In designing any vector suitable for 
the transcription and translation o f the inserted DNA a number o f basic factors are 
required. These include strong, inducible promoters for transcription, a ribosome 
binding site, a start and stop codon for optimal translation efficiency and a transcription 
terminator sequence. The plasmid should also carry an origin o f  replication (Ori) as well 
as genes conferring antibiotic resistance as a means to facilitate selection o f transformed 
bacteria.
2.1.4 pR SE T
The bacterial expression vectors pRSETA, pRSETB and pRSETC (Figure 2-1) are 
derived from the pUC expression vectors and are designed for high-level expression and 
purification o f  recombinant proteins from cloned genes in E. co ll Cloned DNA 
sequences are positioned downstream o f  a T7 promoter which makes high-level 
expression possible. Located downstream fi-om the T7 promoter is an ATG start codon, 
polyhistidine tag, a T7 gene 10 leader sequence to stabilise RNA transcripts, an Xpress 
epitope and an enterokinase cleavage site. A MCS containing 11 unique restriction sites 
follows these sequences. The polyhistidine tag provides a metal binding domain through 
which fusion peptides can be purified by affinity chromatography. The enterokinase site 
located between the 3 kDa His-tag and the recombinant protein allows the removal o f 
the tag from the recombinant protein assuming that an enterokinase sequence is not 
encoded within the inserted DNA sequence.
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RBS ATG HIS XP MCS TERM
pRSET  
2.9 kb
Pr: T7 RNA polymerase promoter
RBS: Ribosome binding site
ATG: Start codcn
XP Express epitope
HIS: 6x His tag
MCS: Miitiple cloning site
TERM: Stop codon
On: pUC orign of replication
fl; fl orign of replication
A": Ampicillin resistance
Figure 2-1: The pRSET bacterial expression vector.
2.1.5 Purification o f  Recombinant Proteins.
The detection and purification of recombinant proteins from crude bacterial 
homogenates has been simplified through the introduction o f bacterial expression 
vectors capable of expressing proteins which have been suitably ‘tagged’. The tag is 
created by the integration o f a short stretch o f DNA encoding a known amino acid 
sequence on to the 5’- or 3’- terminus o f the target gene. The resulting hybrids are then
i
expressed as fusion proteins with the affinity tag attached to the N- or C- terminal of the 
protein. Knowledge of the physical and chemical properties of the tag allows the 
selection of a suitable method for subsequent purification of the target protein.
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The pRSET expression vector used in these experiments results in the fusion o f  a His- 
tag to the protein o f  interest. The purification o f  His-tagged proteins exploits the fact 
that histidine is not an abundant amino acid in most bacterial proteins. The introduction 
o f stretches o f  histidine residues to the protein results in the creation o f a metal binding 
site.
Immobilised metal chelate affinity chromatography (IMAC) is a technique that exploits 
the differences in the affinities exhibited by various amino acids for a metal ligand, 
commonly nickel, for their subsequent purification. The technique can be used for the 
purification o f  His-tagged recombinant proteins. Essentially, metal ions are immobilised 
onto a matrix backbone contained within a chromatography column which has been 
chemically modified by the addition o f  a polydentate ligand. The addition o f the metal 
ions produces a metal ion chelate complex with the potential to form co-ordinant bonds 
with electron donor groups located on the surface o f proteins. IMAC procedures are 
based on bond formation between the imidazoyl side chain o f histidine with 
immobilised Nickel (II) ions. Bacterial homogenates can be passed through and washed 
from the colum n before specifically bound proteins are eluted by the introduction o f 
imidazole. The imidazole acts as a competitive ligand for the metal ions thus disrupting 
the metal-protein interaction resulting in elution from the column.
Although the His-tag system has been widely employed the most important limitation 
with the system is the reduced selectivity o f  the IMAC column for the fusion protein 
when there is an abundance o f  host proteins. This is potentially problematic in situations 
where the recombinant proteins are required for immunoblot analysis or ELISA in 
which patients serum is employed since most patients will have anti-Æ coli antibodies 
resulting in some background signal in the various tests.
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Contamination o f recombinant protein preparations with host proteins can be reduced 
by the inclusion o f  a low concentration o f  imidazole in the binding buffer. The low 
concentration o f  imidazole acts by competing with the aromatic and aliphatic amines o f 
host proteins whilst remaining low enough to facilitate the binding o f the fiision-protein 
to the metal ions. In addition, the use o f  an elution gradient in which the concentration 
o f  imidazole is gradually increased can aid purification by eluting weakly-bound 
bacterial proteins before the His-tagged proteins are eluted.
2.2 Methods.
2.2.1 Preparation o f  Lymphocytes fo r  mRNA Isolation.
Lymphocytes were isolated from whole blood o f  a healthy volunteer using the Accuspin 
System-Histopaque-1077 (Sigma). Histopaque tubes were brought up to room 
temperature prior to use. Fresh, anti-coagulated blood was collected and lymphocytes 
isolated within 2 hours. 15 ml o f blood were poured into the Accuspin tube which was 
then centrifuged at 800 g for 15 min. The plasma layer was aspirated and discarded and 
the m ononuclear band transferred to a sterile centrifuge tube. The cells were suspended 
in 10 ml PBS and centrifuged at 250 g for 10 min. This wash step was repeated twice. 
The cells were resuspended for a final time in 15 ml PBS and the cell count determined 
by microscopy. The cells were aliquotted into 1 ml fractions containing approximately 
1x10^ cells, snap-frozen in liquid nitrogen and stored at minus 80°C until required.
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2.2.2 Preparation o f  Brain Tissue fo r  mRNA Extraction.
Snap-frozen human cerebellar tissue from a neurologically normal individual was 
obtained from the UCL brain bank. 0.5 cm^ sections o f  tissue weighing no more than 50 
mg were prepared under liquid nitrogen and stored individually at -80°C until required.
2.2.3 Total mRNA Isolation.
Total mRNA was isolated using a Micro-FastTrack kit (Invitrogen). Micro-FastTrack 
lysis buffer was prepared by the addition o f  20 pi o f Protein/RNase degrader per ml o f 
lysis buffer. 1 ml o f  isolated lymphocytes or one section o f brain tissue was resuspended 
in 1 ml lysis buffer. The lysate was passed through a 1 cc syringe fitted with a 21 gauge 
needle until the solution was no longer viscous then incubated at 42°C for 20 min to 
promote protein degradation and inactivation o f  ribonucleases. The NaCl concentration 
o f  the lysate was standardised by the addition o f  63 pi 5 M NaCl to each 1 ml o f  lysate 
which was then added to a vial o f  oligo-dT cellulose and left to stand for 2 min. The vial 
was rocked at room temperature for 20 min and centrifuged at 4000 g for 5 min to 
precipitate the oligo-dT cellulose. The supernatant was aspirated from the cellulose and 
discarded. 100 pi o f  elution buffer was stirred into the cellulose slurry, which was 
transferred to a spin-column and centrifuged prior to the addition o f a further 100 pi o f 
elution buffer. 10 pi o f 2 mg/ml glycogen carrier, 30 pi 2 M sodium acetate and 600 pi 
o f absolute alcohol were added to the flow-through from the column and the solution 
frozen on dry ice. The sample was thawed and centrifuged at 16000 g for 15 min at 4°C. 
The supernatant was aspirated and the mRNA resuspended in 2.5 pi o f elution buffer. 
The isolated mRNA was used immediately.
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2.2.4 RT-PCR Amplification o f  a-Enolase and Aldolase C.
The coding sequences for human a-Enolase (GenBank accession no: M l4328) and 
aldolase C (GenBank accession no: NM  005165) were obtained and analysed using 
W ebcutter v2.0 (www.ma.lundberg.gu.se/cutter2). Sense and anti-sense primers were 
designed to flank the complete coding sequence and introduce unique restriction sites 
suitable for ligation into the selected expression vector (Table 2-1). All primers were 
synthesised by Sigma Genosys. RT-PCR was used to amplify cDNA encoding a- 
Enolase and aldolase C using mRNA isolated from lymphocytes and brain respectively.
The RT-PCR reaction was performed using a Superscript one-step RT-PCR kit 
(Invitrogen, UK). The following components were combined in a 0.5 ml tube: 25 pi 2x 
reaction mix, 2.5 pi o f  isolated mRNA, 1 pi sense primer (lOpM), 1 pi anti-sense primer 
(10 pM ), 2 pi RT/Platinum taq HiFi mix. DNase/RNase free water was added to a final 
volume o f 50 pi. A control reaction substituting Ampli/a^ gold for RT/Platinum taq 
HiFi mix was used to confirm the absence o f  genomic DNA in the mRNA preparation. 
In a second control RNA was substituted with 2.5 pi H2O. All RT-PCR reactions were 
conducted under the conditions shown in Table 2-2. RT-PCR reaction products were 
analysed on a 0.7 % agarose gel (Chapter 8).
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Table 2-1: mRNA/cDNA source, primers and predicted length of cDNA encoding 
the target antigens following RT-PCR or PCR.
Protein mRNA'cDNA source Primers Product 
Size (bp)
Required
vector
a-Enolase Human lymphocytes Sense (BamHI site underlined):
5 -CA GGA TCC ATG TCT TAT TCT CAA GAT CCA T-3’ 
Anti-sense (Hind III site underlined):
5 '. GCC CAA GCT TAC TTG (jCC AAG GGG TTT C-3’
1321 pRSETA
Aldolase C Human cerebellum Sense (BamHI site underlined):
5 TCC AGO ATC CAT GCC TCA CTC GTA CC -3’
Anti-sense (Hind III site underlined):
5 - GCT AAA GCT TCA GTA GGC ATG GTT GGC AAT G -3’
1095 pRSETA
PYK I.M.A.G.E clone 
(ID: 3859987)*
Sense (Bam HI site underlined):
5 - CGC GGA TCC ATG TCG AAG CCC C -3’
Anti-sense (Hind III site underlined):
5’ -  AAA GAA TTC TCA CGG CAC AGG AAC AAC ACG - 3 ’
1595 pRSETA
y-Enolase I M A G E  clone 
(ID: 3629603)*
Sense (Xho I site underlined):
5 - GGT ACT CGA GAT GTC CAT AGA GAA GAT CTG GGC -3’ 
Anti-sense (Hind III site underlined):
5’ -  TCC AAG CTT CAC AGC AC A CAC TGG GAT TAC G -3 '
1304 pRSETA
y-Enolase
(Truncated)
I M A G E  clone 
(ID: 3629603)*
Sense (Xho I site underlined):
5 - GGT CAG ACT CGA GAT CCT GGA CTC CCG C -3' 
Anti-sense (Hind III site underlined):
5’ -  TCC AAG CTT CAC AGC ACA CAC TGG GAT TAC G -3 '
1274 pRSETA
I M A G E  clone contains cDNA which was amplified directly by PCR.
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Table 2-2: Reaction conditions for the RT-PCR amplification of a-Enolase and
aldolase C.
First strand synthesis and pre-denaturation PCR amplification Final extension
1 cycle 35 cycles 1 cycle
55°C for 30min Denature: 94°C for 15s 72°C for lOmin.
94°C for 2min Anneal; 60°C for 30s
Extend: 68°C for 1.5min
2.2.5 The Pyruvate Kinase and y-Enolase I. M.A. G. E  Clones.
Bacteria carrying plasmids containing cDNA for PYK Ml (I.M.A.G.E ID: 3859987) 
and y-Enoiase (I.M.A.G.E ID: 3629603) were obtained from the I.M.A.G.E consortium 
library (MRC geneservice, Cambridge). The bacteria were streaked onto SOB 
ampicillin plates and incubated at 37°C overnight. The following day individual 
colonies were grown at 37°C in 5 ml SOB ampicillin over night. 1 ml of bacteria was 
used to produce glycerol stocks which were stored at -80°C. Plasmids were extracted 
from the remaining culture (Chapter 8).
2.2.6 PCR Amplification o f  Pyruvate Kinase and y-Enolase.
The coding sequences of PYK and y-Enolase were analysed using Webcutter v2.0. 
Sense and anti-sense primers were designed to flank the complete coding sequence and 
introduce suitable restriction sites for ligation into the selected expression vector (see 
Table 2-1). A sense primer for the amplification of truncated y-Enolase was designed 10 
bp downstream of the start codon. PCR was conducted using AmpVitaq gold 
polymerase. Plasmid DNA was omitted from the control reaction. cDNA was amplified
83
directly from the plasmid using the reaction conditions shown in Table 2-3. PCR 
products were analysed by electrophoresis in a 0.7% agarose gel (Chapter 8).
Table 2-3: PCR reaction conditions for the amplification of PYK, y-Enolase and
truncated y-Enolase.
Dénaturation Amplification Final extension
1 cycle 35 cycles 1 cycle
94°C for lOmin. Denature: 94°C for 30s. 72°C for lOmin.
Anneal: 55°C for 30s
Extend: 72°C for 2min
2.2.7 Preparation fo r  Expression o f  Recombinant Proteins.
The required pRSET expression vector (A, B or C) was selected following application 
of the translate programme (www.expasy.org/tools/dna) to determine which vector 
would allow expression of full length protein (see Table 2-1).
Following PCR or RT-PCR the amplified DNA fragments were purified from the 
agarose gel and sequentially digested (Chapter 8) using the restriction enzymes 
specified in Table 2-1. The required pRSET expression vector was digested with the 
corresponding enzymes and the DNA and vector ligated. Chemically competent 
TOPI OF’ cells were transformed and selected on SOB containing ampicillin and 
tetracycline. The following day colonies were selected, grown in 5 ml SOB and 
plasmids isolated. Single enzyme restriction analysis was used to determine if ligation
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had been successful. DNA sequencing was performed (Chapter 8) and the sequence 
analysed using the Translate (www.expasv.org) and BLAST 
(www.ncbi.nih.gov/BLAST) tools to confirm ligation into the correct reading frame and 
the identity of the ligated DNA respectively. The pI/MW prediction programme 
(www.expasy.org) was used to predict the molecular weight of the protein. Expression 
vectors containing cDNA in the correct reading frame were used to transform competent 
E. coli BL21 (DE3) pLysS in preparation for expression of recombinant protein.
2.2.8 Expression o f  recombinant antigens
E. coli BL21 (DE3) pLysS (Invitrogen) containing the required plasmid were grown on 
SOB chloramphenicol, ampicillin plates. Seed cultures were prepared the night before 
expression by inoculation of SOB broth containing ampicillin and chloramphenicol with 
a single colony. The following day the cultures were diluted to an optical density (OD) 
of 0.1 in pre-warmed SOB (no antibiotics). These cultures were grown at 37°C to an 
OD of 0.4 to 0.6 and protein production induced by addition of 1 mM IPTG. After 3 
hours the cells were harvested by centrifugation, resuspended in His-binding buffer (8M 
urea, 20mM Tris-HCL, 0.5M NaCl, 20mM Imidazole, ImM 2-mercaptoethanol) 
containing bacterial protease inhibitors (Sigma) and subjected to four 10 second rounds 
of sonication on ice. The crude bacterial homogenates produced were used in 
immunoblots to confirm expression of recombinant protein prior to purification.
2.2.9 Purification o f  Recombinant Antigens.
Each of the recombinant antigens were purified using a HiTrap Chelating column
(Amersham biosciences, UK) and elution gradient as described in Chapter 8. Purified
proteins were subjected to polyacrylamide gel electrophoresis (PAGE) and stained to
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confirm purification. The total protein concentration of each antigen was determined 
and diluted as required (see 2.2.11).
2.2.10 Patients and Controls.
Patient and control samples were investigated for the presence of antibodies against 
recombinant PYK, aldolase C and a and y-Enolase. 131 blinded serum samples were 
kindly provided by Dr R Dale. All diagnoses had been confirmed by the supplying 
clinician although specific clinical details were not available. The number in each group 
is given in Table 2-4.
Table 2-4:Patient and control serum samples used for antibody detection.
Serum Source Number
Healthy control 31
Neurological control 30
Encephalitis 10
Epilepsy 10
Developmental 10
PANDAS 30
OCD 20
TS 20
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2.2.11 A ntibody Detection Using Recombinant Protein Immunoblots.
Unblinded serum samples with and without antibodies against each antigen were 
determined using the method for anti-neuronal antibody detection described by Dale et 
al (2001). Serial immunoblots blots were then conducted using various dilutions of 
recombinant antigen in order to determine the concentration of antigen that gave the 
best discrimination between antibody positive and negative samples. Total protein was 
calculated as described (Chapter 8).
1.5 pg, 5 pg , 6.5 pg, and 13 pg grams of recombinant a-enolase, y-enolase, aldolase C 
and PYK respectively were loaded into a single 4-12 % Bis-Tris gels and (Invitrogen) 
and electrophoresed in MES buffer for 40 minutes prior to transfer and blocking of 
nitrocellulose. Serum samples were diluted 1:300. A positive control antibody was 
included on each blot. Interpretation was conducted blindly by Drs Church, Chapman 
and Dale. Blots were assessed as positive, negative or equivocal. Two similar responses 
were required to label a sample as positive or negative. Equivocal blots (ie no consensus 
reached) were repeated once and counted as negative if no consensus was reached on 
the second blot.
2 3  Results.
2.3.1 Cloning and Expression o f  Human a-Enolase.
2.3.1.1 RT-PCR Amplification and Subcloning o f  Human a-Enolase,
The RT-PCR amplification of human a-Enolase was conducted using mRNA isolated 
from two aliquots of snap frozen lymphocytes. Electrophoretic analysis of the RT-PCR 
reaction mixture demonstrated the amplification of a 1300 bp fragment of DNA (Figure
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2-2). The absence o f DNA in the taq and water controls confirmed the absence of 
genomic or mRNA contamination in the lymphocyte mRNA preparation or reaction 
reagents.
Following ligation, transformation and antibiotic selection eight colonies o f TOPI OF’ 
were isolated. There were no colonies on the negative control plate. Single restriction 
enzyme analysis of the recovered plasmids revealed six o f the colonies contained 
plasmid DNA of approximately 4300 bp size indicating that ligation o f the RT-PCR 
product had occurred (Figure 2-3). These plasmids were designated pRSETAaENO.
A BLAST search using the DNA sequence o f the cDNA confirmed that the encoded 
protein was indeed that o f a-Enolase. Application of the translate program confirmed 
that cDNA had been ligated into the correct reading frame. The predicated molecular 
weight o f the protein was 50 kDa.
Figure 2-2: RT-PCR amplification of hum an a-Enolase
Lane 1 and 2: amplification o f mRNA isolated from lymphocytes. Lane 3: taq control. Lane 4: no mRNA 
added. A fragment o f DNA approximately 1300 base pairs in length was successfully amplified from the 
mRNA isolated from human lymphocytes. Both control reactions were negative signalling that the 
amplified DNA was not from contamination.
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Figure 2-3: Selection of ligated pRSETaAENO.
Plasmids were extracted from transformed E. coli TOPI OF’ and subjected to restriction analysis. Lane 1: 
Un-ligated pRSETA (control). Lanes 2-9: plasmid extracted from transformed colonies. Colonies 2 ,4 , 6-9 
contained a plasmid o f approximately 4300 bases, the predicted length o f successfully ligated 
pRSETAaENO. These plasmids were sequenced to confirm the identity and reading frame o f the insert.
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Figure 2-4: Detecion of recombinant a-Enolase in bacterial homogenate.
Bacterial homogenates o f  pRSETAaENO and pRSETA only were probed with antibodies against a- 
Enolase or His tag. Lane 1 and 3: pRSETAaENO. Lanes 2 and 4 pRSETA only. The dominant band 
recognised by the anti-a-Enolase and anti-His antibodies at 50 kDa was not present in the pRSETA 
control.
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2.3.1.2 Confirmation o f  Recombinant a-Enolase Expression.
Immunoblot analysis of homogenates of induced BL21 (DE3) pLysS containing 
pRSETAaENO or pRSETA control were probed with anti-a-Enolase or anti-His 
antibodies to confirm protein expression. Bands corresponding to the predicted 
molecular weight of recombinant a-Enolase could be clearly seen in homogenates 
prepared from bacteria containing pRSETAaENO when probed with both the anti-a- 
Enolase and anti-His antibodies (Figure 2-4). In contrast, the anti-His antibody did not 
react with the pRSETA control homogenate. A protein in both the pRSETAaENO and 
pRSETA homogenates was detected by the anti-a-Enolase antibody. This protein is 
thought to represent an E. coli protein. The recombinant protein had undergone some 
degradation as evidenced by reactivity of the anti-His antibody with proteins smaller 
than 50 kDa but this was limited in comparison to the reactivity of the intact protein.
2.3.2 Cloning and Expression o f  Human Aldolase C.
2.3.2.1 RT-PCR Amplification and Subcloning o f  Aldolase C.
The RT-PCR amplification of human aldolase C was conducted using mRNA isolated 
from normal human cerebellum. Electrophoretic analysis of the RT-PCR reaction 
mixture demonstrated an amplified DNA molecule of approximately 1100 bp (Figure 
2-5). The absence of DNA in the taq and water controls confirmed that the DNA was 
not amplified from genomic or mRNA contamination in the cerebellar mRNA 
preparation or in the reaction reagents.
90
bp
2000
1000
Figure 2-5: RT-PCR amplification of hum an aldolase C.
Lane 1 : amplification o f mRNA isolated fix>m human cerebellar tissue. Lane 2: taq control. An RT-PCR 
product o f  approximately 1100 base pairs was successfully amplified from mRNA isolated from human 
cerebellum.
Ligation and transformation of TOPI OF’ yielded an excess o f colonies in comparison to 
the control plate. Twenty one o f these colonies were selected to determine if ligation of 
the cDNA had been successful. Single restriction enzyme analysis of seven plasmids 
isolated from transformed TOPI OF’ confirmed successful ligation in all seven colonies 
(Figure 2-6). These plasmids were designated pRSETAaldoC.
Figure 2-6: Restriction enzy me analysis of transfected colonies using H ind lll.
Lane 1 : Unligated, digested pRSET A. Lanes 2-7: Plasmids extracted from transformed colonies. All 
plasmids were approximately 4100 base pairs as predicted. Plasmids were sequenced to check the cDNA 
sequence and reading frame. Successfully ligated plasmids were designated pRSETAaldoC.
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Sequencing and analysis of the DNA confirmed that the encoded protein was aldolase 
C. Application of the translate programme confirmed that the DNA had been ligated 
into the correct reading frame of the expression vector. The predicted molecular weight 
of the recombinant aldolase C was 42 kDa.
2.3.2.2 Confirmation o f  recombinant aldolase C expression.
Immunoblot analysis o f homogenates of induced BL21 (DE3) pLysS containing 
pRSETAaldoC or pRSETA demonstrated the presence o f His-tagged recombinant 
protein in homogenates containing pRSETAaldoC but not in the control preparation 
(Figure 2-7). A smaller protein was also recognised by both the anti-aldolase and anti- 
His antibodies in the pRSETAaldoC homogenate but not in the pRSETA homogenate. 
These smaller proteins are thought to represent breakdown products of the recombinant 
protein.
kD«
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Figure 2-7: Detection of aldolase C in crude bacterial homogenates.
Lanes 1 and 3: Homogenate from E. coli containing pRSETAaldoC. Lanes 2 and 4: Homogenate from E. 
coli containing pRSETA control. The homogenates were probed with anti-His antibody or anti-Aldolase 
antibody. The anti-His and anti-aldolase antibody both detected an antigen at 42 kDa that was not present 
in the control preparation. This dominant band represents recombinant His-tagged aldolase C.
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2.3.3 Cloning and Expression o f  Pyruvate Kinase.
2.3.3.1 PCR Amplification and Subcloning o f  Human PYK from  I.M.A.G.E Clone 
3859987.
PCR amplification of the cDNA contained within the plasmid I.M.A.G.E clone 3859987 
resulted in the amplification of a DNA fragment o f 1600 bp. No DNA amplification was 
detected in the control preparations. Ligation and transformation of TOPI OF’ resulted in 
the production of a number of colonies all of which contained ligated vector as 
determined by single enzyme restriction analysis. Ligated plasmids were designated 
pRSETAPYK. Sequencing analysis confirmed that the DNA encoded PYK. Application 
of the translate progranune confirmed ligation into the correct reading fi*ame of the 
expression vector.
2.3.3.2 Confirmation o f  Recombinant PYK  Expression.
Immunoblot analysis of homogenates of induced BL21 (DE3) pLysS containing 
pRSETAPYK or pRSETA control were probed with anti-PYK or anti-His antibodies to 
confirm protein expression. Both antibodies detected a protein of 62 kDa in the 
pRSETAPYK homogenate. A similar band was not detected when homogenates of the 
control pRSETA E. coli strain were probed. Some proteins were detected by the anti- 
PYK antibody but these all corresponded to a protein recognised in the anti-His lane 
suggesting that these were a result of protein degradation. The concentration of the 
intact protein was greater than that of the smaller proteins.
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2.3.4 Cloning and Expression o f  Recombinant y-Enolase from  I.M.A.G.E Clone
PCR amplification o f cDNA encoding human y-Enolase produced a DNA fragment of 
approximately 1300 base pairs. TOPI OF’ cells transformed with ligated vector were 
analysed by single enzyme digestion. Sequencing analysis confirmed the identity of the 
ligated cDNA and that it had been positioned in the correct reading frame. Crude 
homogenates of induced E. coli (pRSETAyENO and pRSETA control) were probed 
with anti-His and anti-y-Enolase antibody and a protein o f the correct molecular weight 
detected. Purification resulted in the isolation o f a single protein band. During initial 
experiments to detect anti-y-Enolase antibodies in serum samples it was noted that the 
HRP conjugated detector antibody reacted independently with the protein. Thus, a 
truncated version o f recombinant y-Enolase in which the first 10 amino acids were 
removed was produced. This was achieved by repositioning the sense primer 
downstream by 30 base pairs.
y-enolase cDNA was amplified from I.M.A.G.E clone 3629603 using the new start 
primer. An amplified fragment o f approximately 1300 base pairs was obtained and 
ligated into the expression vector. Single restriction enzyme analysis was used to 
confirm ligation. Ligated plasmids were designated pRSETAyENO. Analysis of the 
sequence data using the translate programme confirmed ligation in the correct reading 
.frame.
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2  3.4.1 Confirmation o f  Recombinant y-Enolase Expression.
Homogenates of BL21 (DE3) pLysS containing pRSETAyENO or pRSETA probed 
with anti-y-Enolase and anti-His antibody detected a 49 kDa protein in the 
pRSETAyENO preparation but not in the control. No proteins were detected when 
probed with anti-Human HRP conjugated detector antibody.
2  3.5 Purification o f Recombinant Proteins.
\
Each antigen was successfully purified from the crude bacterial homogenate. An 
example o f pre and post purification is shown in figure (Figure 2-8).
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Figure 2-8: Purifcation of recombinant antigens.
Left hand figure: Pre and post purification o f recombinant a-enolase. Post purification demonstrates clear 
enrichment o f the recombinant antigen from the crude bacterial homogenate. Right hand figure: PAGE 
electrophoresis o f all four purified antigens. Enrichment o f each antigen is clearly shown. The protein 
concentrations used are the same as those used for antibody detection in patients serum.
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2.3.6 Reactivity o f  Patients Serum with Recombinant Putative Antigens.
Each purified antigen was probed with commercial, patient and control antibodies. 
Representative Immunoblots are shown in Figure 2-9.
MW
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Figure 2-9: Recom binant detection using patients serum.
Patients serum was tested for the presence o f antibodies against the four recombinant antigens. 
Representative immunoblots are shown. + = positive control antibody.
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Sera from patients with PANDAS was positive against a-enolase, y-enolase, aldolase C 
and PYK was positive in 23%, 32%, 10% and 35% of samples respectively (Figure
2-10). The incidence of antibodies against recombinant y-enolase in PANDAS was 
significantly higher than the incidence in the healthy control population (32% vs. 6%, x 
= 6.6, p = 0.025) but not significantly different from that of neurological controls (32% 
vs. 20%). Similarly, the incidence of anti-PYK antibodies was significantly different 
from the healthy control group (35% vs. 6%, x ~ 7.9, p < 0.01) but not the neurological 
control group.
Some patients had antibodies against more than one protein. When reactivity against 
any o f the antigens i.e. a positive response against one or more proteins was considered 
there was a significant difference in the incidence of antibodies detected in patient sera 
compared with both neurological (68% vs. 47%, 3.9, p < 0.05) and healthy controls
(68% vs. 26%, X ~ 10.09, p < 0.001). With respect to OCD/TS, we were unable to 
detect a significant difference in the incidence of antibodies against any of the antigens. 
This was also true when a response to any i.e. one or more, antigen was considered.
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Figure 2-10: Reactivity of patient and control serum with recombinant antigens.
Serum from patients with PANDAS ( □  ) or OCD/TS ( □ ) ,  neurological (O  ) or healthy ( g )  controls 
was tested against each of the putative recombinant antigens. There was no significant difference between 
the incidence of antibodies against a-enolase or aldolase C between any o f the groups. There was a 
significantly increased incidence o f antibodies against y-enolase and pyruvate kinase between patients 
with PANDAS and healthy controls. In addition there was a significantly increased incidence of 
antibodies against pyruvate kinase between patients with PANDAS and OCD/TS. Antibodies against any 
of the antigens when considered as a whole were significantly increased in patients with PANDAS 
compared to patients with OCD/ TS, neurological and healthy controls.
2.4 Discussion.
Using a combination o f techniques including ammonium sulphate precipitation, ion 
exchange chromatography and 2D gel electrophoresis the proteins a  and y-Enolase, 
aldolase C and PYK had been identified as candidate auto-antigens recognised by
antibodies in the serum of patients with a host of post-streptococcal neurological 
disorders (Dale et al, 2006). In order to confirm these findings, production of a readily 
available source of each antigen was required to determine the frequency with which an 
antibody response occurred in both patients and controls.
2.4.1 Cloning o f  Human Aldolase C, a-Enolase and PYK.
Cloning of cDNA encoding aldolase C and a-enolase was achieved by RT-PCR of 
mRNA isolated from cerebellar tissue and lymphocytes respectively. The reaction was 
conducted using gene specific primers allowing for the rapid, directional ligation of the 
cDNA into the expression vector. Amplification of cDNA for both proteins was highly 
specific with production of a single band of DNA at the correct length when analysed in 
an agarose gel. Production of cDNA encoding aldolase C and a-enolase was simplified 
by the absence of splice variants of these two proteins.
In contrast, PYK is known that two forms of the protein exist; MI and M2. These two 
proteins differ only by the inclusion of Exon 9 or 10 in isoform Ml and M2 respectively 
(Takenaka, et al, 1991). The use of flanking primers would have been unsuitable for the 
production of cDNA from tissue mRNA, as amplification of both forms of the enzyme 
would have occurred. The size of the reaction products would have been similar, the M2 
isoform being only fifteen bases longer than Ml. This is too small to enable their 
separation via agarose gel electrophoresis. As a result an alternative method of cloning 
was required i.e. oligonucleotide screening of phage libraries. It was fortuitous that a 
clone containing the entire coding sequence for PYK Ml was available fi’om the MRC 
geneservice. The acquisition of this clone ensured that cDNA encoding the correct PYK
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isoform could be amplified while avoiding the cost, inconvenience and potential 
problems associated with mRNA purification and amplification and library screening.
2.4.2 Cloning and Expression o f  Recombinant y-Enolase.
Unexpected problems were encountered during the detection of recombinant human y- 
Enolase. Amplification of the cDNA from the I.M.A.G.E clone proved straightforward. 
However, problems were associated with the detection of the recombinant protein by 
immunoblot. Negative control lanes containing anti-Human IgG only (no primary 
antibody) showed evidence of binding. This had not occurred in the cases of aldolase C, 
a-Enolase or PYK and was not due to interaction with bacterial protein since the 
detector antibody did not react with crude homogenates of control E. coli in earlier 
experiments. The reasons for this phenomenon are unclear. Crude analysis (not shown) 
of the sequence encoded fi’om the pRSETA start codon and the cDNA suggested an area 
of homology between IgG and the recombinant protein. Possible solutions to this 
problem involve the use of a different vector, the cleavage of the His-tag from the 
existing protein in an attempt to interrupt non-specific interaction between anti-Human 
IgG and the recombinant protein and the production of a truncated protein using 
downstream gene specific primers. We opted to produce a slightly truncated version of 
the protein by amplifying the cDNA fi"om the IMAGE clone using a sense primer 30 
base pairs downstream of the start codon in the cDNA. The resulting recombinant 
protein was still detected by the commercial anti-y-enolase antibody and patients’ sera 
whilst preventing interaction with anti-human IgG-HRP detector antibody. Thus it 
appears that the removal of 10 amino acids fi-om the N terminal of the protein did not 
disrupt the epitope required for antibody recognition.
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2.4.3 The Purification o f  Recombinant Proteins.
Production, purification and detection of all four recombinant proteins was successfully 
achieved. In some cases there was some proteolytic degradation of the recombinant 
proteins as evidenced by the number of proteins detected by the specific anti-His 
antibody. However in all cases the production of the mature protein was far in excess of 
these smaller fragments. In the case of a-enolase, the antigen-specific antibodies also 
reacted with the control bacterial homogenates. It is possible that the detected proteins 
represent the bacterial homologues of the human antigens.
The purification of the recombinant antigens using an elution gradient was successful. 
The recovery of the recombinant proteins was much greater than that of any 
contaminating proteins. Whilst the protein preparations used here proved suitable for 
antibody detection by immunoblot, the existence of homologous E. coli proteins and the 
presence of anti-E. coli antibodies in the serum samples may demand refinement of the 
purification protocol if other assays such as ELISA are to be employed. One simple 
method which may merit investigation would be to separate the bacterial homogenate 
into soluble and insoluble proteins prior to IMAC. This could remove some 
contaminating E. coli proteins in a simple step prior to column purification. 
Alternatively a yeast-based expression system could be employed. It may be that 
antibodies against yeast are found with less frequently than against E. coli which is a 
common human commensal organism.
2.4.4 Recognition o f  Recombinant Protein by Patients ’ Sera.
Since the identification of potential auto-antigens in post-streptococcal disease of the
nervous system by Dale et al (2006a) one group has attempted to determine the
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significance of the antibody response towards these proteins (Singer et al 2005). Their 
study utilised commercially available preparations of a-enolase, y-enolase, aldolase C 
and PYK in immunoblots and concluded that antibodies against these proteins did not 
differentiate between clinical groups. However methodological concerns have been 
raised with regard to these findings specifically pertaining to the quantity and type of 
antigen used (Dale et al, 2006b).
In earlier publications the presence of antibodies against the putative antigens using 
basal ganglia immunoblots had a specificity and sensitivity of 100 % and 93 % 
respectively in acute SC and 69 % and 93 % in chronic SC (Church et al, 2002). A 
similar study of patients with TS revealed antibodies against the putative proteins in 24 
% of patients compared with 4 % of controls whilst a study of patients with OCD 
detected antibodies in 42% of patients compared to 10% of controls. However, no study 
has yet examined the frequency with which antibodies against these putative proteins 
can be detected in cohorts of PANDAS patients or how recombinant forms of the 
antigens fare in a diagnostic test.
With respect to the data presented here it is encouraging to see that there is a significant
increase in incidence of antibodies to y-enolase, PYK and ‘all antigens’ in patients with
PANDAS. These findings are less compelling than the figures presented for SC
however, the less stringent diagnostic criteria for the diagnosis of PANDAS may by
associated with a more heterogeneous cohort of patients. In addition since clinical
details were not available it was not possible to correlate antibody positivity with the
stage of the illness or the severity of the symptoms. Since PANDAS is said to follow a
‘saw tooth’ pattern of exacerbations, a serum sample taken during a ‘trough’ could
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potentially give a negative result. Future study would require investigation of serial 
samples for the presence of antibodies together with clinical evaluation at each time 
point using a recognised disease severity score to allow the correlation of antibody 
positivity and clinical status.
In a recent study Kansy et al (2006) used quantitative immunoblotting to evaluate the 
antibody response against PYK in patients with TS with or without OCD. They detected 
an elevated antibody response in those patients with newly acquired GABHS infection 
and symptomatic TS. With regard to the data presented, while there was a greater 
number of OCD/ TS patients with an antibody response this was not significantly higher 
than that seen in the control populations. When OCD and TS were considered 
separately, 30 % and 60 % of patients were positive respectively. To further delineate 
the importance of anti-PYK antibodies in TS it will be important to better define the 
study population with regard to symptom severity and precipitating factors. In addition 
the use of quantitative techniques such as ELISA or quantitative immunoblotting may 
be required to demonstrate elevated antibody titres in study groups compared to 
controls.
One of the major problems with the study appears to be the frequency with which 
antibodies can be detected in the sera of controls. Antibodies against ‘any antigen’ could 
be detected in 47 % of neurological controls and 26 % of healthy controls. These figures 
are significantly higher than those quoted by other investigators and may reflect a 
problem with the recombinant immunoblot assay.
103
Although every effort was made to optimise the immunoblotting method used here a 
few points should be borne in mind. Firstly, no alteration was made to the dilution of 
serum which was maintained as that used in papers in which basal ganglia immunoblots 
were used i.e. 1 in 300. A systematic investigation of serum dilutions is required to 
determine if alternative dilutions provides enhanced differentiation between patient and 
control groups. In addition, alteration of the concentrations of the antigens in the 
immunoblots may have a similar effect. It may be of benefit for those samples deemed 
to be positive for antibodies to be re-screened at increasing dilutions to determine if it is 
possible to further differentiate between groups. These methods may reduce the number 
of positives to a level more in keeping with that of the literature.
Secondly, while negative control groups were included in the study (ie healthy and 
neurological controls) it may have been prudent to include an antigen control in the 
form of an irrelevant recombinant protein. Testing the samples fi*om each group against 
this protein would have highlighted the degree to which false positivity occurred as a 
result of non-specific interaction with contaminating proteins.
Another consideration is that of epitope specificity. It is possible that a discreet antibody
response against a specific epitope is required in order to produce the disease. An
example of this phenomenon has been demonstrated for patients with CAR. Adamus et
al (1996) detected antibodies against a-enolase antibodies in 11/16 (69 %) patients with
CAR compared to 10/110(11 %) of healthy controls. However, in a later study epitope
mapping demonstrated an epitope recognised by patient but not control samples
(Adamus et al 1998). To demonstrate this in post-streptococcal disorders would require
epitope mapping of each antigen. In a similar manner, despite the fact that the nature of
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the antigens was determined by probing denatured proteins, a subgroup of patients 
antibodies may require a conformational epitope in order to recognise the antigenic 
target.
Finally, by their nature, immunoblots are subject to interpretation. Whilst the blots here 
were all interpreted by three investigators, there is likely to be variability in the 
interpretation of the immunoblots. A quantitative assessment of antibody incidence by 
ELISA would provide a quantitative cut off against which a positive test can be clearly 
defined.
In 2006, Dale et al showed increased rates of apoptosis in neuronal cell cultures 
incubated with commercial antibodies against each of the putative antigens. However, 
the data presented here suggest that the antibodies are not detected with increased 
frequency in PANDAS. Unless there is a role for antibodies against a specific epitope 
(see above) it is unlikely that pathogenic antibodies can be found in such a high 
proportion of healthy and neurological controls. Indeed, the high incidence of the 
antibodies in the neurological control groups cast doubt on any hypothesis that the 
antibodies represent anything other that an epiphenomenon of a separate disease 
process.
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3 Chapter 3: Identification of Neuroleukin, a 56 kDa antigen recognised by
antibodies in the serum and CSF of patients with opsoclonus-myoclonus.
3.1 Introduction.
Opsoclonus-myoclonus may have a post-infectious or paraneoplastic aetiology. We 
received serum samples from two patients with post-infectious CM who on routine 
testing for anti-neuronal antibodies were found to have antibodies against a 56 kDa 
antigen. We sought to determine the nature of the antigen using a proteomic approach 
consisting of ammonium sulphate fractionation (ASF), ion exchange (lEX) 
chromatogr^hy and two-dimensional (2D) gel electrophoresis. These techniques had 
already been used to characterise y and a-Enolase, PYK and aldolase C as potential 
auto-antigens in post-streptococcal neurological disease (Dale et al, 2006). We then 
aimed to determine the frequency with which the antibody response occurred in a cohort 
of paediatric and adult OM. An introduction to the principles of some of the techniques 
used in this chapter is provided while a summary of the experiments can be found in the 
following flow sheet.
Cloning and expression of recombinant neuroleukin (Sections 3 3.5 
- 3  3 8)
Determination of frequency of anti-neuroleukin response in patients 
with opsoclonus-myoclonus and controls (Sections 3 3.11 -  3.3.12).
Determination of antibody frequency in the CSF of adult 
paraneoplastic opsoclonus-myoclonus (Section 3 3 19).
Set up of anti-neuroleuki n ELISA and determination of antibody 
frequency using established cut off value (Sections 3.3.13 -  
3.318).
Punfication and identification of the 56 kDa as neuroleukin by 
ammonium sulphate fractionation. 2D gel electrophoresis, ion 
exchange chromatography and m ass spectrometry (Sections 3 3.3 
- 3  3 4 )
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3.1.1 Ammonium Sulphate Fractionation.
Ammonium sulphate fractionation represents a useful technique as it provides a 
convenient method by which complex solutions of protein can be simplified. The 
distribution of charged molecules on the surface of a protein and the properties of the 
solvent into which it is dissolved (including ionic strength and pH) governs the 
solubility of proteins in a given solution. Thus, manipulation of the solvent can alter the 
solubility of the proteins dissolved within. This principle is exploited by ASF. Addition 
of ammonium sulphate to a solution results in the precipitation of proteins. These 
precipitated proteins can be separated from the solvent by centrifugation. Further 
addition of ammonium sulphate to the supernatant results in the precipitation of more 
soluble proteins. This process can be continued until the solvent is saturated. ASF is not 
suitable for the single step purification of proteins, especially when the starting protein 
solution is a homogenate of complex tissue, thus further purification steps would be 
required. However, by taking large fractions in the first instance (0, 25, 50, 75, 100 % 
ammonium sulphate saturation) the fraction containing the target protein can be selected 
and further dissected using smaller ammonium sulphate fractions spanning that 
saturation. The result of ASF is the production of a number of fractions, in one of which 
the protein of interest will be relatively enriched.
i. 7.2 Ion Exchange Chromatography.
Similarly to ASF, lEX chromatography was previously utilised in the characterisation of
potential auto-antigens (Dale et al, 2006). lEX chromatography is a method of protein
purification that exploits the electrostatic attraction between the surface charge of a
protein molecule and charged groups displayed on the matrix of a chromatography
column. During protein separation, the lEX column and proteins are equilibrated in the
107
same buffer, thus the charged groups displayed on the surface of the column matrix and 
the proteins in solution will be associated with ions from the buffer. Introduction of the 
protein solution into the column displaces ions from the column and the resulting 
electrostatic attraction between matrix and protein results in bond formation, the 
strength of which is governed by the overall charge on the surface of a given protein 
molecule. This characteristic is exploited during the elution of proteins from the column 
which is achieved by increasing the ionic strength of the buffer by the addition of NaCl. 
The added ions compete with the proteins for the polar groups of the matrix. At a given 
ionic strength a protein will no longer be attached to the column and will be 
successfully eluted. The gradual increase of NaCl allows those proteins that are weakly 
bound to the column to be eluted earlier than strongly bound proteins. The result is the 
differential elution and thus separation of proteins. Important aspects of lEX 
chromatography include the selection of an appropriate column, the isoelectric point of 
the protein of interest and the pH of the buffer system. The use of a buffer with a pH 
one unit above or below the pi of the protein of interest will result in the production of a 
net negative or positive charge respectively. This influences the choice of the lEX 
column, which exist as anionic or cationic exchangers. Anionic exchanger’s bind 
negatively charged proteins, while cationic exchangers bind positive proteins. Selection 
of the pH and column can ensure that the protein is retained on the column for later 
elution. In other instances a pH may be selected at which a protein has the same charge 
as the column. In this instance the protein will not bind and be collected in the flow­
through while other proteins will remain attached to the column (Scopes, 1993).
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3.2 Methods.
3.2.1 Patients with Opsoclonus-myoclonus.
Serum and CSF from the index paediatric cases of OM were supplied by Dr R Dale. 
These samples had been taken as part of the patient’s diagnostic work up. Serum from 
further paediatric cases of OM were kindly supplied by Professor A Vincent. The 
collection of serum had the appropriate ethical approval however some demographic 
data was not available. Clinical information was withheld until requested. Samples from 
7 adult patients with POM were kindly supplied by Professor J Dalmau. Specific 
clinical details were not available.
3.2.2 Control Patients.
Serum samples from children with and without neurological disease were supplied by 
Dr R Dale. The details are listed in Table 3-1. CSF samples from 14 adult patients with 
inflammatory neurological disease were provided by Dr G Giovannoni. These samples 
consisted of three encephalitis and 11 multiple sclerosis samples.
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Table 3-1: Clinical details of serum and CSF samples (adult and paediatric)
Sample Number
Serum
Paediatric
Opsoclonus-myoclonus 11
Inflammatory conditions 16
ADEM 8
Multiple sclerosis 4
Rasmussen’s encephalitis 2
Cerebral lupus 2
Non-inflammatory neurological conditions 14
Post-streptococcal disorders. 8
Sydenham’s Chorea 4
Glomerulonephritis 4
Healthy controls. 16
CSF
Paediatric
Opsoclonus-myoclonus 2
Inflammatory conditions. 16
ADEM 8
Multiple sclerosis 4
Rasmussen’s encephalitis 2
Cerebral lupus 2
Non-inflammatory neurological conditions 14
Adult
Opsoclonus-myoclonus 7
Encephalitis 3
Multiple sclerosis 11
ADEM = acute disseminated encephalomyelitis
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3.2.3 Sample Preparation.
Human brain tissue provided by the UCL brain bank was snap-frozen within 12 hours of 
acquisition. Wistar rat brains (B&K) were isolated and snap-frozen immediately after 
death. Brain tissue was homogenised in a Teflon homogeniser with Tissue protein 
extraction reagent (1 ml/g brain tissue) (Tper, Pierce, UK) and mammalian protease 
inhibitors (50 pl/g brain tissue) (Sigma, UK). The homogenate was centrifuged at 
10,000g at 4°C for 12 minutes, the supernatant was aliquotted and stored at -80°C until 
required.
3.2.4 Ammonium Sulphate Fractionation.
Ammonium sulphate ft-actionation was performed using 300 pi of rat brain supernatant 
dissolved in 10 ml distilled water containing 50 pi Tris-HCl (pH 9.0). Ammonium 
sulphate was added in stages to give the following saturations: 0-20 %, 20-40 %, 40-60 
%, 60-80 % and 80-100 % as described (Scopes, 1993). At each stage the solution was 
stirred for 1 hour and proteins precipitated by centrifugation at 10,000g for 20 minutes. 
The precipitated proteins were stored at -80°C until required and the supernatant used 
for further ASF. Precipitated proteins were resuspended, subjected to PAGE, stained or 
immunoblotted and probed with the serum from the index patients to determine which 
fraction contained the antigen of interest.
3.2.5 2D Gel Electrophoresis
2D electrophoresis was conducted using the Powerease 500 system and preformed pH
3-10 isoelectric focussing (lEF) gels (Invitrogen, UK). The 40-60 % ammonium
sulphate fraction of rat neuronal tissue was buffer exchanged into sodium phosphate
buffer (pH 7.0) and concentrated using the Microcon system (Millipore, UK). Proteins
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were initially separated by lEF according to pi. 100 pi of sample was suspended in 125 
pi lEF sample buffer (Invitrogen, UK) and 25 pi 0.05 % SDS. Samples were left to 
stand at room temperature for at least 20 min before continuing with further steps. 
Anode and cathode buffer (Invitrogen, UK) were prepared by dilution in water and 
allowed to reach room temperature. A single pH 3 to 10 lEF gel was washed in cathode 
buffer before being locked into the gel tank. Cathode buffer was then poured into the 
inner chamber and anode buffer into the outer chamber. 10 pi of lEF marker was added 
to the first lane. 25 pi of sample was then loaded into each subsequent well. lEF was 
conducted as follows:
Step 1 Step 2: Step 3:
Ihr at lOOv Ihr at 200v 30min at 500v
18mA 18mA 18mA.
Once the focusing was finished the gel was removed fi-om its plastic casing and 
immersed in fixing solution (Appendix 2) for 30 min. The solution was then drained and 
the gel washed a minimum of three times in water. The gel was immersed in Coomassie 
blue stain for 5 minutes followed by destain solution. De-staining was continued for 
approximately 1.5 hr. The gel was then placed in deionised water until required.
Following separation by pi proteins were separated by PAGE. A lane of stained focused 
proteins were cut from the lEF gel and immersed in solubilisation buffer for a minimum 
of 5 min. In the meantime a 1 well PAGE gel was prepared. A section of filter paper 
was cut to match the dimensions of the well in the PAGE gel and labelled 10 and 3 to
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correspond with the pH of the lEF gel. Once the proteins in the cut section of the lEF 
gel had been re-solubilised the gel was rinsed in the same MOPS buffer (Invitrogen, 
UK) as that used to prepare the PAGE gel. The running buffer was then decanted and 
the filter paper applied to the gel strip. The gel was then transferred using the filter 
paper and positioned into the large well of the PAGE gel so that it was flush with the 
well bottom. The proteins were then subject to electrophoresis as described for standard 
PAGE (See chapter 8). Gels were subjected to silver staining or immunoblotted as 
required. Proteins of interest were subjected to in-gel trypsinolysis and identified using 
a Q-Tof hybrid quadrupole / orthogonal acceleration time of flight spectrometer (See 
section 3.2.7).
3.2.6 Ion Exchange Chromatography.
lEX was performed using the ÀKTA fluid phase liquid chromatography (FPLC) system 
and the anionic exchange HiTrap Mono Q FF (5 ml) column (Amersham Biosciences). 
Proteins from the 40-60 % ammonium sulphate fraction were exchanged into lEX 
binding buffer (20 mM Tris-HCl pH 8.35) and injected onto the column. Proteins were 
eluted over a gradient of increasing ionic strength by injection of elution buffer (20 mM 
Tris-HCl 1.5 M NaCl pH 8.35) 0-100 % over 50 ml. Fractions were collected using a 
Frac-900 fraction collector and those corresponding to peaks on the chromatogram 
selected, subjected to PAGE and immunoblotted. The 56 kDa antigen was detected 
using serum from patient one. Further lEX was conducted using proteins from the initial 
lEX separation and a lower pH binding buffer (20 mM Tris-HCl pH 8.0). Proteins were 
subjected to gradient elution as described using 20mM Tris-HCl 1.5M NaCl pH 8.0.
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Fractions were collected, subjected to PAGE and silver stained or immunoblotted as 
required. Silver stained proteins were subjected to in gel trypsinolysis and identified 
using a Q-Tof hybrid quadrupole / orthogonal acceleration time of flight spectrometer 
(see section 3.2.7).
3.2.7 Mass Spectrometry.
Proteins were digested from silver stained PAGE gels following 2D gel electrophoresis, 
lEX or immunoaffinty chromatography. The antigens were identified by MOLDI-TOF 
mass spectrometry by Dr R. Wait using the following method:
In gel trypsinolysis was performed using an Investigator Progest (Genomic Solutions, 
Huntingdon, UK) robotic digestion system, as previously described (Wait et al, 2001). 
Tandem electrospray mass spectra were recorded using a Q-Tof hybrid quadrupole / 
orthogonal acceleration time of flight spectrometer (Micromass, Manchester, UK) 
interfaced to a Micromass CapLC capillary chromatograph. Samples were dissolved in 
0.1% aqueous formic acid, and 6 pi injected onto a Pepmap CIS column (300 pm x 0.5 
cm; LC Packings, Amsterdam, NL), and washed for 3 min with 0.1 % aqueous formic 
acid. The flow rate was then reduced to 1 pi per min, the stream select valve was 
switched to the data acquisition position, and the peptides were eluted into the mass 
spectrometer with an acetonitrile / 0.1% formic acid gradient (5% to 70 % acetonitrile 
over 20 minutes).
The capillary voltage was set to 3,500 V, and data dependant MS/MS acquisitions were 
performed on precursors with charge states of 2, 3 or 4 over a survey mass range 540-
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1200. Known trypsin autolysis products and keratin-derived precursor ions were 
automatically excluded. The collision voltage was varied between 18 and 45 V 
depending on the charge and mass of the precursor. Product ion spectra were charge- 
state de-encrypted and de-isotoped with a maximum entropy algorithm (Max Ent, 
Micromass). Proteins were identified by correlation of uninterpreted tandem mass 
spectra to entries in SwissProt/TREMBL, using ProteinLynx Global Server (Versions 1 
and 1.1, Micromass). One missed cleavage per peptide was allowed, and the fragment 
ion tolerance was set to 100 ppm. Carbamidomethylation of cysteine was assumed, but 
other potential modifications were not considered in the first pass search. All matching 
spectra were reviewed manually, and in cases where the score reported by ProteinLynx 
global server was less than 100, additionsd searches were performed against the NCBI 
database using MASCOT. Identifications were verified by manual sequencing using the 
MassLynx program Pepseq (Micromass).
3.2.8 Production o f  Neuroleukin Specific Antibodies.
Anti-neuroleukin (NLK) antibodies were raised in New Zealand rabbits (CovalAb, UK) 
as described (Niinaka et al 1998). The peptide YFQQGDMESNGKYITK was used as 
the immunogen as this sequence is common to both human and rat NLK.
3.2.9 NLK Detection Using Cultured Neurones.
Live neurones were kindly cultured by Dr S Griffin using the following method:
Pregnant Sprague Dawley rats were sacrificed by cervical dislocation, foetuses were
extracted and cortical tissue removed. Neurones were isolated by mechanical and
enzymatic digestion of tissue. Cells were suspended at a final concentration of 1 x 10^
cells/ml in neurobasal medium (NB) containing 2 mM glutamine, 25 pM Glu and 2 %
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B27 serum supplement. Glass cover slips previously coated in 0.01 % poly-D-lysine 
were incubated in 100 pi of NB containing 2 mM glutamine, 62.5 pM Glu 2 % B27, 5 
% horse serum and 5 % foetal bovine serum. 100 pi of neuronal suspension was 
suspended directly onto the coverslips and left for 1 hr prior to the addition of 2 ml 
supplemented NB. The cells were housed at 37°C in an atmosphere of 5 % CO2/ 95 % 
air at < 90 % humidity. Cell medium was replaced on day 3 and 7 with 1 ml of 
astrocyte-conditioned NB containing cytosine arabinoftiranoside at a final concentration 
of 10 pM.
On day 10 cells were rinsed in Tris- buffered saline (TBS) and fixed by addition of ice- 
cold methanol for lOmin. The methanol was removed, the cells rinsed in blocking 
buffer (TBS, 1 % BSA, 10 % serum (corresponding to the species of the secondary 
antibody) for 2 hours at room temperature. Blocking solution was removed and rabbit 
anti-NLK (diluted 1:1000) or patient serum (diluted 1:70) applied and incubated 
overnight at 4°C. Cells were washed twice in TBS and incubated with the appropriate 
secondary antibody (Swine anti-rabbit TRITC, rabbit anti-human IgG/FITC) (Dako) for 
1 hr at room temperature. The cells were washed and stained with 0.01 % 4, 6- 
diamidino-2-phenylindole HCL (DAPI) for 10 minutes. Cells were mounted on glass 
cover slip slides using 10 pi of citiflour (Dako). Omission of primary and secondary 
antibodies and omission of cells were used as negative controls. A patient with anti-Hu 
antibodies was used as a control to determine if the cell membrane had been left intact. 
Cells were visualised by confocal microscopy using a Zeiss 510 laser scanning confocal 
microscope.
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3.2.10 Production o f  Recombinant Neuroleukin.
mRNA was isolated from human cerebellum using the Micro-FastTrack kit (Invitrogen) 
(See section 2.2.3). cDNA was synthesised using human cerebellar mRNA and gene 
specific primers designed to amplify the entire open reading frame of NLK (GenBank 
Accession No: K03515). The following primers were used. (Sense primer, 5’- 
CCGGAATTCATGGCCGCTCTCTCACCC-3 ' {EcoRI site underlined). Anti-sense 
primer 5’-GCCCAAGCTTATTGGACTCTGGCCTCG-3’ (//zW///site underlined).
The RT-PCR reaction was performed using a Superscript one-step RT-PCR kit 
(Invitrogen, UK). The following components were combined in a 0.5 ml tube: 25 pi 2x 
reaction mix, 2.5 pi of isolated mRNA, 1 pi sense primer (10 pM), 1 pi anti-sense 
primer (10 pM), 2 pi RT/Platinum tag HiFi mix. DNase/RNase free water was added to 
a final volume of 50 pi. A control reaction substituting Amplimg gold for RT/Platinum 
taq HiFi mix was used to confirm the absence of genomic DNA in the mRNA 
preparation. In a second control RNA was substituted with 2.5 pi H2O. The RT-PCR 
reaction was conducted as described in section 2.2.4.
Amplified cDNA was gel-purified and ligated into the pRSETB bacterial expression 
vector (Invitrogen, UK) prior to transformation of E. coli TOPI OF’. Following 
antibiotic selection purified plasmids were analysed by single restriction enzyme 
analysis, sequenced (Chapter 8) and the Translate and BLAST programmes used to 
confirm the identity of the DNA and its ligation into the correct reading frame. 
Successfully ligated plasmids (designated pRSETBNLK) were used to transform E. coli 
BL21 (DE3) pLysS (Invitrogen, UK) in preparation for expression of the recombinant 
protein.
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3.2.11 Expression and Purification o f  Recombinant NLK.
Expression of recombinant NLK (rNLK) was conducted using the method described 
(See sections 2.2.8). A crude bacterial homogenate was used in immunoblots to confirm 
recombinant protein expression prior to purification. Purification of rNLK was 
conducted using the method described for other recombinant antigens (see section 
2.2.9).
3.2.12 Detection o f  Anti-NLK Antibodies.
Recombinant NLK was subjected to PAGE and immunoblotted. Serum samples were 
diluted 1:300 in 0.2 % milk 0.9 % saline solution. CSF samples were diluted 1:50 in 0.2 
% milk 0.9 % saline solution. anti-NLK antibodies were used as a positive control. 
Secondary HRP-conjugated detector antibodies (swine anti-rabbit IgG and rabbit anti­
human IgG) were diluted 1:5000 in 0.2 % milk 0.9 % saline solution and washed after 1 
hour. Blots were developed using Enhanced chemiluminescence (ECL).
3.2.13 Determination o f  Sequence Homology.
A comparison of the amino acid sequences of human NLK and streptococcal proteins 
was conducted using the protein-protein BLAST application 
(www.ncbi.nih.gov/BLAST) set with the default parameters.
3.2.14 Anti-His, Antigen and Detection Antibody Concentration fo r  rNLK ELISA.
Initial attempts to produce a NLK ELISA for the detection of anti-NLK antibodies in
patient’s serum were based upon the use of the anti-His antibody to selectively bind
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rNLK from crude homogenates of E. coli pRSETBNLK. During the initial set up of the 
ELISA the rabbit anti-NLK antibody was used as a positive control.
Anti-His antibodies were diluted 1:500 in 0.05 M carbonate buffer and 100 pi used to 
coat 36 wells. The plate was incubated overnight at 4°C. The following day the plate 
was rinsed 3 times in 0.9 % saline and incubated with 300 pi of 2.5 % bovine serum 
albumin (BSA) for Ih at room temperature. 100 pi of crude homogenate of E. coli 
containing pRSETBNLK was diluted 1:10 to 1:5000 in 0.9 % saline containing 0.2 % 
(w/v) BSA. Omission of bacterial homogenate was used as a negative control. Each 
dilution was incubated with 2 wells containing anti-His antibodies. After incubation at 
room temperature for 1 hr the plate was washed 6 times in ELISA wash solution (0.2 % 
BSA, 0.9 % saline 0.05 % tween). Rabbit anti-NLK antibodies were diluted 1:1000 or 
1:5000 in wash solution and 100 pi applied to each well. Omission of anti-NLK 
antibodies was used as a ftirther control. The plate was incubated at room temp for 1 hr, 
washed 6 times and incubated with 100 pi of swine anti-rabbit HRP conjugated detector 
antibody (Dako) diluted 1:1000 in wash solution. The plate was left for 1 hr at room 
temp, washed as previously described and developed by the application of 100 pi of 3, 
3’, 5, 5’- tetramethylbenzidine (TMB) liquid substrate (Sigma). The reaction was 
continued as appropriate, stopped by the application of 50 pi 1 M HCl and read using 
the Wallac 1420 multilabel counter. Absorbencies were averaged and plots produced 
using Microsoft Excel.
Following the selection of appropriate dilutions of capture antibody and antigen
preparation patients’ sera was tested. Serum from 9 patients with OM and 9
neurologically normal controls were investigated. Serum from patient 1 was always
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included as a positive control as were rabbit anti-NLK antibodies. The ELISA was 
conducted as described above using anti-His capture antibody at 1:500 dilution, a serum 
and antigen dilution of 1:100 and rabbit anti-Human IgG-HRP diluted 1:1000. The 
mean absorbency was calculated. Patients were considered to have a positive ELISA 
result for the presence of anti-NLK antibodies if the absorbencies were greater than the 
mean +2 times the standard deviation of the average absorbencies of the 9 normal 
control serum. As each plate was internally controlled using serum from patient 1 the 
development time of the assay was not standardised at this stage.
Following the initial investigations with patients’ sera an appropriate dilution of the 
HRP-conjugated antibody was sought. Anti-His antibodies diluted 1:500 in 0.05 M 
carbonate buffer were used to coat the ELISA wells. Serum from patient 1 was applied 
in duplicate wells at dilutions of 1:100, 1:500 and 1:1000. A blank well containing no 
patient serum was included. HRP-conjugated antibody was incubated with the well at 
the following dilutions 1:1000, 1:2000, 1:4000 and 1:8000. The absorbencies were 
determined, the mean calculated and divided by the corresponding blank value to 
determine which dilution gave the greatest difference between signal and background. 
The appropriate dilution of antibody was selected and the ELISA using patients’ sera 
repeated using serum diluted 1:100 from the same 18 patients and controls and a HRP- 
conjugated antibody diluted 1:8000. Sera were considered to contain anti-NLK 
antibodies if the mean absorbencies over two wells were greater than the mean +2SD of 
the absorbencies of the controls.
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3.2.15 Determining Factors Responsible fo r  Background Signal
To determine areas of possible improvement a number of blank wells were set up to 
systematically determine factors responsible for the production of background signal. 
Each well was set up with the appropriate solution added in the order described in the 
initial ELISA set up (see section 3.2.14). When a layer of the ELISA was omitted wash 
solution was substituted. Anti-His antibodies were diluted 1:500 in 0.05 M carbonate 
buffer. Serum from patient 1 was diluted 1:100 in 0.9 % saline, 0.2 % BSA and HRP 
conjugated antibody diluted 1:8000 in 0.9 % saline, 0.2 % BSA. When anti-His 
antibody was omitted purified rNLK was incubated in 0.05 M carbonate buffer at a 
dilution of 1:10 and the blocking and detection steps continued as normal. As a final 
experiment the anti-His capture antibody was substituted for the rabbit anti-NLK 
antibody diluted 1:500 in 0.9 % saline, 0.2 % BSA and the experiment conducted using 
patients’ sera and the appropriate blank.
3.2.16 Comparison o f  Blocking Agents
It was noted that some patients and controls had a raised signal when serum was 
incubated with blocked blank wells. To determine whether rabbit serum or BSA 
provided a more suitable blocking agent the serum of patients and controls was tested 
against wells blocked with 2.5, 5 and 10% solutions of BSA or normal rabbit serum 
(Sigma) in saline. Serum from 7 patients and controls was diluted 1:100 in 0.9 % saline, 
0.2 % BSA or 0.9% saline/ 0.2 % normal rabbit serum and detector antibody was 
diluted at 1:1000 0.9 % saline, 0.2 % BSA or normal rabbit serum. Results were 
expressed as the mean absorbance of the samples +/- the SD.
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3.2.17 Comparison o f  Crude Bacterial Homogenates and His-Purifled rNLK
To determine whether His-purified rNLK represented an improved antigen preparation 
over crude homogenates of pRSETBNLK an ELISA was conducted using anti-His 
antibodies (1:500), crude or purified rNLK (1:10), serum (from 7 anti-NLK negative 
samples) diluted 1:100 and anti-human HRP antibodies diluted 1:8000. All dilutions 
used 0.9 % saline, 0.2 % normal rabbit serum. The ELISA was conducted as described 
in section 3.2.14, the absorbencies averaged and compared for the crude and purified 
rNLK preparations. The results were analysed using a Mann Whitney U test to 
determine if there was a statistically significant difference in the absorbencies obtained 
through the use of the different rNLK preparations.
3.2.18 Use o f  Antigen Coated Wells.
As an alternative to the use of a capture antibody we investigated the principle of using
purified rNLK applied directly to the wells. As an initial investigation antigen was
applied to the wells at a dilution of 1:50 in 0.05 M carbonate buffer and incubated
overnight at 4°C. Wells were blocked and washed as described above. The serum of the
index patient was tested at a dilution of 1:100, 1:300, 1:500 and 1:1000 and the
appropriate dilution selected. The rabbit anti-human HRP antibody was also tested at
various dilutions. A dilution of 1:300 for the patient’s serum and 1:1000 for a HRP
conjugate was selected. All dilutions used 0.9 % saline, 0.2 % normal rabbit serum.
Opsoclonus-myoclonus and normal control patients were compared. All sera were also
run against blank wells (Rabbit serum coated, no antigen). In one experiment the blank
value was subtracted from the test wells to allow for non-specific binding. When more
than one ELISA plate was required serum from patient 1 was included and absorbencies
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from other patients expressed as a percentage of the absorbance of patient 1 to allow for 
intra-assay variation. Patients were considered to have a positive result by ELISA if the 
absorbance value was greater than the mean + 2SD of the average absorbencies of the 
control group. The coefficient of variation (CV) for the assay was determined at the 
same time using the serum of 1 patient and 2 controls, each repeated 16 times each and 
the average of the CVs taken.
3.3 Results.
3.3.1 Case History One
One week after a febrile illness and pharyngitis, a previously well 10 year-old girl
presented with chaotic, multi-directional eye movements. The opsoclonus progressed
rapidly over the next few days, and was complicated by myoclonus and ataxia. In
addition, she became profoundly insomniac and suffered a change in personality. Her
speech became pressured, disinhibited and inappropriate, and she experienced auditory
hallucinations. MRI brain, EEG and echocardiogram were normal. CSF revealed 85
lymphocytes/mm^, CSF protein of 0.48 g/dl and normal CSF glucose and lactate. CSF
gram stain was negative. The patient was started on acyclovir and ceftriaxone pending
CSF PCR for herpes simplex, varicella and enterovirus all of which were negative. No
organisms were cultured from the CSF. Extensive serology for mycoplasma, influenza.
Chlamydia, adenovirus, Epstein-Barr virus and measles virus were all negative or
normal. ASOT was elevated (400 lU/ml, normal < 200 lU/ml). Throat culture was
negative. Biochemistry including copper metabolism, liver and thyroid ftmction tests
were normal. Urinary vanillylmandelic acid and homovanillic acid were negative.
Ultrasound of abdomen and metaiodobenzylguanidine scanning were normal. She was
treated with ACTH 40 U/day for 3 days, and then oral prednisolone 2 mg/kg for 2
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weeks. In addition, she was given penicillin 500 mg bd for 2 weeks. Within 1 week, her 
sleep pattern and movement disorder significantly improved although her mood became 
labile. Convalescent ASOT performed 6 weeks after the first was < 200 lU/ml. The 
prednisolone dose was tapered over 6 weeks, during which time her opsoclonus and 
movement disorder steadily improved leaving only a residual intention tremor. One year 
after her illness, she had no neurological signs, although she remained hyperactive, a 
finding not reported prior to the onset of the neurological disease.
3.3.2 Case History Two
A 16 year-old girl presented with a neurological disorder one week after a febrile illness
characterised by pharyngitis and rash. The neurological dysfimction was initially
characterised by gait disturbance followed by generalised myoclonus. In addition, her
eye movements demonstrated jerky pursuit and reduced pupillary response to
accommodation. MRI brain, EEG, EGG and echocardiogram were normal. CSF was
acellular with CSF protein 0.5 g/dl and normal CSF glucose and lactate. CSF PCR for
herpes simplex, varicella and enterovirus were negative. Serology for mycoplasma.
Chlamydia, Epstein-Barr virus, HIV, Lyme disease and measles virus were all negative
or normal. ASOT was elevated (800 lU/ml, normal < 200 lU/ml) although throat culture
was negative. Biochemistry including copper metabolism, urine toxicology, liver and
thyroid ftmction tests, autoimmune profile and immunoglobulins were all normal.
Urinary vanillylmandelic acid and homovanillic acid were negative and an ultrasound of
the abdomen was normal. She was treated with oral prednisolone and 2 g/kg intravenous
immunoglobulin over 24 hours. Her illness was resistant to the initial treatment, and
progressed over the next month with the development of frank opsoclonus. In addition,
her illness became complicated by the development of psychiatric symptoms,
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particularly anxiety and low mood. A repeat ASOT 6 weeks after the first had fallen to 
235 lU/ml. The patient remained on 2 mg/kg of prednisolone for 2 months. The dose 
was tapered over a further 2 months. A repeat MRI at 6 months remained normal. Her 
CM had completely resolved by 9 months, although 2 years later she required 
rehabilitative care for her impaired motor function resulting from her prolonged 
admission.
3.3.3 Anti-neuronal Antibody Detection
Antibodies in the serum and CSF of both patients reacted with a 56 kDa protein present 
in both human and rat brain homogenate (Figure 3-1, A) which was also present in the 
40 to 60% ammonium sulphate fraction of rat brain (Figure 3-1, B).
B
Figure 3-1: Antibodies against a 56 kDa protein in serum and CSF of OM patients.
A: Lane I: Control serum. Lane 2: Serum from patient 1. Lane 3 and 4 serum and CSF from patient 2 
respectively. Arrow: 56 kDa antigen. The common lower band represents human IgG within the tissue 
preparation. B: Comparison o f human and rat brain. Serum from patient 1 detects the 56 kDa antigen in 
both human brain (lane 1) and the 40-60 % ammonium sulphate fraction of the rat brain homogenate (lane 
2) (Arrow). The lower band (lane 1) represents human IgG in the preparation o f the tissue homogenate.
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3.3.4 Identification o f  the 5 6 kDa A uto-antigen.
Following ammonium sulphate fractionation the 40 to 60 % rat brain fraction was 
subjected to further purification. 2D gel electrophoresis achieved good separation of 
proteins. Immunoblotting showed that the 56 kDa protein had an approximate pi of 8.0. 
Figure 3-2 shows the immunoblot and silver stained gel, with the candidate 56 kDa 
protein arrowed. The protein was removed from the gel, digested and subjected to Q- 
TOF mass spectrometry.
kDa I kDa
56 • -  ^  56
BA
3 ---------------  pH   10 3   pH   10
Figure 3-2: 2D gel electrophoresis of neuronal proteins following ammonium 
sulphate fractionation (40-60% saturation).
A: Silver stained gel. B; Immunoblot probed with serum from patient 1. A strong reactivity could easily 
be identified on the immunoblot with a corresponding protein clearly visible on the stained gel. The 
protein was digested from the gel and subjected to mass spectrometry.
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Figure 3-3: Two rounds of ion exchange chromatography were used to purify the 
56 kDa antigen.
A: Partially purified proteins from the 40-60 % ammonium sulphate fraction were separated. Peaks I - 5
were selected, separated by PAGE and the gel stained or immunoblotted and probed with serum from 
I
patient 1. Immunoblotting showed that the antigen was contained within peak 2. B: The proteins from 
peak 2 were subjected to further lEX under different conditions. A number o f peaks were selected and the 
antigen again detected by immunoblotting. The antigen was contained in peak 6. A silver stain showed a 
single protein at 56 kDa, the molecular weight o f the antigen. No other proteins were observed in the gel. 
The band was digested and subjected to mass spectrometry. (N H 4 = pre-IEX 40-60 % ammonium 
sulphate fraction o f rat brain homogenate).
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The protein was also purified using lEX. The 40 to 60% ammonium sulphate fraction 
was subjected to ion exchange chromatography in 2 stages. During the initial step, the 
56 kDa candidate auto-antigen eluted when the elution buffer equalled 55 % of the 
elution gradient. During the second stage of elution the 56 kDa protein eluted when the 
elution buffer equalled 10% of the elution gradient. This approach allowed purification 
of the 56 kDa auto-antigen to near purity (Figure 3-3). Both proteins isolated by 2D gel 
electrophoresis and lEX were identified as neuroleukin following Q-TOF mass spectral 
analysis.
3.3.5 Comparison o f  Human NLK and Streptococcal Glucose-6-phosphate Isomerase 
(GPI).
There is significant sequence homology between human NLK and streptococcal GPL A 
BLAST comparison of the amino acid sequences of human NLK with streptococcus 
pyogenes GPI revealed 89 exact amino acid matches (23% of total sequence), with 147 
close matches (38%) (expected chance homology was less than 1 x 10"^ ).
3.3.6 RT-PCR Amplification o f  Human Neuroleukin.
Electrophoresis of the RT-PCR reaction mixture revealed a dominant band of 
approximately 1700 bp. In addition, a number of smaller reaction products could be 
visualised ranging from approximately 900 to 1200 bp. No reaction product could be 
seen in the taq or water control suggesting that the amplified fragments were not a result 
of contamination of the mRNA preparation with genomic DNA or due to contamination 
of the reagents.
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3.3.1 Analysis o f Ligated pRSETB
Thirteen colonies were isolated from the plates containing bacteria transformed with 
ligated pRSETBNLK. A large number of colonies were also found on the negative 
control plate (pRSETB only) suggesting that double digestion of pRSETB had not been 
particularly efficient. Single restriction enzyme analysis of the recovered plasmids 
demonstrated that 2 of the 13 colonies contained a plasmid into which the cDNA had 
been successfully ligated (Figure 3-4).
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Figure 3-4: Selection of pRSETBNLK
Plasmids were extracted from transformed E. coli TOPI OF’ and subjected to restriction analysis. Top 
figure: 13 colonies were selected and digested with EcoRI. Lane 1: Un-ligated pRSETB (control). Lanes
2-13: plasmid extracted from transformed colonies. Colonies 12 and 13 appeared to contain ligated 
plasmid. Lower figure: Plasmids from colonies 12 and 13 were redigested and ligation confirmed. Lane 1 
= Un-ligated pRSETB control.
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3.3.8 Sequencing o f  Successfully Ligated pRSETB
Sequencing of the ligated pRSETB was conducted in order to check the cDNA 
represented the complete open reading frame of NLK (according to the published 
sequence: GenBank Accession No: K03515) and to determine whether the cDNA had 
been inserted into the correct reading frame. Sequence analysis of the two ligated 
plasmids revealed that they both contained cDNA encoding the entire reading frame of 
neuroleukin and that the sequence was in the same reading frame as the start codon on 
pRSETB.
3.3.9 Production and Purification o f  Recombinant Neuroleukin.
Immunoblots of crude bacterial homogenates in which protein expression had been 
induced were probed with anti-His antibody to detect the recombinant protein. The anti- 
His antibody detected a protein with a molecular weight of 60 kDa. The antibody did 
not recognise a protein when used to probe bacterial homogenates containing pRSETB 
only. rNLK was efficiently isolated from homogenates of BL21 (DE3) pLysS 
pRSETBNLK by IMAC using an elution gradient (Chapter 8). A stained PAGE gel of 
the homogenate, flow-through and elution fi-actions revealed that a protein of 
approximately 60 kDa was eluted from the column during the elution phase. The eluted 
protein was immunoblotted (see chapter 8) and probed with both anti-His and rabbit 
anti-NLK antibodies. Both antibodies reacted with the 60 kDa protein confirming that it 
was rNLK.
3.3.10 Probing Purified Neuroleukin with Patients serum
An immunoblot of purified rNLK probed with a rabbit anti-neuroleukin antibody and
serum from the index patients used to identify the antigen revealed that both antibodies
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reacted with a protein at approximately 60 kDa thus confirming that the patient had an 
immune response against NLK. In addition a number of bands were recognised by the 
patients’ sera both above and below the 60 kDa antigen. These proteins had not reacted 
with the anti-His antibody in the previous experiment, nor did they react with the rabbit 
anti-neuroleukin antibody, therefore these proteins most likely represent contaminating 
E. coli proteins that had not been removed by the purification process.
3.3.11 Probing rNLK with Sera from  a Cohort o f  OM Patients.
We tested the sera of a further nine patients with OM for the presence of anti-NLK 
antibodies, seven of which were positive (9/11 total (82 %)) (1 result was equivocal). 
Five of 54 (9%) controls showed reactivity with rNLK (cerebral lupus n = 1, normal n = 
3, encephalitis n = 1). A representative blot is shown (Figure 3-5, A) There was a 
significant difference between patients and controls (Fischer’s exact test, p = <0.0001). 
The sensitivity and specificity for the western blot was 82 and 91% respectively. CSF 
was only available for the index cases but both patients showed reactivity against rNLK. 
The blot using CSF from patient 2 is shown (Figure 3-5, B). Only 1 of 30 (3%) CSF 
controls was positive. This patient had cerebral lupus with 
cognitive impairment and gait disturbance.
131
Table 3-2: Paediatric OM patient details and investigation results for anti-NLK
antibodies.
Patient Sex Aetiology
Immunoblot 
Serum CSF ELISA Cell Staining
1 F Post-infectious + + + +
2 F Post-infectious + + + +
3 F Neuroblastoma - NA - -
4 M Idiopathic +/- NA + -
5 F Post-infectious + NA + +
6 F Neuroblastoma + NA + NA
7 F Post-infectious + NA + +
8 F Idiopathic + NA + NA
9 M Post-infectious + NA + NA
10 F Idiopathic + NA - NA
11 M Idiopathic + NA - NA
NA -  Not available.
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Figure 3-5: Immnuoblot using patients serum and CSF.
A; Immunoblot o f rNLK probed with patients serum. NLK: Rabbit anti-NLK (positive control). Lane 1: 
Patient 1 (index case). Lanes 2 - 7 :  Patients 3 - 8 .  Anti-NLK antibodies were detected in all samples 
(arrow head) with the exception o f patient 3 (who was anti-Hu positive). B: Antibodies against rNLK 
were detected in the CSF. Lane 1 : Rabbit anti-NLK (positive control). Lane 2: CSF from patent 2. Lanes
3- 7:  Control CSF.
3.3.12 Immunocytochemistry
Permeabilisation steps were omitted during the preparation of freshly cultured rat
neurones in an attempt to determine whether NLK is present on the plasma membrane.
No cytoplasmic or nuclear staining was observed in neurones stained with the rabbit
anti-NLK antibody. An area of bright staining continued around the perimeter of the cell
(Figure 3-6). Serum from patients 1, 2, 5 and 7 produced a staining similar pattern to
that o f rabbit anti-NLK. Serum from patients 3 and 4 were negative. No nuclear
staining was produced when the serum of patient 3 (Hu positive) was used suggesting
that the integrity o f the plasma membrane had been maintained during the preparation
of the slides. The results largely correlated with those produced with immunoblots of
rNLK with the exception o f serum from patient 4 who was positive on immunoblot
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(Figure 3-5, A. Lane 3) but negative on immunofluoresence. Secondary antibodies and 
serum from one healthy control and one patient with acute disseminated 
encephalomyelitis (ADEM) did not stain the cells.
Figure 3-6: lmmuDocytochemistr>.
Live rat neurones were incubated with A: rabbit anti-NLK antibody and B: serum from patient 1. Staining 
can clearly be seen localised to the plasma membrane. Staining o f the cytoplasm did not occur as 
evidenced by the separation o f the nucleus (blue) from the stained membrane.
3.3.13 The His Capture ELISA.
As proof of principle rabbit anti-NLK antibodies were used in the initial stages of 
ELISA development. Signal was raised above background when rNLK was diluted 
1:1000 and 1:100 for 1:1000 and 1:5000 dilutions of anti-NLK antibodies respectively. 
Signal continued to increase with application of lower antigen dilutions when rabbit 
anti-NLK antibodies were applied at either 1:1000 or 1:5000 dilutions suggesting that 
the rabbit anti-NLK antibodies were in excess of the antigen. Omission of rabbit anti-
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NLK established that there was no interaction of the detector antibody with the other 
components of the ELISA (See Figure 3-7).
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Figure 3-7: Investigating the use of a capture antibody (anti-His) ELISA for the 
detection of anti-NLK antibodies.
Anti-His capture antibody was diluted 1:500. Antigen (crude bacterial homogenate o f E. coli 
pRSETBNLK) was incubated with capture antibodies at various dilutions. Rabbit anti-NLK antibodies 
were used at 1:1000, 1:5000 dilutions or omitted (control). Swine anti-rabbit HRP detector antibodies 
were diluted 1:1000. Background signal was similar for both dilutions o f  anti-NLK antibody when no 
antigen was incubated in the wells. Signal began to rise with an antigen dilution o f  1:1000 and 1:100 
when the anti-NLK antibodies were diluted 1:1000 and 1:5000 respectively. The continued rise in signal 
at lower dilutions o f  antigen suggests that there was an excess o f anti-NLK antibodies over antigen. 
Signal produced when anti-NLK antibodies were omitted was minimal thus excluding cross-reactivity 
with other components o f the ELISA.
The ELISA was repeated with the substitution of rabbit anti-NLK antibodies with
patient and neurologically normal control serum diluted 1:100. Anti-His antibodies were
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used at a dilution of 1:500 and antigen 1:100. Development of this ELISA produced 
disappointing results. High signal approaching the limits of the linear range of the 
detecting equipment were obtained within 5 min of development.
3.3.14 Determination o f  Detector Antibody Concentration.
The application of detector antibody was investigated at increasing dilutions and the 
signal to noise ratio calculated. A 1:8000 dilution of detector antibody was found to 
give the highest signal to noise ratio (Figure 3-8).
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Figure 3-8: Determination of optimal detector antibody dilution.
To determine the appropriate dilution o f  detector antibody doubling dilutions were applied to wells 
containing anti-His antibody (1:500), rNLK (1:10) and patients serum diluted 1:100, 1:500 or 1:1000. 
Values were expressed as a ratio o f  signal compared to blank well (no serum). A dilution o f  1:100 
patients serum and 1:8000 HRP conjugated antibody provided the greatest discrimination between signal 
and background.
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A repeat o f the ELISA using patient and control serum demonstrated a difference 
between patient and control groups (Figure 3-9). However the results o f this ELISA 
correlated poorly with those demonstrated by immunoblotting with rNLK and the 
colour reaction was complete in less than 5 minutes. In addition, absorbencies were 
raised in some blank wells (no NLK) when serum was applied. This problem had not 
been apparent during the development o f the ELISA using the rabbit anti-NLK 
antibodies and suggested an underlying problem with the ELISA technique. This 
problem was not remedied by the application o f patient serum at increased dilutions 
(1:500, 1:1000). In fact discrimination between the two groups grew weaker with 
increasing serum dilution.
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Figure 3-9: Initial NLK ELISA using patients serum.
An ELISA was conducted using anti-His antibody (1:500), rNLK (1:10), patient (n=9) or control serum 
(n=10) diluted 1:100 and rabbit anti-Human HRP (1:8000). A significant difference was observed 
between patients and controls (Fischer’s exact - p = 0.0345), however the rapid development times and 
the poor correlation with the previous immunoblot resulted in attempts to improve the method.
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3.3.15 Determining Factors Responsible fo r  Background Signal
A series o f controls were established to determine which, if  any o f the elements o f the 
initial ELISA set-up were causing raised background. There was some cross-reaction o f 
the rabbit anti-Human HRP detector antibody with the anti-His capture antibody (Figure
3-10, panel 3). This binding was not a result o f reactivity with the blocking agent since 
wells coated with BSA only remained blank (Figure 3-10, panel 11). The well 
containing anti-His antibodies, patient serum and detector antibody (no antigen) 
produced absorbencies far in excess o f other blank wells (Figure 3-10, panel 1). This 
effect may have been a result o f the number o f layers employed in the ELISA since 
substitution o f the anti-His antibody for rabbit anti-NLK antibodies resulted in the 
production o f similar background noise (data not shown). It is o f  interest that incubation 
o f BSA coated wells with patients serum and HRP conjugated antibody produced raised 
background (Figure 3-10, panel 9). This observation led to the investigation o f BSA as a 
suitable blocking agent (see section 3.3.16). Finally, antigen coated wells incubated 
with patient serum and HRP conjugated antibody also resulted in the production o f 
signal (Figure 3-10, panel 5). This could have been a result o f the non-specific reaction 
against the blocking agent as already described. However, the use o f antigen coated 
wells was also investigated (see section 3.3.18).
138
2 3 A 6 7 8
,HRP
.1. lii w LJ
^H R P
Lli ù
,HKP
lij u
OD-2JD O D - Q j O D >O J
AnU-His c^ tu re  antibody Antigen coated veil*
X
i
Y
r
•  BSA (Blodbnc4c»<)
A d O £
9 10 11 12
.HRP
LÜ LiJ Ù u
O D «O J
Blocking agent only
Figure 3-10: Determination of factors contributing to background signal in rNLK 
ELISA.
3.3.16 Comparison o f  Blocking Agents.
It was noted that some sera produced high absorbance values in blank wells (containing 
no antigen). Thus the suitability o f BSA as a blocking agent was compared to that of 
normal rabbit serum. It was clear that rabbit serum was a much more suitable blocking 
agent. Background absorbance was lower than that produced in BSA-coated wells at all 
percentages (2.5, 5 and 10 % w/v). In addition use of rabbit serum produced more 
consistent absorbance (Figure 3-11). 2.5 % rabbit serum incubated for I hr at room 
temperature was sufficient to block the wells since any increase in the concentration of 
the blocking agent did not reduce the level of background.
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Figure 3-11: Comparison of BSA and rabbit serum as blocking agents.
Sera from 7 patients and controls incubated with wells blocked with increasing concentrations o f  blocking 
solution. The mean absorbance and the standard deviation were calculated for both blocking agents at 
each concentration. Rabbit serum was found to produce a consistently lower background signal than 
BSA.
3.3.17 Comparison o f  Crude Bacterial Homogenates and IMAC Purified rNLK  
Comparison o f the mean signal produced when crude and purified NLK were tested 
with control sera resulted in a non-statistically significant difference between 
preparations (Mann Whitney U = 21 p = 0.279) (Figure 3-12). The lack o f significance 
may be attributed to the rise in signal produced by one sample upon use o f purified 
NLK. However the mean absorbance produced by the purified preparation (0.683) was 
lower than that o f the crude preparation (0.859) with a fall in absorbance in 6/7 (86 %) 
o f the sera tested. Thus purified NLK was selected as a more suitable preparation for the 
ELISA.
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Figure 3-12: Comparison of crude homogenates of E. coli pRSETBNLK and 
purified rNLK in the NLK ELISA.
The mean absorbance for the ELISA using the crude antigen preparation was 0.859. The mean 
absorbance fell to 0.683 when the purified antigen preparation was used. The difference between the two 
preparations was not statistically different (Mann Whimey = 21 p = 0.279).
3.3.18 Use o f  Antigen Coated Wells.
The investigations into the cause o f the background noise suggested that the use o f 
antigen coated wells may provide an alternative form of ELISA. The initial 
investigations suggested that an antigen dilution o f 1:50, a serum dilution o f 1:300 and a 
detector dilution o f 1:1000 would be suitable. The final ELISA utilised the serum o f 11 
patients and 13 controls (Figure 3-13). Anti-NLK activity was detected in 7/11 (63%) 
patients using the determined cut o ff (mean + 2SD). The difference between patients 
and controls was statistically significant (Fisher’s exact test -  p = 0.003). Although 
rabbit serum had been selected as a more suitable blocking agent some background 
signal was produced in blank wells (block only). To allow for this non-specific binding,
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blank values were subtracted from the absorbencies produced in test wells (antigen 
coated). In this assay serum from 8/11 (72%) patients had a signal greater than the mean 
+ 2SD o f the anti-NLK negative controls. The difference between patients and controls 
was statistically significant (Fisher’s exact test -  p = 0.0002). The CV of the assay was 
calculated as 15%. The CV for the positive sample was 3%. The CV for the two 
negative samples was 33 and 26%. The results o f the assay appeared to correspond to 
the intensity o f the signal on the immunoblot o f rNLK. Patients 3, 8 and 9 were negative 
for serum anti-NLK antibodies and a review o f the immunoblot shows that the serum 
from these patients produced a faint band against rNLK on immunoblot (Patient 3 is 
shown. Figure 3-5 A, lane 3).
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Figure 3-13: Final rNLK ELISA.
An ELISA was conducted using antigen-coated wells blocked with rabbit serum. Patient serum was 
diluted 1:300 and the detector antibody (rabbit anti-human HRP) diluted 1:1000, Results were expressed 
as a percentage of the signal produced by patient 1 to allow for interassay variation. In one experiment 
blank values were not subtracted. In this experiment 63 % of patients had a positive result (greater than 
the mean +2SD the absorbance of the controls). On subtraction of the blank 72 % of patients had a 
positive result. In both experiments there was a significant difference between patients and controls 
(Fisher’s exact test; p = 0.003 (no blank subtracted) and Fisher’s exact test; p = 0.0002 (blank 
subtracted)). The result correlated well with the immunoblotting. Patients 3, 8 and 9 were negative on the 
ELISA. On the immunoblot patient 3 was negative and patients 8 and 9 reacted weakly against rNLK.
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3.3.19 Anti-NLK Antibodies in the CSF o f  Adults with Paraneoplastic Opsoclonus- 
myoclonus.
A  total of seven CSF samples from adults with POM and 14 control CSF samples were 
analysed for the detection o f anti-NLK antibodies. A total of 2/7 samples from the 
patient group had anti-NLK activity in contrast to 0/14 control CSF samples.
3 4
Figure 3-14: Detection of anti-NLK antibodies in the CSF of patients with OM.
Lane 1: Rabbit anti-NLK antibody (positive control). Lanes 2 - 5 :  CSF from adults with POM. Lanes 6 
9: Representative CSF controls. Antibodies against NLK were detected in 2/7 patients (29 %) (Lanes 2 
and 4) compared to 0/14 controls.
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3.4 Discussion.
3.4.1 The Index cases.
We have described the first two documented reports o f post-streptococcal OM. Both 
patients presented with a one-week history o f febrile illness and upper respiratory tract 
infection prior to the onset o f OM. Both patients had indirect evidence o f streptococcal 
infection by way o f a raised ASOT.
The cases were both unusual with regard to the histories. Based on the extreme 
differences between the mean age o f onset o f adult and paediatric OM it is unclear as to 
which o f these the index cases should be classified. As discussed, paediatric OM occurs 
within the first 36 months o f life while adult disease is most common over 50 years o f 
age. The patients fit more easily into the ‘idiopathic’ definition applied to OM as used 
by Bataller et al (2001) Most importantly, the OM in both index patients all but 
resolved following the instigation o f immunomodulatory therapies. Given these 
observations and the findings o f published reports it may be more appropriate to regard 
OM as a rare post-infectious disease occurring at any age onto which the occurrence o f 
adult and paediatric paraneoplastic OM can be superimposed. Given the post­
streptococcal aetiology implied in the pathogenesis o f OM in the index cases it will be 
o f interest to determine the frequency with which streptococcal infection proceeds the 
onset o f OM in other non-paraneoplastic cases.
3.4.2 Protein Purification and Identification.
As has been discussed, consistent anti-neuronal antibody markers o f both paraneoplastic
and post-infectious OM have not been described. Both patients reported in this thesis
had antibodies against a 56 kDa protein found in homogenates o f neuronal tissue. Given
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the history o f upper respiratory tract infection and the molecular weight o f the 
recognised antigen these antibodies were initially thought to react with PYK (See 
chapter 2). However, testing o f serum against recombinant PYK was negative, thus 
protein purification techniques were applied to purification o f the target antigen.
Ammonium sulphate fractionation was used to provide a  partially purified preparation 
o f rat brain homogenate in which the 56 kDa antigen was relatively enriched. Simple 
2D gel separation allowed the clear identification o f  a protein which was well separated 
fi*om contaminating proteins and recognised by patients serum. The separation was 
sufficient to allow the protein to be digested fi’om the 2D gel for characterisation by 
mass spectrometry without the need for further purification. As an additional check the 
56 kDa protein was purified using lEX chromatography. The two proteins isolated by 
independent methods (2D and lEX chromatography) were analysed by mass 
spectrometry and in both cases the protein was identified as NLK. These findings were 
confirmed using rNLK. In addition by probing immunoblots o f rNLK we were able to 
demonstrate the presence o f  anti-NLK antibodies in the CSF o f both patients. This 
suggests that the antibodies have access to the antigen within the nervous system and 
thus the potential to induce disease.
3.4.3 Cohort Findings: Immunoblotting.
Serum samples from a group o f 9 paediatric patients with OM were investigated for the
presence o f anti-NLK antibodies 7 o f whom were found to be positive (9/11 total (82
%)) . Two patients in the cohort had an underlying neuroblastoma, five were post-
infectious and two were ‘idiopathic’ i.e. no tumour detected. It would appear from these
initial investigations that an anti-NLK response may be a  marker o f OM irrespective o f
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aetiology. ECL was used for the development o f the immunoblots since the total 
volume o f sera from the patients was limited and this method o f development allows the 
use o f smaller volumes o f sample in the immunoblot. The majority o f control 
immunoblots were easily interpretable. However, immunoblots using patient sera were 
a little harder to interpret. A consistent response against rNLK was observed, but 
multiple bands were detected. These additional bands may have been related to the 
presence o f degraded recombinant proteins, contaminating bacterial proteins or the 
sensitive nature o f ECL development. The subjective nature o f immunoblotting leaves 
the technique open to some differences in interpretation.
3.4.4 Cohort Findings: rNLK ELISA.
The use o f rNLK immunoblots demonstrated the existence o f anti-NLK antibodies in a 
number o f patients with OM. However, given the objective nature o f the interpretation 
o f the blots an ELISA was devised in an attempt to provide a quantitative assay for 
detection o f anti-NLK activity.
Due to concerns regarding the existence o f residual E. coli proteins in the rNLK 
preparation initial attempts at ELISA development utilised anti-His coated wells. Since 
the anti-His antibody is highly specific it was thought that this approach would prevent 
E. coli contamination. In fact the capture method was hindered by the non-specific 
interaction o f some o f the components, and was later adapted for the use o f antigen 
coated wells.
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To establish the cut-off value, serum samples from neurologically normal controls were 
selected. This may have artificially lowered the cut-off value as patients with 
neurological disease may have anti-NLK activity. Ideally, a further group o f 
neurological controls should have been included to further test the cut-off value. Any 
positive samples could then be tested against rNLK by immunoblot to determine if a 
specific anti-NLK antibody response could be detected. With this caveat in mind, the 
ELISA demonstrated an anti-NLK response in 8/11 (73 %) patients. The results 
correlated roughly with the findings produced by immunoblot (see Figure 3-5 and 
Figure 3-13).
These initial investigations highlight a potentially frequent anti-NLK response in the 
serum o f  OM patients. Further investigations with a larger cohort are required to 
confirm the frequency with which anti-NLK antibodies occur. However, it is clear that 
the initial studies using sera from the index cases have led to the identification o f 
antibody association in OM.
3.4.5 NLK.
NLK has both intracellular and extracellular function and is therefore an example o f a 
moonlighting protein. Intracellularly NLK acts as the cytosolic enzyme, GPI, which 
catalyses the interconversion o f glucose 6-phosphate and fhictose 6-phosphate in the 
glycolytic pathway. Extracellularly the protein has various functions including the 
regulation o f cell migration during tumour invasion and metastasis (autocrine motility 
factor, AMF) and cell maturation (maturation factor, MF).
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The name NLK was ascribed as a result o f the neurotrophic effects observed when the 
protein was incubated with cultures o f spinal and sensory neurones (Gumey et al, 
1986). Direct evidence for the role o f NLK in the nervous system is limited. Most 
studies involved the detection o f NLK expression in cell lysate, or the effects o f the 
protein in vitro. It has been suggested that within the nervous system NLK is secreted 
and that its extracellular effects are mediated though interaction with the cell surface 
glycoprotein gp78 (Hage et al, 2000). It is also possible that a form of NLK is 
associated with the plasma membrane. This is supported by the fact that NLK has been 
detected within synaptosomal membrane preparations (Knull and Fillmore, 1985) and 
that other glycolytic enzymes have been shown to be associated with the plasma 
membrane (Nakajima et al, 1994). Evidence for the association o f NLK with the plasma 
membrane is supported by the staining o f neuronal cultures as described in this thesis.
A function for NLK in the nervous system can be inferred from its role in neurological 
disease. Antibodies against NLK have been implicated in motor-neurone disease 
(Gumey et al, 1984), interference with its function has been implicated in AIDS- 
associated neuropathology (Lee et al, 1987) and mutation in the NLK gene has been 
connected with neurological myopathy and mental retardation (Kugler et al, 1998). 
Thus, NLK is evidently required for the normal development and function o f the 
nervous system and interference with that function has the capacity to cause disease. 
However the clinical phenotype o f motor-neurone disease and OM are very different 
and it is unclear if  anti-NLK antibodies could cause such distinct disorders.
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3.4.6 NLK: A Reasonable Antigenic Target?
It may be o f use to review the criteria antibody-mediated autoimmunity and for 
molecular mimicry provided in sections 1.5 and 1.7.2 respectively. The criteria satisfied 
by anti-NLK antibodies as agents in antibody-mediated disease and molecular mimicry 
are summarised in Table 3-3 and Table 3-4 respectivly.
Table 3-3: Criteria for pathogenicity of NLK and NLK antibodies.
Criterion Evidence
Antibodies directed against the appropriate tissue 
type
Passive transfer o f  antibodies/
Immunisation
Immunotherapy
NLK is found in association with the neuronal 
surface but its expression is not restricted to the 
nervous system.
Neither passive transfer o f  antibodies nor 
immunisation o f  animals has been shown to cause 
OM
Limited evidence to suggest that symptoms 
improve following immunomodulatory therapies.
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Table 3-4: Criteria satisfied for anti-NLK antibodies in molecular mimicry.
Criterion Evidence
Epidemiological association with infectious agent.
Presence o f antibodies.
An antigenic mimic must be identified.
Animal model.
Limited evidence. Many infectious agents have 
been associated with OM but evidence is limited to 
case reports. An extensive epidemiological 
investigation has not been conducted.
The data presented here suggest that anti-NLK 
antibodies may frequently be associated with OM. 
NLK is an evolutionary conserved protein found on 
the surface o f  streptococcus.
An animal model o f  OM has not been produced.
As discussed in the introductory chapter a number o f anti-neuronal antibodies have been 
described although only a few have been shown to be pathogenic. In the majority of 
reports, antibodies against intracellular targets such as Hu, NOVAl and CDR62 have 
not been shown to cause disease, possibly because the target antigen is normally 
inaccessible. However, antibodies targeting cell surface proteins (Anti-Ach receptor, 
anti-VGCC) have been shown to cause disease. The extracellular location o f NLK and 
its association with the plasma membrane make it an accessible antigenic target.
As has been discussed, patients with ‘idiopathic’ OM often have substantial if  not 
complete resolution o f their neurological symptoms which is consistent with the lack of 
pathological findings at autopsy (see sections 1.2.4 and 1.11). Thus, it is unlikely that 
the pathological mechanism o f the disease is cell death. Alternatively, antibodies may 
subtly interfere with normal neuronal function following interaction with surface bound
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NLK or from disruption o f the interaction o f NLK and gp78. Such a mechanism would 
not produce characteristic inflammatory features or neuronal cell loss.
Since NLK represents a component o f the glycolytic pathway it is unsurprising that it is 
found in all cells. There are a number o f explanations as to why antibodies against this 
globally expressed protein could cause neurological disease. One answer may lie in 
accessibility o f the antigen as discussed previously. It may be that in most tissues NLK 
is only expressed within the cytoplasm o f cells, in which case the antibodies may only 
interfere with the secreted or cell surface form o f the protein and thus exert pathogenic 
effects specific to the nervous system. Since a rigorous study o f NLK expression in 
systemic tissues has not been conducted we cannot say for certain that NLK does not 
appear on the cell surface o f other cell lines.
There are two main reasons why anti-NLK antibodies may not have been previously 
detected in OM. Firstly, one o f the commonest methods by which antibodies associated 
with disease are detected (prior to characterisation o f the antigen) is to use 
photochemical or immunoblotting techniques. Since NLK is systemically expressed in 
the cytoplasm o f all cells reactivity may have been disregarded due to non-neuronal 
specificity without realisation o f the neuronal roles o f NLK.
The second commonly-employed method for the identification o f putative auto-antigens
is that o f bacteriophage expression library screening. The use o f this technique with
serum from OM patients has had little impact in defining commonly recognised
antigens (Bataller et al, 2003). During the production o f rNLK it was noticed that the
anti-NLK antibodies reacted with a bacterial protein in the crude preparations o f control
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cultures (pRSET only). It is well-known that the development o f the glycolytic pathway 
predates the split between eukaryotes and prokaryotes (Hattori et al, 1995) and thus it is 
not unreasonable to assume that E. coli, the bacteria used for library screening, carry a 
homologous protein to human NLK. If  this was the case then library screening would be 
an unsuitable method by which NLK could be characterised as the antibodies would 
have been non-specihcally bound to the bacterial homologue.
A BLAST search revealed 89 exact amino acid matches (23 % o f the total sequence) 
with 147 close matches (38 %) (expected chance homology was less than 1 x 10^) 
between streptococcal GPI and human proteins making this a potential molecular mimic 
and thus satisfying the third criteria for molecular mimicry. It is particularly interesting 
to find NLK associated with the membrane o f streptococcus (Huges et al, 2002). 
However, it must be recognised that homology between bacterial and human proteins 
does not guarantee cross reactivity between species. It would be useful to check that the 
anti-NLK antibodies reacted with a purified streptococcal form of NLK and that 
reactivity with NLK could be removed by pre-incubation o f patient’s serum with 
homogenates o f streptococcus. In addition, only two o f the cases described here had 
evidence o f streptococcal infection. However, since NLK represents a conserved protein 
it may be that a number o f pathogens have the capability to induce autoantibody 
formation. Clearly, a rigorous study into the nature o f associated pathogens is required 
in a larger cohort o f patients.
3.4.7 NLK: A Unifying Antigenic Target?
The similarities between PIOM and paraneoplastic POM have been discussed. It is
interesting that post-infectious and paraneoplastic processes could result in the same
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clinical phenotype and may suggest that there is a common antigenic target in both 
paraneoplastic and post-infectious OM. We have presented data from a limited cohort of 
adult patients which suggests that anti-NLK antibodies can be detected in the CSF of 
POM cases although antibody detection was not a consistent finding. Clearly, a larger 
study is requied to expand on these findings. However, there is circumstantial evidence 
to suggest that this may be the case. Firstly,
NLK is thought to have a role in directing the metastatic spread o f tumour following 
secretion from neoplastic tissue. In addition, patients who develop paraneoplastic OM 
frequently have tumours that are limited in size and metastatic spread when compared to 
neurologically intact controls. It is thus possible to theorise that anti-NLK antibodies 
could occur in a cancer patient as a result o f the inappropriate secretion o f normally 
sequestered NLK, and that these antibodies prevent NLK-mediated spread o f neoplastic 
cells. The anti-NLK antibodies would also interfere with the normal neuronal fimctions 
o f NLK. This would account for both the limited spread o f the tumour and the 
neurological disease.
If antibodies are important in the pathogenesis o f paraneoplastic and post-infectious OM
why should one group do remarkably better? It has been clearly documented that
patients with ‘idiopathic’ OM have a better neurological outcome than do the
paraneoplastic patients. In one study the majority o f the patients with idiopathic OM
experienced complete or significant resolution o f their neurological syndrome (Digre,
1986). In contrast the patients with an underlying malignancy fared worse. These
findings are mirrored by those o f Bataller et al (2001). The answer may lie in looking at
the stimulus for antibody synthesis. In the case o f  post-infectious OM it is possible that
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as the infectious agent is cleared by the host’s immune system the stimulus for antibody 
production is removed resulting in a self-limiting illness. In the case o f paraneoplastic 
OM, immunomodulation may lower the titre o f pathogenic antibodies but does not 
remove the stimulus for antibody production and may in fact reduce anti-tumour 
activity thus allowing tumour growth. Indeed, surgical intervention is the only therapy 
found to have significant effect on paraneoplastic OM. However this theory does not 
explain why so many patients, especially in the paediatric population, are left with 
neurological deficit following successful tumour therapy.
3.4.8 Areas fo r  Future Research.
The experimental findings presented here provide some evidence for an interesting 
antigenic target associated with the presence o f serum antibodies in OM. It is clear that 
questions remain unanswered. In order to address these, a number o f investigations can 
be conducted.
Firstly, a larger epidemiological study is required. The number o f patients presented
here is limited. This is a result o f the rarity with which OM occurs. It would be
necessary to acquire clinical data on a larger number o f patients. In particular, it would
be o f interest to see what proportion o f patients have evidence o f an anti-NLK response
and a clearly defined association with a pathogenic organism. Such a cohort could be
acquired through the use o f organisations such as the British National Neurological
Surveillance (BNSU). In addition, further control data will be required to support the
findings o f this thesis. Increased numbers o f neurological and healthy controls will be
needed. More importantly, it would be o f considerable value to determine the frequency
of an anti-NLK response in post-streptococcal diseases and patients with neuroblastoma
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but no neurological deficit. Similarly the testing o f  patients serum against unrelated 
recombinant proteins should be conducted as a  matter o f course to ensure any results are 
not the result o f non specific reactivity with E. Coli proteins in recombinant protein 
preparations.’
Secondly, the experiments presented above have not addressed the issue o f  whether the 
antibodies are pathogenic. Incubation with cultured neurones and measurement o f cell 
death or disruption o f function would be o f value.
It would be o f interest to confirm that anti-NLK antibodies from the index patients 
cross-reacted with both human NLK and streptococci GPI. The use of streptococcal 
homogenates to absorb out anti-NLK antibodies would quickly resolve this issue. It 
would be o f particular interest to determine if the immunisation of animals with 
streptococcal GPI could invoke an anti-NLK response and replicate OM.
Finally, a cohort o f  patient with POM is required in whom malignant tissue is available. 
It would interesting to determine the level o f NLK in patients serum or the arberrant 
expression o f the antigen by malignant cells and determine if  an antibody response is 
associated with limited metastatic spread.
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Overview of Chapters Four, Five and Six,
The following chapters describe a series o f experiments in which a patient with a 
paraneoplastic cerebellar syndrome was selected on the basis o f the presence o f anti­
neuronal antibodies against an unidentified 97 kDa antigen. The patient was selected 
from a series o f patients with paraneoplastic disease who had been identified through a 
national surveillance programme. The clinical findings o f each patient and associated 
antibodies are summarised along with the clinical characteristics o f the selected patient. 
In the subsequent investigations 2D gel electrophoresis, ion exchange chromatography 
and immunoaffinty chromatography were applied in an attempt to purify the antigen in 
preparation for identification by mass spectrometry. The reasons for the failure o f these 
methods to produce significant amounts o f  purified antigen are discussed.
Since the majority o f anti-neuronal antibodies have been characterised by 
application o f  bacteriophage screening this method was used to determine the nature o f 
the antigen recognised by the antibodies o f our index patient. While the 97 kDa was not 
isolated the technique identified an antigen which was recognised by both the index 
patient and those found in the serum o f a second patient with paraneoplastic cerebellar 
disease. The relevant experiments and the sections in which they can be found are 
summarised in the following flow chart.
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Chapter 4
Ammonium sulphate fractionation of the 97 kDa antigen (Section 4 .3.4).
Demonstration of anti-neuronal specificity (Section 4.3.3).
Antigen purification using ion exchange chromatography (Section 
4.3.4).
Identification of a paraneoplastic patient with antibodies against a 97 
kDa antigen from a cohort of 63 patients with paraneoplastic d isease  
(Section 4.3.1).
Chapters
Production of immunaffinty column using patient IgG (Section 5.3.1).
Antigen isolation and testing (Sections 5.3.2 -  5.3.3).
Outline of principles behind immunaffinity purification (Section 5.1.1).
Chapter 6
Demonstration of lack of reactivity against out of frame bacteriophage 
protein (Section 6 3 5 - 6  3.6).
Demonstration of reactivity of patient serum with recombinant protein 
expressed from longest open reading frame. (Section 6 .3.7 -  6.3.8).
Principles of bacteriophage expression library screening (Sections 
6 .1 .1 -6 .1 .7 ) .
Isolation of reactive bacteriophage, testing against control serum and 
cDNA sequencing (Section 6 .3 .1 -6 .3 .4 ) .
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4 Chapter 4: Identification of a patient with a paraneoplastic syndrome and novel 
anti-neuronal antiboy directed against 97 kDa antigen.
4.1 Introduction.
The majority o f  epidemiological studies concerning PND consist o f series o f selected 
patients with specific cancers (Elrington et al, 1991), specific anti-neuronal antibodies 
(Sillevis et al, 2002; Dalmau et al, 1992) or specific neurological syndromes (Gultekin 
et al, 2000; Peterson et al, 1992) but information o f a more general nature is not readily 
available.
Using a nation-wide reporting scheme run by the BNSU data concerning patients with 
suspected PND was collected. We investigated the clinical spectrum o f PND, the 
associated tumours and anti-neuronal antibodies, and the response o f the PND to 
treatment o f the underlying malignancy or immunomodulatory treatment. By reviewing 
anti-neuronal antibody reports we were able to identify patients with atypical anti­
neuronal antibodies whose serum could be employed in antigen characterisation using 
previously successful methods.
4.2 Methods.
4.2.1 Paraneoplastic patients.
The British Neurological Surveillance Unit was used to consult members o f the
Association o f British Neurologists (ABN) as to whether they had encountered cases o f
paraneoplastic disease affecting the CNS. Data collection was conducted between
February 2000 and January 2001. Further information was sought by means o f a
questionnaire. Patients were included if  they had a neurological disease in association
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with a known malignancy or recognised anti-neuronal antibodies in the absence o f a 
tumour. In some cases patients were referred directly to Dr J Rees. Patients were 
classified as either definite PND i.e. a neurological disorder occurring in association 
with an identified malignancy for which there was no other explanation, probable PND 
(anti-neuronal positive with no identified malignancy) or possible PND. Where 
possible, case notes were reviewed to obtain further clinical information. The study was 
approved by the Ethics Committee o f the National Hospital for Neurology and 
Neurosurgery. In some instances anti-neuronal antibodies were identified as part o f the 
routine diagnostic service offered at the National Hospital for Neurology and 
Neurosurgery. Serum was considered anti-neuronal antibody positive if  the 
immunohistochemical staining o f  rat cerebellar tissue sections and immunoblotting o f 
crude brain homogenate produced a pattern consistent with recognised anti-neuronal 
antibodies in PND (Table 1-3). On occasion the staining pattern produced or the 
molecular weight o f the detected antigen did not conform to these patterns. Such 
samples were described as containing ‘miscellaneous’ anti-neuronal antibodies and 
were considered for use in antigen characterisation.
4.2.2 Sample Preparation, Ammonium Sulphate Fractionation and 2D
Electrophoresis.
Pig cerebellum was selected as the tissue if  choice as there was a ready supply available
at the time o f experimentation. Immunobloting was used to confirm the presence o f the
97 kDa before the tissue was used in subsequent experiments. Cerebellum was isolated
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and frozen within 10 minutes o f sacrifice. Cerebellar homogenate was produced as 
described in section 3.2.3. ASF was conducted using the method described in 3.2.4. 
Initial wide fractions at 0 - 25, 25 - 50, 50 - 75, and 75 -100 % saturations were used. 
The 97 kDa protein was detected by immunoblot using sera from the index patient. The 
individual fractions were analysed using PAGE and Coomassie staining. The process 
was repeated using 10 % fractions from 0 -  60 %.
The 20 % fraction was selected as it contained relaivly enriched protein and buffer- 
exchanged into sodium phosphate buffer (pH 7.0) and concentrated using the Microcon 
system (Millipore, UK). Proteins were separated by pi and molecular weight as 
described in section 3.2.5. The target antigen was identified using patient serum and an 
immunoblot o f  the 2D gel. Reactive proteins were identified in the corresponding silver- 
stained gel and subjected to mass spectrometry if  appropriate (See section 3.2.7).
4.2.3 Ion Exchange Chromatography.
lEX chromatography was performed using the ÀKTA FPLC system and the anionic 
exchange HiTrap Mono Q FF (5ml) column (Amersham Biosciences). Proteins from the 
20 % ammonium sulphate fraction were exchanged into lEX binding buffer (20 mM 
Tris-HCl pH 8.00) and injected onto the column. Proteins were eluted over a gradient of 
increasing ionic strength by injection o f elution buffer (20 mM Tris-HCl 1.5 M NaCl 
pH 8.35) 0-100% over 120 ml. Fractions were collected using a Frac-900 fraction 
collector and those fractions corresponding to peaks on the chromatogram selected, 
subjected to PAGE and immunoblotted. The 97 kDa antigen was detected using serum
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from the index patient. Identified proteins were silver-stained and identified using mass 
spectrometry where appropriate.
4 3  Results.
4.3.1 Identified Patients, Underlying Tumours and Diagnosis o f  PND.
A total o f 63 patients were identified (48 females, 15 males). O f these 52 patients 
were classified as having a definite PND. Detailed analysis o f the cohort can be 
found in the publications at the back o f the thesis. O f the 52 patients, 10 were 
known to have malignant disease before the onset o f PND. The tumours in this 
group consisted o f two SCLC, three breast (one with concurrent colonic cancer) 2 
ovarian, 1 prostate, 1 mesothelioma and 1 endometrial carcinoma. In the remaining 
42 patients the tumour was identified as a result o f investigations for a suspected 
PND. O f these patients 22 were found to have lung cancer (17 SCLC, 5 non-SCLC 
(NSCLC)), 6 breast cancer, 4 adenocarcinoma o f unknown primary, 4 Hodgkin’s 
disease, 3 ovarian cancer, 1 melanoma, 1 malignant neuroendocrine tumour and 1 
plasmacytoma.
A diagnosis o f  a probable PND was made in 10 patients because they had serum 
anti-neuronal antibodies (9 anti-Hu and 1 anti-Yo positive) but no tumour was 
found. One patient who presented with clinical features o f  limbic encephalitis and 
motor neuropathy was diagnosed as having a possible PND because the phenotype 
was compatible with a PND but no tumour or anti-neuronal antibody were 
identified.
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4.3.2 Anti-neuronal Antibody Detection.
Results o f anti-neuronal antibody screening were positive in 44 out o f 58 patients (76 
%). O f these, 39 had known antibodies (25 with anti-Hu antibodies, 11 with anti-Yo 
antibodies, 2 with anti-Tr antibodies and 1 with anti-amphyphysin antibodies). Five 
further patients had anti-neuronal antibodies demonstrated by immunohistochemistry or 
western blotting that did not recognise known antigens these were therefore classified as 
‘miscellaneous’. The tumour associations for each antibody are documented in Table
4-1. O f particular note is that anti-Yo antibodies were found in one patient with NSCLC 
and 2 patients with adenocarcinoma o f unknown primary (AUP) and that one patient 
with anti-Tr antibodies had AUP.
Table 4-1: Tumour associations in patients with positive serum anti-neuronal
antibodies.
y I 1 1 1 &X g § 1 1
Hu 9 3 3 1 9 25
Yo 1 3 3 2 1 1 11
Tr 1 1 2
Amphiphysin 1 1
Mise 1 1 3 5
SCLC = small cell lung cancer, NSCLC = non-small cell lung cancer, AUP = adenocarcinoma o f  
unknown primary, NE= neuroendocrine, HD = Hodgkin's disease, NTF = no tumour found.
4.3.3 Details o f  Patient with Miscellaneous Anti-9 7 kDa Antibodies 
A 61 year old right-handed female presented in 1999 following the acute onset o f 
vertigo which settled after a few days leaving the patient with some difficulty in
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walking. Two weeks later she experienced the abrupt onset o f unsteadiness that caused 
her to fall. This episode was accompanied by shaking in all limbs. Since the second 
attack the patient had been unable to walk. Her condition remained stable until two 
months later when she developed diplopia. Her speech was unaffected but her mouth 
had become dry. There was no bladder or bowel disturbance. The patient had a history 
o f laryngeal carcinoma in 1985 that was treated with radiotherapy. There was also a 
history o f glaucoma and inflammatory bowel disease. There was no family history o f 
note. The patient smoked 25 cigarettes a day.
The patient was able to stand with her feet together, but was rather unsteady. She was 
Romberg negative. She had a broad-based gait and truncal ataxia. There was no 
dysarthria. Eye movements were abnormal with reduced elevation in the left eye 
accompanied by diplopia on looking upwards, to the left and in the primary position. 
Upper limb co-ordination showed slight finger-nose ataxia, but definite 
dysdiadochkinesis in both hands. There was severe heel-shin ataxia. Power was normal 
throughout. Reflexes were diminished but post-pertantic potentiation could be elicited. 
Planters were flexor and sensation was normal in all modalities.
An MRI o f  the brain revealed a small right cerebellar cortical infarct which was not 
thought to be the cause o f her ongoing problems. Investigation for anti-VGCC 
antibodies was positive (552, >100 = positive). Investigation for the presence o f anti­
neuronal antibodies reported the presence o f an antibody against a 97 kDa protein in 
guinea pig brain homogenate on immunoblot. Histochemistry against rat cerebellar 
sections was reported as negative. The diplopia, dry mouth and potentiation o f reflexes
coupled with the positive anti-VGCC antibodies suggested a diagnosis o f LEMS.
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Electrophysiological testing confirmed this diagnosis. Due to the association of LEMS 
with underlying SCLC the patient was investigated for the presence o f an underlying 
malignancy. A chest X-ray failed to demonstrate a focal lesion. However a full body 
PDG pet scan was conducted which showed increased uptake in the left upper lung field 
with a linear distribution extending towards the midline (Figure 4-1). A fine cut CT scan 
showed a 1 cm irregular nodule in the apical segment o f the left lower lobe. A 
retrospective viewing o f a CT scan conducted in 1999 showed that the mass had been 
present at that time, and that its appearance had not changed in the last 3 years. 
Bronchoscopy revealed no abnormality and broncho-alveolar lavage was negative for 
cytology. In view of the patients poor lung function an exploratory thoracotomy was not 
conducted. Instead the decision was taken to monitor the lesion using repeat CT scans. 
Treatment with 3, 4 - diaminopyradine was instigated for her LEMS.
Figure 4-1: [18F|fluoro-2-deoxyglucose-PET scan.
The scan shows increased uptake in the left upper lung field with a linear distribution extending towards 
the midline.
Investigation for the presence o f anti-neuronal antibodies was repeated. The 
immunoblot again demonstrated that the patient had antibodies against a 97 kDa protein
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that was found in human and pig cerebellum. The reactivity could also be identified in 
pig cortex. The immunoblot of pig liver did not produce a similar band suggesting that 
the recognised antigen was neuron specific.
kDa 
98
Figure 4-2: Evidence for an anti-neuronal response against a 97 kDa neuronal 
protein.
Immunoblot of 1: human cerebellum, 2: pig cerebellum, 3: pig cerebral cortex and 4: pig liver using 
serum from the index patient.
4.3.4 Ammonium Sulphate Fractionation.
An immunoblot o f the 25, 50, 75 and 100 % ammonium sulphate fractions of pig
cerebellar homogenate probed with patient serum demonstrated strongest reactivity with
the 97 kDa antigen in the 50 % fraction. In addition a relatively small amount was also
detected in the 25 % fraction (Figure 4-3, B). A stained gel o f the fractions revealed the
differential precipitation o f proteins but no obvious individual protein at the 97 kDa 
(
level could be detected in either the 25 or 50 % fractions (Figure 4-3, A). In addition, 
fractionation uncovered antibody reactivity with three hitherto unrecognised proteins; 
one in the 75 % and two in the 50 % ammonium sulphate fraction (Figure 4-3, B). 
These proteins had not been detected when crude human or pig brain homogenates had 
been probed (see Figure 4-2).
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Figure 4-3: Ammonium sulphate fractionation of pig cerebellum (wide fractions).
Crude homogenates o f  pig cerebellum were subjected to ammonium sulphate fractionation using 25, 50, 
75 and 100 % ammonium sulphate saturations. The precipitated proteins were subjected to PAGE and the 
gel A: stained or B: immunoblotted. The immunoblot detected some antigen in the 25 % fraction but the 
majority was precipitated at 50 % ammonium sulphate saturation. Other proteins also appeared to be 
reactive at a lower level at both 50 and 75 % ammonium sulphate saturation. The stained gel did not show 
discrete proteins at the 97 kDa level.
Repeat fractionation using 10 % fractions from 0-40 % demonstrated that the antigen 
precipitated in the 10, 20 and 30 % fractions, but was relatively enriched in the 20 % 
fraction (Figure 4-4, B). Staining revealed the differential precipitation of proteins but 
again no clear protein could be seen at the 97 kDa level (Figure 4-4, A). The additional 
bands observed at the higher ammonium sulphate saturations were not detected in any 
of the smaller fractions.
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Figure 4-4: Ammonium sulphate fractionation of pig cerebellum (narrow 
fractions).
Ammonium sulphate fractionation was repeated using smaller fractions; 10, 20, 30 and 40 % ammonium 
sulphate saturation. Fractions were subjected to PAGE and A: stained or B: immunoblotted. The 97 kDa 
protein was precipitated at 10-30 % ammonium sulphate saturations with a relative increase in 
concentration in the 20 % fraction. The stained gel revealed a partial purification o f the whole 
homogenate but no 97 kDa proteins were clearly discernible in any o f the fractions. Further purification 
was therefore required.
4.3.5 2D Gel Electrophoresis.
2D gel electrophoresis was performed using the 20 % ammonium sulphate fraction of
pig cerebellar homogenate. Silver staining revealed that the majority o f the proteins
migrated to a pi of 5 to 10. A protein could be identified at the 97 kDa level with a pi of
approximately 8. Immunoblotting and probing with patient’s serum identified a protein
with a higher molecular weight (between 97 and 198 kDa) (Figure 4-5, B). Both the
silver stain and the immunoblot (developed using ECL) required extended developing
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time possibly as a result o f the low protein load. Attempts to increase the signal using 
increased concentration o f proteins were unsuccessful resulting in poorly focused 
proteins or failure to detect the antigen on immunoblot. The initial results were not 
reproducible. In no instance could a clearly separated antigen be correlated with 
reactivity on an immunoblot, thus protein identification was deemed not to be possible 
using this approach.
4.3.6 lE X  Chromatography.
Fractions corresponding to the peaks on the chromatogram clearly showed the 
separation o f proteins in different fractions (Figure 4-6). However, the immunoblot (not 
shown) could not detect the 97 kDa antigen in any o f the fractions. Repeated attempts 
using increased protein concentration did not facilitate purification or detection o f the 
antigen.
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Figure 4-5: 2D gel electrophoresis of cerebellar proteins precipitated at 20 %  
ammonium sulphate saturation.
A: Silver stained gel. B: Immunoblot probed with patients serum. A band of protein with a molecular 
weight between 97 and 191 kDa extending from approximately pH 10 was recognised by the patients 
serum. The stained gel revealed proteins at a lower molecular weight level. Both staining and ECL 
development required extended periods suggesting a low concentration o f protein.
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Figure 4-6: lEX purification of the 97 kDa antigen.
A: Partially purified proteins from 20 % ammonium sulphate fraction of pig cerebellum were separated.  ^
Peaks 1 - 8 were selected. B Proteins were separated by PAGE and the gel stained or immunoblotted (not 
shown) and probed with patients serum. lEX resulted in the separation o f proteins, however patients 
serum did not detect an antigen in any o f  the lanes. (NH4 = pre-IEX 20 % ammonium sulphate fraction o f  
pig cerebellar homogenate).
4.4 Discussion.
4.4.1 Anti-Neuronal Antibody Results.
The utility of anti-neuronal antibodies in both aiding diagnosis and directing the search
for an underlying malignancy is well-documented (Dalmau et al, 1990; Anderson et al,
1998; Luque et al, 1991; Voltz et al, 1999). However, while most tumour associations
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were consistent with those described in the literature we found four unusual 
associations, one anti-Yo antibody associated with NSCLC and two AUP and one anti- 
Tr antibody associated with AUP. The association o f anti-Yo antibody with AUP has 
been previously reported (Peterson et a/, 1992; Sutton et al, 2001) but is rare. However 
to the best o f our knowledge the association o f anti-Tr with AUP has not been 
previously described. In the case o f anti-Hu positive patients the commonest tumour 
found was that o f  SCLC. However in an equal proportion o f anti-Hu positive patients no 
tumour was located. The apparent absence o f  malignant disease is not inconsistent with 
a diagnosis o f PND as on occasion the tumour may be too small to be detected even by 
sensitive imaging techniques (Anderson et al, 1998; Croft et al, 1965). The 
unexpectedly high percentage o f tumour negative anti-Hu patients in this study may be 
a consequence o f  limited autopsy or PET investigations in these patients.
4.4.2 The Index Case
Five o f the 63 patients (8 %) on whom data were collected were found to have
antibodies against a neuronal protein which had not been previously described. O f these
one was selected for further investigation on the basis o f a compelling clinical picture,
strong anti-neuronal response against crude brain preparation and availability of
relatively large amounts o f  serum for use in investigations. Repeat investigation for
anti-neuronal antibodies in the patient’s serum confirmed a strong anti-neuronal
antibody response against a 97 kDa protein expressed in the cerebellum and cerebrum
but not in non-neuronal tissue. This patient had a sub-acute cerebellar syndrome and
LEMS. It is important to note that an absolute diagnosis o f  PND can not be assigned
since the patients poor lung function precluded tissue sampling o f the suspected
underlying lung mass. However abnormal uptake on FDG-PET scanning confirmed by
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CT scanning in a smoker with LEMS (60% o f cases are tumour associated) is strong 
evidence. The association o f  SCLC, cerebellar degeneration and LEMS has been 
previously described. In 1992, Clouston et al described a series o f nine patients with 
LEMS and PCD usually associated with an underlying tumour and suggested that the 
association occurred more frequently than would be expected by chance. In a different 
study Mason et al (1997) detected anti-VGCC antibodies in up to 24% o f patients with 
SCLC and PCD (in patients with clinical and subclinical LEMS). Whether the anti- 
VGCC antibodies are responsible for the PCD is unclear. In one study (Fukuda et al, 
2003) a reduction o f P/Q-type calcium channels in post-mortem specimens o f PCD and 
LEMS. These findings are yet to be verified and significant levels o f anti-VGCC 
antibodies in CSF samples have yet to be demonstrated.
It is likely that some patients have multiple antibody response to multiple onco-neuronal 
antigens. Indeed patients have been described with anti-Hu and anti-VGCC antibodies. 
In the case report described here, the patients had clearly demonstrable anti-VGCC 
antibodies and an antibody response against an unidentified 97 kDa neuronal protein. 
Reactivity with a 97 kDa protein by sera from PCD/ LEMS patients has not been 
reported. It is entirely possible that the antigen recognised by this patients antibodies are 
unique to this case o f PCD/ LEMS, however, identification o f the protein may provide 
insight into the nature o f the disease in the index patient with a view to investigating a 
larger cohort o f patients at a later date.
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4.4.3 Antigen Purification by Ammonium Sulphate Fractionation, 2D Gel 
Electrophoresis and lE X  Chromatography.
We attempted to characterise the 97 kDa antigen recognised by the antibodies in the 
serum o f the index patient through the use o f ASF, 2D gel electrophoresis and lEX 
chromatography. We were able to partially purify the protein using ASF. Interestingly 
the 50 and 100 % fractions o f the pig brain homogenate revealed previously 
unrecognised antibody activity against proteins with a molecular weight lower than 97 
kDa. The appearance o f this antibody activity may be related to the relative enrichment 
o f the target proteins within the fractions or a result o f dissociation o f peptides from the 
97 kDa auto-antigen. Further characterisation o f these proteins was not pursued 
although it provides evidence for the potential existence o f other auto-antibodies, a 
factor which may have hampered attempts to immunopurify the 97 kDa antigen (see 
chapter 5). Attempts to separate the protein by 2D gel electrophoresis proved 
unsuccessful despite the application o f increasing concentrations o f protein. Similarly, 
the 97 kDa protein could not be detected following lEX chromatography. Previous 
experience in our laboratory has demonstrated that successful characterisation o f 
antigens can be achieved using these well-established techniques o f protein separation 
(see chapter 3).
Protein separation techniques have previously been applied by other groups to the
characterisation o f antigens recognised by the serum o f neurologically normal patients
with various forms o f cancer. Brichory et al (2001) used 2D PAGE and
immunoblotting to separate proteins isolated from both human tumour tissue or tumour
cells lines and identified the protein ‘protein gene product 9.5’ as a target antigen
recognised by antibodies from 9/64 (14 %) patients with lung cancer. In this example
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the partial purification o f proteins was not required as antigen characterisation could be
achieved from the crude homogenates o f whole tissue. Similarly, Prasannan et al (2000)
used homogenates o f neuroblastoma tumour tissue and neuroblastoma cell lines in 2D
PAGE to identify p-tubulin as the antigen recognised by the antibodies o f 11 patients
with neuroblastoma. The use o f cell lines in these experiments has obvious merit. A
homogenous population o f  cells will contain similar proteins allowing reproducible
result, while the absence o f  other cell types reduces the overall number o f proteins that
could hamper purification attempts. This approach is dependent on the availability o f a
suitable cell line. It should however be noted that antigen expression may vary from
individual cell cultures from the same cell line depending on the conditions in which
they are cultured thus repeated testing o f antigen expression may be required prior to
purification attempts. Future attempts at purification o f the 97 kDa antigen could
involve the selection o f an appropriate cell line in order to simplify the composition o f
the initial homogenate and assist purification. Our experiments required the use o f  brain
tissue for the identification o f antigens. While we have had previous success using the
proteomic approach it is well-documented that problems exist in the isolation and
separation o f proteins from brain tissue. Beranova-Giorgianna et al (2002) noted the
lack o f membrane bound proteins when mouse brain was used to produce 2D gels.
Similarly, a two dimensional map o f human brain proteins was recently found to be
composed o f only 2% membrane bound proteins (Langen et al, 1999) a figure much
lower than the predicted 25-33% (Cascio et al, 2002). It is known that membrane
proteins, with their low solubility (due to the existence o f intramembrane hydrophobic
regions) and tendency to aggregate during IBP, results in their under-representation on
2D gels using conventional conditions. One solution is to enrich a protein preparation
for membrane-bound proteins by isolating membrane fractions from the brain
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homogenate. Such a technique, coupled with various salt washes to detach peripheral 
proteins was employed by Friso and Wikstrom (1999) in their analysis o f cerebellar 
membrane proteins. Their approach resulted in the production o f a 2D map composed of 
a larger number o f membrane proteins which was complementary to that produced from 
tissue treated in a standard manner (Beranova-Giorgianni et al, 2002). Problems relating 
to the solubility o f the 97 kDa antigen could be a factor in our inability to characterise 
the antigen. In contrast to NLK which precipitated at 40-60 % ammonium sulphate, the 
97 kDa protein precipitated at 20 % ammonium sulphate, suggesting that the protein is 
relatively hydrophobic and thus may be associated with a membrane. However, this 
does not explain the inability to separate the protein by lEX chromatography. 
Hydrophobic areas o f a protein may reduce the affinity with which a protein binds to a 
column although the protein should still be present in the flow-through or elute upon a 
small increase in the ionic strength o f the buffer. It is possible that the protein forms an 
aggregate that is unable to pass through the column. Future attempts to characterise the 
97 kDa protein using proteomics should focus on ways to improve the preparation of 
the protein sample prior to analysis.
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5 Chapter 5: Characterisation of the 97 kDa neuronal antigen by immunoaffinity 
chromatography,
5.1 Introduction.
Attempts to identify the 97 kDa antigen using established techniques o f protein 
separation and purification was unsuccessful and the potential reasons for this have 
been discussed in the previous chapter. As a result a new technique was employed 
involving the use o f the patients IgG to immunopurify the antigen.
5.1.1 Immunoaffinity Chromatography.
Affinity chromatography separates proteins or other molecules on the basis o f a 
specific, reversible interaction with a ligand immobilised on a suitable matrix in a 
chromatography column. The technique can be applied whenever there is a suitable 
ligand for a target protein. With highly selective protein: ligand interactions a thousand­
fold purification o f specific molecules is possible. Many ligands have been described 
and applied in various situations. The general principles o f affinity chromatography are 
shown in Figure 5-1.
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Figure 5-1: The principle of affinity chromatography.
1: A column containing a suitable matrix is coated with ligand (i.e. antibody) prior to the 2: the 
introduction o f the protein solution from which the target protein is to be isolated. 3: The specific protein: 
ligand interaction allows retention o f the protein while contaminants are washed away. 4: The conditions 
within the column (pH, ionic strength) are altered to facilitate dissociation o f the protein: ligand bonds. 
The purified protein can then be collected.
If a suitable ligand for a target protein is not available an antibody raised against the
protein o f interest can be used. Monoclonal antibodies provide a means of obtaining
highly purified protein and are most useful when the identity of the target is established.
When a suitable monoclonal antibody is not available polyclonal antibodies may be
employed. Purification schemes using polyclonal sera commonly use antibodies raised
in rabbits by repeated immunisation. Using this technique up to 10% of the total
immunoglobulin may be specific for the target protein. The antibodies can then be
coupled to a chromatography column. Theoretically, if 1 mg of immunoglobulin is
attached to a column, only 0.1 mg will be capable o f antigen capture (Scopes, 1993).
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Although only a small amount o f protein would be purified from such a column, re­
using the column over multiple runs or immobilising larger amounts o f immunoglobulin 
to the matrix can circumvent these problems.
Patient serum has been used as the source o f polyclonal antibodies in the following 
experiments. While it is difficult to estimate the proportion o f antibodies in a given 
sample that are specific for the 97 kDa antigen, patients with PND frequently have high 
titres o f anti-neuronal antibodies. Thus it is probable that a significant amount o f anti-97 
kDa antibodies can be applied to an immunoaffinity chromatography column.
5.1.2 Pre-A ctivated N-hydroxysucinnimide Columns Matrices
A pre-Activated N-hydroxysucinnimide (NHS) column was used for the production o f 
an immunoaffinity column. These columns couple protein ligands through the amino 
groups in their structure. The NHS matrix consists o f cross-linked agarose beads with a 
ten-atom spacer arm attached by epichlorodyrin and activated N-hydroxysucinnimide. 
Proteins couple to the matrix spontaneously by nucleophilic attack o f the ester linkage 
to form a stable amide bond (Figure 5-2). 30 mg o f IgG can be coupled per millilitre of 
NHS matrix. Once antibodies have been bound to the matrix, unoccupied binding sites 
can be blocked using an excess o f a solution containing amino groups. Blocking the 
column in this way prevents non-specific binding o f proteins to the column when 
protein solutions are introduced.
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Figure 5-2: Protein binding by NHS activated chromatography column.
5.2 Methods.
5.2.1 Purification o f  IgG from  Serum.
The High Trap rProtein A column is designed for the purification of IgG. A HiTrap
rProtein A column (Amersham Bioscience) was installed onto the ÀKTA FPLC 920
and equilibrated with 10 mis o f affinity elution buffer followed by 10 mis of affinity
binding buffer. Serum was centrifuged (10,000g for lOmin) to remove any insoluble
proteins and the supematent diluted in immunoaffinity binding buffer and loaded onto
the 10 ml sample loop. IgG was purified from a total volume of 10 mis of serum in 2 ml
purification steps. The sample was introduced onto the column at a flow rate o f 0.5
ml/min. The flow of affinity binding buffer was continued until contaminating proteins
had been removed and absorbance returned to baseline. The flow-through was collected
for analysis. Purified IgG was removed from the column using a single step pH change
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o f 7 to 3 by introduction o f 100% immunoaffinity elution buffer. 0.25 ml fractions were 
collected using the FRAC-900 and neutralised using neutralisation buffer. Fractions 
containing protein were selected with reference to the chromatogram and pooled.
The total protein concentration o f the serum, flow-through and purified IgG fraction 
was calculated as described (Chapter 8). A commercial source o f purified IgG was used 
as a control. Each sample was standardised to a total protein concentration o f 0.05 
mg/ml, subjected to PAGE and stained with Coomassie blue or immunoblotted. The 
immunoblots were incubated overnight at 4°C with goat anti-human IgG and goat anti­
kappa/lambda antibodies both diluted 1:5000 in 0.2 % milk 0.9 % saline solution. Both 
antibodies were used in order to correlate which bands in the stained gel represented the 
kappa/lambda chains o f the denatured antibody molecules. Immunoblots were washed 
and incubated with rabbit anti-goat HRP conjugated secondary antibody diluted 1:1000 
in 0.2 % milk 0.9 % saline solution. After a second wash immunoblots were developed 
chromogenically. Isolated IgG was concentrated to a final volume o f 1ml using the 
Microcon system prior to immobilisaiton on the chromatography column.
5.2.2 Coupling Purified IgG to the NHS Activated Column.
Purified IgG was buffer exchanged into IgG coupling buffer. The isopropanol 
preservative was removed from a 1 ml HiTrap NHS-activated HP column (Amersham 
bioscience) with 6 ml-ice cold HCl (ImM ). 1 ml o f the antibody solution was injected 
onto the column which was then left to stand for 30 min at room temperature to allow 
the coupling reaction to occur. The antibody solution was removed from the column by
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injection o f 3 ml o f IgG coupling buffer prior to inactivation o f the remaining binding 
sites in the column using alternate washes o f NHS inactivation buffers A and B.
5.2.3 Isolation ofAntigen from  Cerebellar Homogenate.
The IgG-coupled NHS column was primed using 25 ml o f affinity binding buffer 
followed by 25 ml affinity elution buffer and re-equilibrated in affinity binding buffer. 
The 20 % ammonium sulphate fraction o f cerebellar homogenate (see chapter 4) was 
diluted 1:10 in affinity binding buffer and injected onto the column at a rate o f 0.25 
ml/min. Flow was continued until absorbance returned to baseline. At this point, antigen 
was eluted fi"om the column into 0.25 ml fractions using affinity elution buffer. 
Fractions containing protein were pooled and neutralised. Seven cycles o f purification 
were conducted using fractionated cerebellar homogenate each time.
5.2.4 Analysis o f  Eluted Proteins.
Proteins were concentrated using a YM-10 spin column and subjected to PAGE. Gels 
were then either stained using colloidal blue or transferred to nitro-cellulose. 
Immunoblots were incubated with the patient’s serum at 4°C overnight; washed and 
incubated with rabbit anti-human HRP antibody diluted 1:15,000. Immunoblots were 
developed using ECL. Stained gels were sent for analysis by mass-spectrometry using 
the method described in section 3.2.7. Proteins around the 97 kDa molecular weight 
marker were analysed. Antigens were selected for further investigation if they were 
specific to the nervous system and had a molecular weight o f between 95 and 110 kDa. 
To confirm the identity o f the immunoaffinity purified antigen the 20% fraction o f 
cerebellar homogenate was probed with antigen specific antibodies and patients serum.
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5.3 Results.
5.3.1 Isolation o f  IgG from Patients Serum.
A representative chromatogram demonstrating IgG isolation from patient serum is 
shown (Figure 5-3, A). Fractions containing the flow-through and isolated IgG were 
pooled and subjected to analysis. Immunoblotting did not detect the presence of IgG 
within the flow-through fraction while it could be clearly identified in the IgG fraction 
as evidenced by the presence o f a pattern identical to the commercial control (Figure 
5-3, B). A Coomassie stained gel (not shown) o f the same fractions showed that the 
purified IgG contained no other significant proteins not associated with the heavy or 
light chains o f IgG.
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Figure 5-3: Purification of IgG from patients serum.
A: Spun serum was introduced to the column and the flow-through collected (peak I). The column was 
washed until the absorbancy returned to baseline. IgG was eluted from the column by the introduction of 
100 % elution buffer (peak 2). B: Whole serum (lane I), flow-through (lane 2) and purified IgG (lane 3) 
were subjected to PAGE. Lane 4 = human IgG control. No IgG was detected in the flow-through fraction. 
IgG was efficiently purified.
183
5.3.2 Antigen Isolation from Cerebellar Homogenate.
Extractions were performed as described. A representative chromatogram is shown in 
Figure 5-4, A. The extracted and concentrated proteins were electrophoresed and 
stained (Figure 5-4, B). Some purification o f protein had occurred however a larger 
number o f contaminating proteins could be seen at a range o f molecular weights. 
Distinct bands around 97 kDa could be visualised in the gel. Immunoblotting of the 
proteins showed that the 97 kDa antigen had been extracted following the 
immunoaffinity protocol, however two other reactive proteins were also identified 
(Figure 5-4, C) one o f which was thought to be IgG heavy chain. The low yield of 
protein prevented further experimentation.
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Figure 5-4: Immunoaffînty purification of the 97 kDa antigen.
Purified IgG was used to construct a tailored immunoaffinity column. The column was used to purify the 
97 kDa antigen from the 20 % ammonium sulphate fraction o f cerebellar homogenate. Purification was 
repeated 7 times using the protocol shown in A. The collected eluted proteins were subjected to PAGE 
and the gel stained. B shows the proteins collected from the first two runs. Protein from run 1 was 
immunoblotted (C) and probed with patients’ serum. A 97 kDa protein was detected (top arrow head). 
Two other, previously undetected proteins were also present. It is thought the lowest band represents IgG 
contamination from the column (bottom arrow). Proteins around the 97 kDa molecular weight marker 
were subjected to analysis by mass spectrometry.
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J.3.3 Mass Spectrometry.
A number o f bands from around the 97 kDa protein level were extracted and analysed 
and a number of proteins identified. In an attempt to determine which protein was 
important subsequent analysis was restricted to those proteins that were related to the 
nervous system and had a molecular weight o f between 95 to 105 kDa. Tandem mass 
spectrometry identified one protein that satisfied these requirements, F3/F11/contactin 
precursor. Six peptides matched those in the primary amino acid sequence of this 
protein (Figure 5-5). Cerebellar homogenates were probed with patient’s serum and a 
commercial anti-contactin antibody (Figure 5-6). Both reacted with a protein in the 
cerebellar homogenate, however the anti-contactin antibody recognised a protein with a 
higher molecular weight than that recognised by the patients serum.
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Figure 5-5: Peptide matches with Amino acid sequence of F3/F11/Contactin 
precursor.
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Figure 5-6: Detection of contactin in cerebellar homogenate.
An immunoblot o f  pig cerebellar homogenate was probed with patients’ serum (left) and a mouse anti- 
contactin monoclonal antibody (right). The detected proteins are not at the same level suggesting that the 
patients antibodies do not react with contactin.
5.4 Discussion.
5.4.1 Antigen Purification by Immunoaffinity Chromatography.
Immunoaffinity chromatography has the potential to rapidly isolate antigens from crude 
mixtures o f proteins. We attempted to apply the technique to the purification o f the 97 
kDa antigen from partially purified pig cerebellum. The antigen was present in the 
protein mixture obtained during the elution phase o f the immunoaffinity protocol as 
determined by immunoblot, however the resulting protein fraction contained many 
proteins.
It is possible that the immunoprécipitation o f antigen was no more than an artefact o f 
non-specific interaction of proteins with the column or IgG. Since total IgG and not 
antigen-specific antibody was coupled to the column, non-specific antibodies could
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have isolated the contaminating proteins. It is clear that our patient has antibodies 
against VGCCs as well as antigens other than the 97 kDa antigen (see Figure 4-3), and 
we have already described the existence o f auto-antibodies in cancer patients all o f 
which may have bound proteins.
To circumvent this problem two methods could be employed to increase the proportion 
o f antigen-specific IgG. Firstly, proteins could have been isolated from the 97 kDa level 
o f PAGE gel and used to immunise animals in order to narrow the IgG repertoire 
immobilised on the column. Such a technique has proven successful in other studies, but 
is hampered by the expense o f employing an external laboratory in which to raise the 
antibodies, and the production o f specific antibodies to proteins that co-migrate in the 
PAGE gel. Alternatively, patient serum could be enriched for neuron-specific antibodies 
by the pre-incubation o f patients serum with non-neuronal tissue to remove non-specific 
contaminating auto-antibodies. The resulting IgG preparation would have increased 
specificity for the antigen and would theoretically yield a protein fraction of increased 
purity following affinity purification o f neuronal tissue. Such an approach, known as 
‘reverse immunoaffinity chromatography’ has been successfully employed in the 
identification o f auto-antigens in patients with autoimmune gastritis (Goldkom et al, 
1991). A drawback to this approach is the requirement o f a large amount o f starting 
material. The identification o f auto-antigens from patients with autoimmune gastritis 
required IgG isolated from 40 ml o f serum.
A second potential reason for the precipitation o f a large number o f molecules is the
process o f co-precipitation. The association o f proteins in tight complexes can result in
an increase in the number o f proteins purified during affinity purification. The co-
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precipitation o f proteins during affinity purification is a recognised phenomenon and 
provides a means by which interacting proteins can be identified. This is eloquently 
demonstrated by Husi et al (2000) who employed immunoaffinity isolation o f the N- 
methyl-D-aspartate (NMDA) receptor from mouse brain to study the associated 
proteins. Their approach resulted in the identification o f 77 co-precipitated proteins. In 
this instance co-precipitation was desirable. With regard to the experiments presented 
here it is unlikely that all proteins other than the 97 kDa antigen were retained due to 
protein-protein interactions (see above), however adapting the method for the 
preparation o f the brain homogenate may have reduced the level o f contaminating 
proteins. Disruption o f protein-protein interactions by denaturing proteins in SDS and 
reduction o f di-sulphide bonds with DTT may be a suitable approach since the 
denatured 97 kDa antigen can be detected following denaturing PAGE electrophoresis 
and immunoblotting. Indeed, systematic investigation o f various protein preparations 
could be employed to ascertain which preparation procedure yields the highest signal to 
noise ratio.
5.4.2 Investigation o f  Potential A uto-antigens.
Probing immunoblots o f the purified proteins revealed that the target antigen was
present in the proteins isolated from the column during the elution phase. However, a
stronger signal was produced by a protein at approximately 55 kDa. Patients serum had
not reacted previously with a protein o f this molecular weight. It was thought that this
protein corresponded to IgG although there was not a sufficient yield to determine
whether this is true (by probing the proteins with anti-human IgG antibody only). It may
have been possible to circumvent this by thorough washing o f the column with elution
buffer prior to introduction o f brain homogenate, however, it is also possible that the
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acid elution protocol resulted in the destruction o f the IgG-column bond and thus the 
elution from the column. If  this was the case the useful life o f the column would be 
finite. Alternative elution strategies such as ionic elution may have proved more suitable 
and should have been investigated.
Despite the disappointing purification o f the antigen a stained gel o f the 
immunopurified proteins following PAGE showed a number o f distinct bands around 
the level o f 97 kDa. Analysis o f these proteins was largely inconclusive. However one 
protein, F3/F11/Contactin precursor, was regarded as a potential antigen but was 
subsequently found to be incorrect following immunoblotting and comparison o f the 
reactivity seen by patient’s serum and an anti-contactin antibody.
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6 Chapter 6: Characterisation of the 97 kDa antigen by means of screening a 
bacteriophage expression library,
6.1 Introduction.
Characterisation o f the majority o f well-recognised anti-neuronal antibodies associated 
with PND has been achieved through the screening o f bacteriophage expression 
libraries. While protein purification techniques had been successfully applied to the 
characterisation o f the 56 kDa protein associated with OM they did not facilitate 
purification o f the 97 kDa protein recognised by antibodies in the serum of the index 
patient with paraneoplastic disease. Attempts to immunopurify the antigen were also 
unsuccessful. The potential reasons for this have been discussed. Due to the previously 
successful application o f phage screening techniques to the identification o f PND- 
associated antigens it was decided that further attempts to identify the 97 kDa antigen 
should be conducted using these methods. An introduction to the technique o f library 
screening is provided below.
6.1.1 Bacteriophage Lambda.
Bacteriophage X has become one o f the most extensively studied viruses o f E. colt. It 
has provided a wealth o f information regarding the regulation o f gene expression and 
has been manipulated to produce a useful tool in the creation o f cDNA libraries.
Bacteriophage X consists o f a 150 nm tail attached to a 50 nm capsular head containing 
a linear 48.5 kbp double stranded DNA molecule. Infection o f a cell follows the binding 
o f a maltose receptor and injection o f the entire strand o f DNA into the host. The
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overlapping 5’ ends o f the linear genome are then ligated by E. coli DNA ligase to form 
newly circularised DNA. Once a host cell has been infected the bacteriophage can enter 
one o f two pathways in the continuation o f its life cycle. These are the lytic and 
lysogenic lifecycles.
It is the lytic phase o f the life cycle that is essential for the screening o f a phage 
expression library. During this phase the circularised genome o f bacteriophage is 
initially replicated producing progeny that are composed o f circularised genomes before 
replication becomes asymmetric resulting in the production o f linear DNA molecules. 
These molecules are packaged into the head o f the bacteriophage and assemble with a 
tail. Accumulation o f new phage results in the lysis o f the host cell after which phage 
are free to infect new host bacteria. Lysis also allows proteins encoded by cDNA 
inserted into the bacteriophage genome to leave the host cell making them accessible for 
detection.
6.1.2 Early libraries.
Completion o f the sequence o f the Bacteriophage X genome (Sanger et al, 1982) 
identified a non-essential DNA sequence and facilitated the development o f early 
bacteriophage expression libraries. Young and Davis (1983) substituted this non- 
essential region with the complete E. coli LacZ gene, encoding beta-galactosidase and 
its promoter to produce bacteriophage Xgtl 1. A Xgtl 1 library is constructed through the 
fusion o f foreign cDNA sequences into a unique Eco R I  site at the beginning o f the 
LacZ gene. cDNA sequences inserted in the correct orientation and reading frame can 
be expressed as fusion proteins by growing A-gtl 1-infected E. coli on plates containing
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IPTG. By screening these proteins with an appropriate antibody bacteriophage carrying 
cDNA for the target protein can be identified and analysed to determine the identity o f 
the antigen. Modem vectors such as X.ZAP (see below) have been designed to facilitate 
this process through the inclusion o f auto-excision protocols which allow automatic 
subcloning o f inserted cDNA fi"om the bacteriophage vector into a plasmid. These 
modem libraries draw on the understanding o f the biology o f the M l3, fl and fd 
coliphage viruses o f E. coli.
6.1.3 Coliphage.
Following penetration o f coliphage into the cytoplasm o f the bacterial host the viral or 
(+) strand is released fi-om its protein capsid, and rapidly converted into double stranded 
‘replicative form’ (R f ) DNA by the action o f host RNA polymerases. The RF molecule 
is then replicated until approximately 100 RF molecules have been produced. At this 
point the accumulation o f viral gene II protein directs asymmetrical replication by 
introducing a nick into the (+) strand o f the RF DNA. Subsequent elongation o f the 3’ 
end o f  the nick displaces the old (+) strand via a rolling circle mechanism. The 
displaced strand is ligated to form a circle o f single stranded DNA molecule which is 
then packaged into a viral particle and extmded non-lytically from the cell.
Investigation into coliphage replication has allowed the isolation o f the ‘fimctional
origin o f replication’. This sequence, when introduced into a plasmid allows it to enter
the fl replicative cycle upon superinfection o f the host with wild type fl helper phage.
Importantly plasmids that enter the fl cycle o f replication are packaged as M l 3-like
particles and extmded, along with wild type M l3, into the culture medium. It was later
discovered that the fl origin o f replication consists o f two similar, overlapping
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sequences, an initiator and a terminator (Dotto et al, 1984). Positioning these sequences 
on different areas o f a plasmid, directs the formation o f single stranded circular DNA 
molecules containing an intact fl origin o f replication and the interposed plasmid DNA.
6.1.4 AZAP
Short et al (1988) exploited the knowledge o f the M l3 life cycle to create the AZAP 
bacteriophage vector. Essentially, the AZAP vector is composed o f three major regions:
1: The plasmid pBluescript (pBS) (see section 6.1.5) into which cDNA is
inserted. This is flanked by:
2: The initiator and terminator regions o f fl all o f which is inserted into:
3: The non-essential region o f the bacteriophage.
The merit o f this vector lies in the ease with which cDNA can be isolated from 
recombinant phage. Once a A,ZAP bacteriophage has been purified from a library, 
excision o f pBS is achieved by co-infecting E. coli with recombinant phage and M l3 
‘helper phage’. As M l3 replicates, gene 2 protein recognises the initiator domain in the 
recombinant phage and initiates excision o f the DNA between the initiator and 
terminator sequences (pBS and cDNA). The resulting single-stranded pBS DNA is 
packaged as M l3 like virus particles and extruded from the cell into the culture 
medium. Removal o f E. coli from culture medium by centrifugation leaves a solution 
containing wild type M l 3 viruses and the M l 3-like virus particle.
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Re-infection o f a second strain o f E. coli which suppresses wild type M l3 replication 
easily separates the virus and virus-like particles. Following infection o f this second 
strain the single stranded pBS from the M l 3-like virus particles is converted to double 
stranded DNA. Selection o f E. coli containing pBS is achieved by plating the bacteria 
on media containing ampicillin. The recovered plasmid contains the reactive cDNA 
suitable for production o f recombinant protein, and can be isolated from the cells ready 
for sequencing.
6.1.5 pB l ue script.
As described above, pBluescript (pBS) is central in the design o f XZAP. The four major 
regions o f the plasmid all have a role to play in the screening and recovery protocol 
applied to A,ZAP libraries. Ampicillin resistance provides a selectable marker while 
ColEl serves as the initiation point for plasmid replication. The fl origin o f replication 
allows the plasmid to enter the f l  replicative cycle (see above) and plays a role in the 
auto-excision o f pBS containing cDNA from selected recombinant bacteriophage. The 
final major area o f pBS is the LacZ gene containing the multiple cloning site (MCS). 
The principles underlying the importance o f this region are similar to those described 
for the use o f the LacZ gene in A,gtll libraries. In contrast to LacZ in Z g tll, which 
encodes the entire protein with only one restriction site (EcoRI), the LacZ gene in pBS 
is incomplete, encoding only the alpha chain o f beta-galactosidase, but with the 
advantage o f a multiple cloning site (MCS) containing 21 unique restriction sites. The 
21 MCS is provided by the introduction o f a synthetic polylinker into the LacZ gene. 
The MCS does not disturb the formation o f a functional alpha peptide until introduction 
o f cDNA causes insertional activation o f the gene.
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6.1.6 Construction o f  A ÀZAP Library.
Modem commercial libraries are prepared using a number o f techniques which enhance 
their application. For example, libraries consist o f cDNA developed using random 
primers in an attempt to develop a better representation o f epitope expression from a 
given tissue (as opposed to the enrichment for 3’ epitopes produced when poly-A 
primers are used during mRNA RT-PCR). In addition, directional insertion o f cDNA 
into the vector ensures that cDNA is inserted in the correct orientation in preparation for 
expression. In doing so the total number o f clones that need to be screened are reduced 
by maximising expression o f inserted cDNA.
6.1.7 Screening a Bacteriophage Library.
All bacteriophage libraries are screened using similar protocols (Figure 6-1). Molten 
agar containing infected E. coli is poured over a solid agar base and incubated. This 
results in the production o f a lawn o f plaques that can be screened efficiently up to 
density o f up to 5x1 O'* plaques per 90 mm plate. Traditional methods o f screening 
involve the placement o f IPTG soaked nitro-cellulose membranes over these plates at 
the beginning o f plaque formation (approximately 3hrs after plating). This ensures a 
more complete representation o f encoded epitopes by delaying the expression of 
potentially toxic foreign proteins. The membranes are then probed with the antibody of 
interest and the appropriate secondary antibody. By referring from the nitro-cellulose 
‘map’ to the original agar plate, phage encoding a recognised protein can be rescued, 
eluted from the agar plug and processed through further rounds o f screening to provide 
a purified phage. Due to the reported occurrence o f false positives when screening it is 
common for duplicate nitrocellulose membranes to be created from each plate.
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1 : Lawn of unselected bacteriophage g:own
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2: Bacteriophage overlaid with IPTG soaked 
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expression from inserted cDNA
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4; Reactive fiaques are mapped back to plate on 
which bacteriophage were grown and those phage 
selected. The cycle is repeated using the selected 
phage until all plaques are reactive.
3: Membranes are probed with antibody of interest 
and conjugated detector antibocfy
Figure 6-1: Screening a bacteriophage expression library.
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6.2 Methods.
6.2.1 Cancer Controls.
Serum from neurologically intact cancer patients were kindly supplied by Dr J Rees 
following application to the relevant ethics committee. Data pertaining to the age and 
sex of the patient and the type o f the cancer were supplied.
6.2.2 Multiple Sclerosis Controls.
Serum from patients with multiple sclerosis was supplied by Dr G Giovannoni. The 
appropriate permission to conduct research using the samples had been obtained. The 
diagnosis had been made by the supplying consultant. No specific clinical information 
was obtained
6.2. S cDNA Library.
A commercial cerebellar cDNA library (Stratagene) was used. The library had been 
developed using cDNA from 11 cerebellar samples from males and females aged 22 to 
70 years using random primers and directional recombination to create a library 
consisting o f 2x10^ primary plaques with an average insert size o f 1.9kb.
6.2.4 Preparation o f  XL 1 -blue M RF \
E. coli XL 1-blue MRF’ were used for the propagation o f bacteriophage. XL 1-blue cells
were streaked onto LB tetracycline plates and incubated overnight at 37°C. A single
colony o f XLl blue cells was used to inoculate 50 ml LB broth supplemented with 10
mM MgS0 4  and 0.2 % maltose. The cells were grown overnight at 30°C to prevent
overgrowth o f  bacterial cultures. The bacteria were harvested the following day by
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centrifugation at 2000 rpm for 10 min and re-suspended in 10 mM MgS0 4  to an OD = 
0.5. Cells were stored at 4°C and used within 5 days o f preparation.
6.2.5 Titrating and Testing fo r  cDNA Insertion.
2 ml o f freshly prepared XLl-Blue MRF’ were infected with dilutions o f bacteriophage 
from the library ranging from 1:10 to 1:1000 in SM buffer. After incubation at 37°C for 
20 min the E. coli were mixed in 25 ml o f molten NZY top agar and applied to a large 
plate (243 mm x 243 mm x 18 mm) containing NZY base. The plates were incubated 
overnight at 37°C. The following morning an appropriate dilution for screening was 
selected. To ensure that cDNA had been ligated into the MGS o f pBS 200 pi of 
prepared XLl-Blue MRF’ were infected with 1 pi o f bacteriophage from the library. 
The infected cells were mixed into 2 ml o f molten NZY top agar which had been 
supplemented with 10 mM IPTG and Xgal (6.25 mg/ml). The agar was poured onto 
petri dishes containing NZY base, allowed to set and incubated at 37°C for 6 to 8 hours.
6.2.6 Infection and Plating o f  X L l blue fo r  screening.
Large (243 mm x 243 mm x 18 mm) NZY agar plates prepared 2 days prior to use were
dried at 42°C for at least one hour. NZY top agar was melted and divided into 25 ml
aliquots which were cooled to 50°C in a water bath. Stock bacteriophage library was
diluted 1:66 in SM buffer and stored at 4°C until required. 1 pi o f diluted bacteriophage
was used to infect 1.2 ml o f XLl blue (prepared as above) by incubation at 37°C
without shaking for 20 min. Infected bacteria were then combined with the molten NZY
top agar, mixed gently and poured over the dried NZY base plates. The plates were left
to set for 10 min before incubation at 42°C for 3.5 hours. Nitro-cellulose membranes
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were labelled and soaked in 10 mM IPTG. The membranes were dried between paper 
towels and placed on the bacterial plates at the end o f the 3.5 hr incubation. The 
temperature was reduced to 37°C and incubation continued overnight.
6.2.7 Probing Nitrocellulose Membranes.
Prior to the removal o f the nitro-cellulose membranes the plate lids were removed for 30 
min. The membranes and underlying agar were pierced using a pin to provide 
orientation marks for later reference and the membranes carefully removed to avoid 
disturbing the underlying top agar. The membranes were then placed directly into TNT 
buffer and any top agar removed using a gloved finger prior to blocking for Ihr in TNT 
blocking buffer. Blocking buffer was then substituted with patients serum diluted 
1:1000 in TNT containing 0.2% dry milk powder. The membranes were incubated with 
this solution overnight at 4°C. Removal o f anti-E. coli antibodies was not required at 
this stage as the density o f E .coli antigen meant any background reactivity was 
sufficiently reduced to allow signal to be detected. Following incubation the antibody 
solution was decanted and saved for subsequent rounds o f screening. The antibody 
solution was periodically used to probe immunoblots o f pig cerebellum to ensure that 
reactivity with the 97 kDa antigen remained. The membranes were washed for 1 hr with 
6 changes o f TNT buffer containing 0.1% BSA and then incubated with HRP- 
conjugated rabbit anti-human IgG antibody solution (diluted 1:1000 in TNT buffer 
containing 0.2% dry milk powder) for 1 hr at room temperature prior to further rounds 
o f washing. The membranes were then developed in chromogenic developing solution 
for one hour. Positive plaques were mapped onto acetate sheets which were then used to
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refer back to the original plates. Plaques were cored using a pipette tip and placed in 1 
ml SM buffer, vortexed and stored at 4°C for further investigation.
6.2.8 Subsequent Screens.
Positive bacteriophage were diluted 1:10, 1:100, 1:1000 and 1:5000 in SM buffer. 1 pi 
o f each dilution o f bacteriophage was used to infect 200 pi X Ll blue as described above 
and combined with 3 ml molten NZY top agar. The top agar was poured over 9 cm 
NZY plates and incubated overnight at 37°C. A suitable dilution o f phage was selected 
to allow individual plaques to be selected and protein expression conducted using the 
IPTG-soaked membranes as detailed for the initial screening round. Successive rounds 
o f screening were continued until greater than 90 % of the plaques yielded a positive 
signal. The final selected phage was designated phage 20A, B or C.
6.2.9 Testing Selected Phage Using Control Serum.
Step 1:
25 ml o f NZY top containing 1200 pi o f X Ll Blue infected with 1 pi o f unselected 
phage from the raw library was poured over large NZY bases plates (243 mm x 243 mm 
X 18 mm). The plates were then incubated at 42°C for 3.5 hours before dry 9cm^ 
squares of nitro-cellulose were placed over the top. The plates were then incubated 
ôvemight. The next day the nitro-cellulose membranes were prepared as described 
above with both washing and blocking steps before being placed into 10 well manifolds. 
Control sera diluted 1:1000 in 0.2 % milk, 0.9 % saline was then incubated in individual 
wells with the membranes overnight to reduce the level o f E. coli antibodies. In the 
meantime, large (243 mm x 243 mm x 18 mm) plates o f selected phage 20A were
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prepared using a phage dilution that allowed the growth o f well-defined plaques evenly 
distributed across the plate. After 3.5 hours incubation at 42°C 9 cm^ sections of nitro­
cellulose impregnated with 10 mM IPTG were placed over the phage and incubation 
continued at 37°C overnight. The next day the membranes were washed and blocked as 
described for the initial library screening, and placed into 10 well manifolds. The sera to 
be tested was then transferred from the manifold containing the non selected phage and 
used to probe for specific reactivity with the selected phage. Secondary rabbit anti 
human HR? antibody was diluted 1:1000.
Step 2:
Some serum required a second screening for anti-phage activity. Serum samples that 
were thought to have some anti-phage activity in stage 1 were tested using the second 
stage. Selected phage 20A and raw library were titered and the dilutions which gave 
approximately 50 plaques used. 200 pi of E.coli were infected with both phage 20A and 
non-selected phage using those dilutions and the E. coli spread on NZY plates. The 
resulting lawns consisted o f 50 % selected phage. Membranes were produced as 
described and incubated with pre-absorbed serum (see stepl). The serum from the index 
patient was always included as a positive control. Samples were defined as negative if 
there were no anti-phage antibodies or the percentage o f positive plaques was greater 
than produced by the positive control as this would imply global background reactivity, 
not a phage specific response.
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6.2.10 pBluescript Excision.
The SOLR strain o f E. coli is designed for use in the pBluescript excision protocol. It 
allows only excised pBS phagmid to replicate and removes the possibility o f co- 
infection with helper phage. SOLR were plated grown on LB kanamycin plates (75 
ng/ml) and incubated at 37°C overnight. Single colonies o f X Ll and SOLR were grown 
overnight at 30°C in LB broth supplemented with 10 mM MgS0 4  and 0.2 % maltose. 
The cells were harvested by centrifugation and re-suspended in MgS0 4  to OD = 1.0. 
200 jil o f XLl-Blue were combined with 250 pi o f the selected bacteriophage and 1 pi 
o f helper phage and incubated at 37°C for 15 min. 3 ml o f LB broth was added to the 
excision reaction and incubated for a further 3 hrs at 37°C with shaking. The reaction 
mixture was then heated at 70°C for 20 min to kill the XLl-blue cells which were then 
removed by centrifugation. The supernatant containing the excised pBluescript 
packaged as filamentous particles was decanted and stored. 200 pi o f SOLR cells were 
combined with 100 pi o f the phage particles, incubated at 37°C for 15 min to allow 
infection to take place. SOLR containing the excised pBluescript were selected by 
plating 200 pi o f the infected bacteria on the LB ampicillin plates and incubating 
overnight at 37°C. Cells were then grown in LB broth supplemented with the 
appropriate antibiotics and glycerol stocks were produced. In addition, the plasmid was 
extracted from 4 ml o f culture using the method described (See Chapter 8) and used for 
characterisation o f the encoded protein.
6.2.11 Restriction Analysis and Sequencing o f  pBluescript.
Restriction enzymes that cut as close as possible to the cloning site used in the creation
of the cDNA library were selected. The restriction digest reaction consisted o f 2 pi lOx
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BSA, 2 buffer 2 (New England Biolabs), 1 |il DNA and 13 pi H2O. The reaction 
mixture was mixed gently by pipette and 1 pi o f both Bam H I and Xho I  added. The 
reaction was left under paraffin at 37°C for at least 4hrs before analysis by 
electrophoresis through a 0.7 % agarose gel. A 1 kb DNA ladder was also included to 
allow estimation o f insert size. Digests were visualised under UV illumination and 
pictures recorded. The sequence o f the inserted cDNA was determined using the method 
described in section 8.2.6.
6.2.12 Expression and Detection o f  Protein From pBluescript 20A.
Glycerol stocks o f SOLR containing pBS recovered from bacteriophage 20A were 
plated on LB ampicillin plates and incubated overnight at 37°C. The following evening 
a single colony was selected and used to inoculate 5 ml o f LB ampicillin broth. Protein 
expression was induced as described (section 8.2.10). The cells were pelleted by 
centrifugation at 4000 rpm for 10 min, the supernatant decanted and the cells snap 
frozen in liquid nitrogen. The cells were stored at -80°C until required. SOLR 
containing pB S lC l isolated from a previous experiment with which the patients serum 
did not react were prepared as described above and used as a control.
Bacterial homogenates were prepared as described (see 8.2.11). The total protein 
concentration o f the pBS20A and pB S lC l homogenates was calculated and then 
standardised by the addition o f water to the more concentrated sample. 65 pi o f each 
sample were added separately to 25 pi o f LDS and 10 pi DTT. The samples were 
subjected to PAGE using a 4-12 % Bis-Tris gel in the presence o f MOPS buffer. Gels
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were stained or immunoblotted. Immunoblots were probed with serum from the index 
patient diluted 1:1000 and developed using ECL.
6.2.13 Removal o f  A nti-E. coli A ntibodies from  Patients Serum.
The excessive background signal produced when probing the immunoblots o f pBS20A 
and pB S lC l highlighted the need to apply preparative steps to the patient’s serum. A 5 
cm^ section o f nitro-cellulose membrane was incubated with 2 ml of SOLR pB S lC l 
bacterial homogenate at room temperature for 5 hours. The homogenate was decanted 
and the membrane blocked with 2 % milk 0.9 % saline solution. Patients serum was 
diluted 1:1000 and 3 mis o f this solution incubated with the E. co/Tcoated membrane 
overnight. The serum was then used to probe immunoblots o f the bacterial 
homogenates containing pBS20A or PBS I C l .
6.2.14 Subcloning o f  20A IntopRSETB.
Sequence data obtained from pBS20A, the published sequence o f the pRSET vectors, 
and restriction analysis o f the cDNA insert were used to select a vector into which the 
cDNA sequence could be inserted that would maintain the same reading frame as found 
in the pBS vector. The restriction enzymes BamHI and X ho l were selected to digest the 
cDNA from pBS20A. The resulting fragment was predicted to contain a small fragment 
o f pBS at the 5’ end o f the molecule. pRSETB and pBS20A were both digested 
overnight at 37°C with both BamHI and Xhol, separated in a 0.7 % agarose gel and the 
appropriate fragment purified from the gel. 2 pi o f CIP was included in the digestion 
reaction o f pRSETB to reduce the level o f background produced in the ligation reaction. 
The cDNA fragment from pBS20A and pRSETB was ligated and 2 pi o f the ligation 
reaction was then used to transform competent TOPI OF’ cells.
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Cells were grown in 5 ml SOB broth, harvested by centrifugation and the plasmids 
isolated. The plasmids were analysed by single digestion using X hol and separated by 
electrophoresis through a 0.7 % agarose gel. Unligated pRSETB was used as a negative 
control. Colonies found to contain a successfully ligated vector were designated 
pRSETB20A and used to produce glycerol stocks.
6.2.15 Subcloning o f  20A Into pRSETC.
To allow the production o f full length protein sequence data from pBS20A, the pRSET 
vectors and genebank were used to determine which bacterial expression vector the 
cDNA could be inserted into to allow transcription o f the longest open reading frame. 
pRSETC was selected for ligation with the cDNA. pRSETC and pBS were digested 
with BamHI and Xhol. The ligation reaction, transformation and analysis o f colonies 
were conducted as described (Section 6.2.14).
6.2.16 Sequencing and Protein Prediction.
Ligated pRSET plasmids were sequenced using a primer complementary to the T7 
promoter o f the pRSET plasmid (5’-AATACGACTCGGG-3’). The known sequence of 
each pRSET plasmid and the inserted DNA from the bacteriophage was used to 
establish the reading frame o f the inserted sequence. The predicted molecular weight of 
the recombinant protein was calculated using the translate and mw/pi tools on the 
Expasy website (www.expasy.org/tools). Once it had been established that the pBS 
fragment had been inserted into the correct reading frame the vectors were used to 
transform BL21 (DE3) pLysS in preparation for expression which was conducted
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exactly as described for previous proteins expressed by the pRSET vectors (See 
chapters two and three).
6.2.17 Detection o f  Expression o f  His-Tagged Proteins From pRSETB20A.
E. coli containing pRSETB20A or pRSETB were grown, protein expression induced 
and homogenates produced. The total protein for both homogenates was calculated and 
standardised by the addition o f water to the more concentrated sample. The same 
volume o f both bacterial preparations was subjected to IMAC. Post-purification samples 
were prepared for PAGE, applied to a 4-12 % Bis-Tris gel and subjected to 
electrophoresis and immunoblotting as described (Chapter 8). Blots were probed using 
anti-His and patients serum, and developed using ECL. In addition, homogenates 
separated by PAGE were stained with colloidal blue to allow visualisation o f bands 
corresponding to the recombinant proteins.
6.2.18 Comparison o f  Reactivity o f  Serum with Crude Bacterial Homogenates o f  
pRSETB20A andpRSETC20A.
E. coli BL21 (DE3) pLysS containing pRSETC20A were grown overnight at 37°C on
SOB agar containing chloramphenicol and ampicillin. Protein expression was
conducted and homogenates o f pRSETB, pRSETB20A and pRSETC20A were
produced. 3 ml o f lysate produced from cells containing pRSETB only was used to coat
two 5 cm^ sections o f nitrocellulose membrane. Following incubation with the lysate for
5 hours at room temp the membrane was blocked for one hour using 2 % milk/ 0.9 %
saline solution. Patients serum was diluted 1:1000 in 8 ml o f 0.2 % milk/ 0.9 % saline
solution applied to the membranes and incubated overnight at 4°C. The total protein of
the three lysates was calculated, the concentration standardised and 25 pi of each
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sample subjected to electrophoresis through a 4-12 % Bis-Tris PAGE gel. An 
immunoblot o f the homogenates was then prepared as described (Chapter 8). Following 
blocking, the membranes were incubated overnight with the serum which had been pre­
absorbed by incubation with the pRSETB membrane. Following washing rabbit anti­
human HR? secondary antibody was applied to the membrane at a dilution o f 1:5000. 
Blots were developed using ECL.
6.2.19 Avoiding Proteolysis o f  Recombinant Protein pRSETC20A:
6.2.19.1 Timed Expression o f  Recombinant Protein from  pRSETC2 OA:
Cells containing pRSETC20A were grown to an OD of 0.4-0.6. A 1 ml aliquot was 
removed (designated time 0) and IPTG added to a final concentration o f 1 mM. 1 ml 
aliquots were subsequently taken every 30 min for 3 hours. The aliquots were spun at 
4000 rpm for 5 min, the supernatant removed and the pellet flash frozen in liquid 
nitrogen. Pellets were stored at -80°C until required. Homogenates were prepared from 
the pellets as described (Chapter 8). The protein concentration of each pellet was 
determined and adjusted to 1 mg/ml with H2O. The samples were prepared for 
electrophoresis by the addition o f 25 pi o f LDS and 10 pi of DTT to 65 pi o f each 
homogenate. The samples were heated at 65°C for 15 min and 25 pi of each 
electrophoresed through a 4-12 % Bis-Tris PAGE gel. Immunoblots were prepared as 
described (Chapter 8) and probed with anti-His antibody diluted 1:5000. Blots were 
developed using ECL.
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6.2.19.2 Varying Bacterial Protease Inhibitors:
In an attempt to reduce the level o f proteolytic degradation a variety o f bacterial 
protease inhibitors were used. E. coli containing pRSETC20A were grown and induced 
as described (Chapter 8). Homogenates were prepared with the addition of
1 : Bacterial protease inhibitor cocktail (Calbioscience).
2: Bacterial protease inhibitor cocktail (Sigma).
3: Bacterial protease inhibitor cocktail (Sigma) with the addition o f PMSF.
The protein concentration o f each homogenised sample was determined and 
standardised. Proteins were separated by PAGE and immunoblotted. Blots were probed 
with anti-His antibodies and developed using ECL.
6.2.19.3 Varying Homogenate Production:
To determine if  expressed proteins were being degraded during preparation o f the 
bacterial homogenates alternative methods o f preparation were explored. Cells 
containing recombinant protein were produced and lysed as described. Alternatively 
cells were lysed with Bug Buster (Pierce, UK) containing protease inhibitors 
supplemented with PMSF with the omission o f the sonication step. Samples were 
subjected to PAGE and immunoblotted. Blots were probed with anti-His antibodies and 
developed using ECL.
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6.3 Results.
6.3.1 Antigen Identification Using Patient’s Serum to Screen a Bacteriophage 
Expression Library.
The cerebellar library was selected as immunoblotting o f cerebellar tissue had 
confirmed cerebellar expression o f the antigen (See section 4.3.3). Serum from the 
patient o f interest was used to screen a total o f 1.75x10^ plaques. A single reactive 
plaque was identified and was purified through subsequent screens until greater than 90 
% of the plated plaques reacted with the patient’s serum (Figure 6-2).
6.3.2 Control Reactivity with Selected Phage.
During the initial testing o f control serum phage 20A was used to create control 
membranes against which up to 10 patients sera could be tested for reactivity (Figure 
6-3). The secondary antibody (rabbit anti-human HRP) did not react with the selected 
phage (Figure 6-3, lane 10). The results obtained using control sera are shown in Table 
6-1 (centre column).
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Figure 6-2: Screening for and selection of positive plaques.
A: Nitrocellulose membrane probed with patients serum after incubation with bacteriophage which had 
been passed thorough a number o f rounds of screening to produce a population o f which 90 % produced a 
protein recognised by patient’s serum. B: Patients serum did not react with non-selected phage titred to 
give a similar density o f plaques at each stage o f screening. Anti-Human IgG did not react with the 
selected phage on any o f the control blots.
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Figure 6-3; Testing control serum against phage 20A (stage one).
9cm^ sections o f nitrocellulose membrane were incubated with selected phage (20A) and probed with 
preabsorbed serum from the index patient and controls. Lane 1 : positive control (index patient). Lanes 2-4 
and 11-17: Anti-Hu positive. Lanes 5, 6 and 18, 19: Anti-Yo positive. Lanes 7-9 and 20: Neurologically 
normal adult control. Lane 10: Secondary antibody only. + = Positive for anti-phage antibodies.
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Table 6-1: Control serum tested against phage 20A
Control group, n Number positive: 
First screen
Number positive: 
Second screen
Paraneoplastic neurological disease, (19) 5 1
Anti Hu positive, (13) 3 0
Anti-Yo positive, (6) 2 1
Multiple sclerosis, (33) 12 0
Cancer controls, (4) 1 0
Encephalitis, (3) 0 NA
Movement disorders, (12) 0 NA
Dystonia, (9) 0 NA
Parkinson’s disease, (3) 0 NA
Neurologically normal adult controls, (15) 1 0
Total, (86) 19 1
Unexpectedly, a total o f 19 serum samples reacted with the selected phage despite pre­
absorption o f serum against E. coli and non-selected phage. In particular, serum from 
12/ 33 (36%) patients with multiple sclerosis gave a positive result. However as a 
consequence o f the method design a negative control lane containing unselected phage 
and E. coli was not included on the same blot. Thus the first screen only facilitated the 
detection o f non-reactive serum controls. There was no way of determining whether a 
signal was due to specific phage reactivity or due to presence o f residual anti-E. coli 
antibodies. Subsequently, sera that reacted during the first screen were subjected to 
testing against membranes prepared using a mixture o f plaques containing 50 % phage 
20A and 50 % unselected phage. This method provided an internal control. Samples
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either did not react, reacted with all phage or reacted with selected phage. Samples that 
reacted with all phage could not contain phage specific antibodies. Representative 
membranes are shown in Figure 6-4.
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Figure 6-4:Testing control serum against phage 20A (stage two)
Membranes were produced from cultures infected with a 50:50 mix o f selected phage 20A and unselected 
phage. Serum samples were considered negative for anti-phage antibodies if there was no reactivity or 
serum reacted with all phage. Membrane A shows a globally reactive serum sample. In contrast the serum 
from the index patient recognised only specific phage (membrane B). Only 1 of 86 control sera showed 
selective reactivity with the selected phage (membrane C). Clear delineation between background 
reactivity and true signal can be seen at over lapping plaques (arrow).
Control data from the second screen is given (Table 6-1), right hand column. Of a total 
of 86 control samples tested using the first and second screen protocols only one patient 
with PCD and anti-Yo antibodies had a specific anti-phage 20A antibodies. The serum 
from this patient clearly reacted more strongly with the selected phage (Figure 6-4, 
membrane C).
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6.3.3 Case Details o f  Anti-Yo Positive Patient Reactive Against Phage 20A 
A 46-year-old female underwent a left mastectomy with axillary node clearance for 
ductal carcinoma in July 1999. The patient subsequently received a course of 
chemotherapy following the histological identification o f axillary node involvement. 
There were no reported neurological signs at the time of treatment.
In December 1999 the patient was referred to a consultant neurologist with a one month 
history o f unsteadiness with altered sensation in the fingertips of her left hand. The 
patients gait was slow and careful but there was no fi*ank ataxia. Power in the upper 
limbs was good with slight reduction in the lower limbs. Deep tendon reflexes were 
absent. Plantar responses were flexor. Position sense o f the toes was absent and 
vibration sense was reduced. The consulting neurologist doubted a generalised 
neuropathy due to the asymmetrical nature o f the signs and symptoms and suggested a 
metastatic or paraneoplastic cause relating to the original breast tumour.
Examination o f the CSF revealed seven white cells and a protein of 1.8 g/1. 
Immunohistochemical investigation revealed weak staining o f the Purkinje cell 
cytoplasm with stronger staining o f the DRG. The serum also reacted with recombinant 
Yo. By March 2000 the patient’s condition had deteriorated significantly however 
specific details were unavailable.
The patient died in July 2000 and an autopsy was performed. This revealed the presence 
o f a carcinoma o f the right lung with lymph node involvement and a broncho­
pneumonia. Histology demonstrated a SCLC.
215
6.3.4 Sequencing pBluescript 20A, B, C.
Three plaques were selected from the final plate o f bacteriophage. pBS was excised and 
designated pBS20A, pBS20B, pBS20C. Restriction analysis o f each plasmid using 
double digestion yielded an identical band pattern suggesting that that the three selected 
clones contained an identical insert. The inserted cDNA was approximately 7400 bp in 
length.
The cDNA insert was sequenced as described. The sequence from each plasmid (pBS 
20A, 20B and 20C) was identical. A BLAST search identified the insert as an 
incomplete fragment o f transcription factor-like nuclear regulator (TFNR). TFNR 
cDNA has a 6762 open reading frame. Comparison o f the published DNA sequence of 
TFNR (accession no: AJ238520) with the DNA sequence obtained from pBS 20A 
showed that the cDNA extended from base number 2017 and incorporated all the 
following 4745 bases listed in the published sequence to the stop codon. The remaining 
2600 (approx) bases downstream of the stop codon could not be sequenced. 
Examination o f the sequence data revealed that the inserted cDNA was not in the same 
reading frame as the start codon incorporated into the pBS plasmid (Figure 6-5).
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pBS start codon
ATG ACC ATG ATT ACG CCA AGC TCG AAA TTA ACC CTC ACT AAA GGG AAC AAA AGC
M T M I  T P S S K L T L T K G N K S
TGG AGC TCC ACC GCG GTG GCG GCC GCT CTA GAA CTA GTG GAT CCC CCG GGC TGC
W S  S T A  V A  A A L E  L V D  D P  P G
Inserfid cDNA
AGG AAT TCG GCA CGA GGA TCAAACAGAAAA TGTTAA 
C R N S  A G S N R K C  stop
Figure 6-5: DNA and amino acid sequence of the TFNR cDNA inserted into 
pBS20A.
Only the final 5 amino acids are encoded by the inserted cDNA before a stop codon is encountered. This 
sequence, including the amino acids encoded by pBluescript encodes a peptide with a molecular weight 
of approximately 10 kDa.
6.3.5 Reactivity o f  Patients Serum with Proteins Producedfrom pBS20A 
A  colloidal stained gel of bacterial homogenates containing pBS20A or pB SlC l 
(control pBS) were prepared as described. Interpretation of the gel was hampered since 
recombinant proteins were not purified from the crude homogenate resulting in a large 
number of bands corresponding to bacterial proteins. Colloidal blue staining failed to 
show an additional protein at the predicted molecular weight o f 10 kDa in the pBS20A 
homogenate. Pre-absorbed serum using homogenates of pB SlC l successfully reduced 
the level of background signal produced when probing immunoblots o f bacterial 
homogenates with patient sera and ECL. However, no additional band could be 
observed when pBS20A bacterial homogenate was probed with the patient’s serum.
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63.6  Subcloning o f  cDNA 20A Into the Bacterial Expression Vectors pRSETB: 
cDNA from pBS20A was subcloned into the pRSETB expression vector to provide a 
detectable tagged protein while maintaining the original reading frame. A total o f eight 
colonies were grown from transformed E. coli TOPI OF’ following antibiotic selection. 
Restriction analysis using Xhol revealed that seven o f the eight colonies contained 
plasmids that were of the correct size (10,400 bp approx).
Sequencing from the T7 promoter of the pRSET vector revealed that all seven plasmids 
contained the cDNA inserted into the expected reading frame and that the stop codon 
that terminated transcription in pBS20A had been preserved. The predicted molecular 
weight of the tagged recombinant protein was calculated as 8kDa, the final 5 amino 
acids encoded in the pBS20A vector were conserved (Figure 6-6).
pRSETB start codon
ATG COG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA
M R G S H H H H H  H G M A S M T G  G
Original pBS vector
CAGCAA ATG GOT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CCC CCG GGC TGC
Q Q M G  R D L Y D  D D D K D P  P G  C
bistrUd cD}tA
AGG AAT  T C G GCA CGA GG4  TCAAACAGAAAA TGT TAA 
R N  S A R G S N R K C  stop
Figure 6-6: DNA and amino acid sequence following subcloning of TFNR from 
pBS20A into the pRSETB bacterial expression vector.
Subcloning o f the cDNA from pBS20A into pRSETB allowed the addition o f a His tag to the original 
peptide allowing easy purification for further analysis. The final 5 amino acids encoded by the cDNA 
were conserved.
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Expression o f recombinant protein was conducted from E. coli containing pRSETB or 
pRSETB20A and His-tagged proteins purified using IMAC. WTien proteins purified 
from the pRSETB20A vector were probed with anti-His antibody a protein with a 
molecular weight o f approximately 8 kDa was detected (Figure 6-7, C). In contrast no 
protein was detected when the antibodies were used to probe post-IMAC proteins from 
pRSETB (not shown). The patient’s serum reacted with numerous post-IMAC proteins 
from E. coli containing pRSETB20A (Figure 6-7, A) however these proteins were also 
recognised in post-IMAC preparations o f pRSETB (Figure 6-7, B). Importantly, a 
specific reactivity at the molecular weight o f the His-tagged proteins in pRSETB20A 
could not be detected (compare Figure 6-7 A and C). These results suggest that the 
patients serum did not react with the peptide encoded by the out o f frame cDNA in 
pRSETB20A and thus did not recognise the protein encoded from the start codon o f 
pBS in pBS20A.
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pRSETB20A pRSETB pRSETB20A
Serum ([ndex patient) Anti-His
Figure 6-7: Reactivity of patients serum and anti-His antibodies against post- 
IMAC proteins from pRSETB20A and pRSETB.
As predicted, the anti-His antibody detects a protein with an approximate molecular weight of 8 kDa. 
Patient’s serum also recognised a number of proteins however the reactivity was also present in the 
control preparation of E. coli. These results indicate that the antibodies in the patient’s serum do not 
recognise the protein encoded by the out-of-frame TFNR cDNA as found in the original pBS20A 
plasmid.
6.3.7 Subcloning o f  cDNA 20A Into the Bacterial Expression Vectors pRSETC 
cDNA from pBS20A was subcloned in to pRSETC in an attempt to express 
recombinant protein corresponding to the available open reading from of TFNR. Six 
colonies were grown from transformed TOPI OF’ following antibiotic selection. No 
colonies were grown from the plate inoculated with double digested pRSETC only. 
Single enzyme restriction analysis with Xhol revealed that all six colonies contained a 
successfully ligated plasmid of the correct size (10,400 bp).
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Sequencing from the T7 promoter showed that the cDNA had been inserted in frame 
with respect to the start codon contained within pRSETC (Figure 6-9). The predicted 
molecular weight o f the recombinant protein was calculated as 190 kDa. The ligated 
plasmids were designated pRSETC20A.
Protein expression and purification revealed that a range of proteins were recognised by 
anti-His antibody and that this reactivity was similar when the purified proteins were 
probed with serum from the index case.
pRSETC start codon
ATG CGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA
M R G S H H H H H  H G M A S M T  G G
O r^iiulpB S vecter
CAG CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CGA TCC CCC GGG
Q Q M G R D L Y D D D D K D R S  P G
Inserted cDNA
CTG CAG GAA TTC GGC ACG  AGG A.AT CAA ACA GAA A AT G7T AAA CCA ATG TTG AGA  
L Q E  F G T R N Q T E N V K P M L R
GGT CGC TTC CAAAGA CCT...................
G R F Q R P
Figure 6-8: DNA and amino acid sequence following subcloning of TFNR cDNA 
frompBS20A into the pRSETC bacterial expression vector.
6.3.S Reactivity o f  Patients Serum with Homogenates o f  pRSETB20A and 
pRSETC20A:
The patient’s serum pre-absorbed with the crude homogenate produced from BL21
(DE3) pLysS still contained residual anti-E. coli as evidenced by the production of
bands when the control homogenate was probed on immunoblot (Figure 6-9, lane 1). In
confirmation of the previous experiment (Figure 6-9), the patient’s serum did not
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recognise a protein at the 8  kDa level when probing immunoblots o f crude E. coli 
containing pRSETB20A. However, intense signal was produced over a range from 49 to 
150 kDa which was not seen in the control lane. A similar pattern o f intense signal was 
also seen when the pre-absorbed patient’s serum was used to probe homogenates from 
pRSETC20A but with the addition o f some bands at lower and higher molecular 
weights (28 - 188 kDa). The large number o f reactive proteins in pRSETC20A suggests 
that proteolytic degradation had occurred which was later confirmed (see section 6.3.9). 
Since the cDNA inserted into pRSETB is out of frame the common bands seen in the 
pRSETB20A and pRSETC20A protein preparations must be a result o f transcription of 
the cDNA from a codon contained within the inserted sequence, and not due to 
expression from the pRSET start codon. This may account for the apparent lack of 
reactivity o f patients serum with the predicted proteins encoded from the start codon in 
both pBS and pRSETB20A. That none o f the out o f frame proteins were His-tagged 
would also explain the lack o f reactivity with post-IMAC preparations o f pRSETB20A 
(Figure 6-7, A) since any non-tagged recombinant proteins would have been removed 
from the column during the washing step.
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Figure 6-9: Comparison of reactivity of patients serum with pRSETB20A and 
pRSETC20A.
Immunoblot o f E. coli homogenates containing 1: pRSETB 2: pRSETB20A 3: pRSETC20A were probed 
using patients serum following incubation with the pRSETB homogenate. Additional bands could clearly 
be identified in lanes 2 and 3.
6.3.9 Timed Expression o f  Recombinant Protein From pRSETClOA Confirms 
Degradation.
To determine whether the multiple reactive bands detected in the pRSETC20A 
homogenate were a result of proteolytic degradation and whether this breakdown could 
be prevented by reducing the induction time, expression was conducted and samples 
taken at 30 min intervals. Homogenates of each sample were prepared, immunoblotted 
and probed with the anti-His antibody.
Some His-tagged proteins could be detected at time zero indicating that there was some 
‘leak’ of the expression vector. In addition a larger number of proteins were detected
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with molecular weights ranging from 20 to 188 kDa. The number o f bands increased 
with the length of induction. The reactivity corresponded roughly to the proteins 
detected when the patient’s serum was employed to probe the pRSETC20A immunoblot 
(see Figure 6-9, lane 3). At no time was a single His-tagged protein detected.
kDa
188
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49
28
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Figure 6-10: Timed protein expression from pRSETC20A.
Samples o f induced BL21 pRSETC20A were taken at 30 minute intervals, homogenised, immunoblotted 
and probed with anti-His antibodies. Some tagged protein could be detected prior to induction with IPTG. 
Following induction the number o f His tagged proteins visibly increased. These proteins had a MW 
ranging from 20 to 98 kDa (approx). The bands broadly corresponded to those seen when blots of  
pRSETC20A were probed with patient’s serum.
6.3.10 Reducing proteolytic degradation o f  recombinant protein 20A
In an attempt to reduce the amoimt of proteolytic degradation of protein 20A the
composition o f the bacterial protease inhibitors was altered and their effect assessed by
probing immunoblots of crude homogenates with the anti-His tagged protein. None of
the different inhibitor cocktails or the inclusion of PMSF with the cocktail had any
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noticeable effect on the prevention o f degradation. To determine whether the process of 
sonication was increasing the breakdown o f the recombinant protein a detergent lysis 
method was employed in the preparation o f the bacterial homogenate. The use o f this 
method had no noticeable effect in the reduction of the number o f recombinant proteins 
detected by the anti-His antibody.
6.4 Discussion.
Many PND associated antigens have been characterised through the screening o f 
bacteriophage expression libraries (see section 1.4). During our investigations the 
application o f protein purification techniques to the identification o f the 97 kDa 
neuronal protein recognised by the serum o f the index patient proved unsuccessful. As a 
result the decision was taken to screen a cerebellar expression library as a means o f 
characterising the target antigen.
6.4.1 Screening the Library: Technical Considerations.
A number o f points regarding the methodology o f screening a bacteriophage expression
library should be noted. Firstly, the use o f patient serum to screen a bacteriophage
library carries with it potential problems. For example, given that a large number o f
plaques must be screened a large volume o f serum may be required. In addition, using
E. coli as a vehicle for the production o f the recombinant protein may be problematic
given the occurrence of anti-E. coli antibodies in serum samples. In the experiments
described here both o f these problems were avoided simply by re-using antibody
solution over a number o f nitro-cellulose membranes. The benefits of this are twofold.
Firstly, the re-use of antibody solution dramatically decreases the total volume o f serum
required to efficiently screen a large number o f phage while the quality of the antibody
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solution can be easily assessed by its application to immunoblots o f neuronal tissue. 
Secondly, reusing the antibody solution results in the removal o f anti-E.co/z antibodies 
with each membrane probed thus increasing the signal to noise ratio with each round o f 
screening. In reality the use o f dense lawns o f plaques and large nitro-cellulose 
membranes in the initial screening process negates the need to remove contaminating 
anti-E. coli antibodies as the anti-E. coli response is spread so widely that no 
background signal can be detected even on the first use o f the serum. However, the pre­
absorption o f E. coli antibodies becomes more important during subsequent rounds of 
screening when lower numbers o f phage are plated.
As discussed in earlier chapters potential auto-antigens such as a-enolase and NLK may 
have been conserved during evolution. Probing homogenates o f E. coli with commercial 
anti-NLK antibody resulted in the identification of a bacterial protein which could have 
conceivably been due to anti-NLK recognition o f E. coli glucose-6 -phosphate 
isomerase. With this in mind it may be a worthwhile precaution to determine if  the 
antibody o f interest can be absorbed out by preincubation with crude E. coli 
homogenates. Antibodies which do so will undoubtedly be unsuitable for screening 
bacteriophage libraries.
Finally, during the screening process it must be remembered that detection o f a protein
can only be achieved if  a bacteriophage encoding the recognised antigen is plated.
cDNA may be cloned into the expression vector in one o f three reading frames thus
increasing the total number o f bacteriophage that must be screened to detect the protein.
The process is even more difficult if  the protein is relatively under-expressed or toxic to
E. coli thus preventing its expression. While an attempt to avoid toxicity is made by
226
inducing protein expression after plaque formation, some proteins may simply not be 
detectable. These caveats should be remembered when attempting to screen a 
bacteriophage library and a decision made as to when screening should cease.
6.4.2 Screening with Patients Serum.
We used the serum of the index patient with a PND to screen a cerebellar expression 
library. Re-use o f serum meant that only a small amount was required to screen the 1.75 
X 10  ^plaques. The patients antibodies reacted with a single plaque which was purified 
until a homogenous population o f bacteriophage were isolated.
The cDNA was rescued by application o f the pBS recovery protocol in preparation for 
sequencing and protein expression. Initial attempts to express the protein from pBS 
proved problematic. Thus a novel strategy was employed to test control sera against the 
bacteriophage to determine if further investigation was worthwhile. This method used a 
two-stage process using a 50/50 mix of phage 20A and unselected phage. Control sera 
from 8 6  subjects were tested. A similar method for screening controls has previously 
been described by Bataller et al (2003). This group identified an association between 
anti-MAZ antibodies and Tr positive patients with PCD. Similarly to our experiments, 
attempts to immunoblot the MAZ recombinant protein from pBS were unsuccessful. 
The group suggested that this was a result o f loss o f a conformation epitope which was 
conserved during plaque formation but lost during sample preparation o f proteins for 
immunoblotting, a suggestion which may not be true o f the results presented here (see 
below 6.4.4). O f the 8 6  control sera tested only one sample contained antibodies that 
specifically reacted with phage 20A. The case history o f this patient has been provided 
(see section 6.3.3).
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6.4.3 The Reactive Patients.
There are similarities between the histories o f the index and reactive control patient. 
Interestingly, both patients had undergone treatment for malignant disease prior to the 
onset o f neurological symptoms, but in both cases neurological disease was thought to 
be related to the occurrence o f a second malignancy. While malignant tissue was never 
isolated from the first case, the occurrence o f LEMS with anti-VGCC antibodies and 
radiological changes was highly suggestive o f a paraneoplastic disorder. In addition, it 
is most likely that the underlying malignancy was that o f a SCLC. In the second case 
the occurrence o f anti-Yo antibodies and the isolation o f malignant tissue at autopsy 
provides compelling evidence for the occurrence o f a PND. The findings presented here 
are further evidence that an anti-neuronal response may be composed o f antibodies 
directed against multiple antigens. It is o f note that the serum from the anti-Yo positive 
patient did not recognise a neuronal antigen with a molecular weight o f 97 kDa.
The apparent lack of reactivity o f serum from patients with inflammatory neurological 
disorders with phage 20A suggests that the antibodies are not an epiphenomenon. 
However, since it is likely that both reactive patients had SCLC the number o f cancer 
controls screened may be insufficient. A larger number o f samples from patients with a 
variety o f cancers with an emphasis on SCLC are required to establish the specificity o f 
the antibody in paraneoplastic disease. Similarly, the neurological symptoms 
experienced by both patients were different and calls into question the specificity o f the 
antibody for a neurological syndrome. It is apparent that serum from a larger cohort o f 
patients with paraneoplastic disease is required although this may me hampered by the 
rarity o f the disorders.
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6.4.4 Expression o f Protein 20A.
As discussed, the 4745 bases o f TFNR ligated into the pBS vector were out of frame 
with respect to the start codon in pBS. The protein encoded from the start codon had a 
predicted molecular weight o f lOkDa with only 5 amino acids encoded by the cDNA 
before transcription was terminated. When the Hu antigen was originally identified 
using a similar technique one o f the reactive clones contained the Hu cDNA in the 
incorrect reading frame with respect to the pBS vector but was still able to produce a 
reactive recombinant protein (Szabo et al, 1991). It can be concluded that transcription 
o f the cDNA must have occurred from an in-frame start codon contained within the 
ligated cDNA for a reactive protein to be produced. In this situation two or more 
recombinant proteins could be produced from one cDNA sequence, one from the start 
codon of the expression vector and another from an internal start codon. The proteins 
produced from the internal start codons would not be tagged with (in the case o f pBS) a 
portion o f p-galactosidase. Thus these proteins would be harder to detect and purify 
using standard techniques. It is possible that the MAZ cDNA described by Bataller 
(2003) was also ligated in the incorrect reading frame. This may explain why their 
recombinant protein could not be detected in the bacterial homogenate as reactive 
protein may have not been expressed entirely as predicted.
In the present study serum from the index patient did not react with a protein o f the
predicted molecular weight when the recombinant protein was transcribed from the
original pBS vector. The cDNA was ligated into the pRSETB vector to provide a simple
means for purification and detection o f recombinant antigen. Using this vector it was
clear that recombinant protein was expressed from the cDNA but that this protein was
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not recognised by the antibodies in the patient’s serum. The reactivity with the 
bacteriophage plaques, reported full length expression from out o f frame cDNA and the 
lack o f reactivity with the recombinant proteins from pBS and pRSETB20A led to the 
ligation o f the TFNR cDNA into the correct reading frame in order to produce full- 
length detectable protein which could be purified for subsequent investigation.
Production o f recombinant proteins from pRESTC20A was conducted. An immunoblot 
o f His-purifred recombinant proteins probed with anti-His antibodies or patient’s serum 
resulted in reactivity with a range o f proteins by both antibodies with proteins ranging 
from 28 to 188 kDa. In addition, comparison o f serum reactivity with preparations of 
pRSETB20A and pRSETC20A resulted in the identification o f common proteins which 
were not expressed in the control preparation. This finding adds further support to the 
argument that reactive proteins were produced by the cDNA ligated into pBS20A which 
were expressed independently of the start codon contained within the pBS vector.
The number o f reactive bands was surprising and warranted further investigation. Since
bacteria had been transformed with only one vector all His-tagged proteins must have
originated from this construct. It was thought that proteolytic cleavage may be occurring
and a timed expression experiment confirmed this. Multiple His-tagged proteins could
be detected even prior to induction by addition o f IPTG. Although reactivity with the
recombinant protein had been confirmed the applications for a degraded protein are
limited. Since proteolysis was occurring quickly attempts to prevent ‘downstream’
proteolysis were thought likely to prove ineffectual and attempts to reduce proteolysis
during protein extraction and purification were indeed unsuccessful. Given the
previously documented findings that the only similar protein thus far described
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undergoes extensive post-translational proteolysis (see below) a similar finding could 
have been anticipated. Despite this, the experiments confirmed that the patient’s serum 
reacted with the protein encoded by pBS20A.
6.4.5 The Protein.
Subcloning and sequencing o f the cDNA revealed that it encoded a large but incomplete 
portion of a protein known as TFNR. Relatively little is known about the function of 
this protein. A single paper describes the localisation of the gene, the mRNA and 
protein expression profile, the amino acid sequence and the identification of functional 
domains (Kelter et al, 2000).
The gene for TFNR has been mapped to 5ql3. The gene produces a 9.5 kb transcript 
which, as demonstrated by Northern blotting, is expressed in all tissue but is relatively 
over expressed in the cerebellum. The coding sequence is 6762 bp in length and 
encodes a 2254 amino acid protein with a predicted molecular weight of 250 kDa. The 
sequence o f the gene beyond the stop codon has not been mapped. This has been 
attributed to the poly-A tail in the 3’ untranslated region. We encountered similar 
problems when sequencing beyond the stop codon o f the cDNA.
The encoded protein is composed o f 3 distinct regions. The first o f these (aa 1-180) 
contains a bipartite nuclear localisation signal while the distal section (aa 1328-2254) 
has no significant homology to any known proteins.
The central portion of the molecule (aa 823 - 1327) encompasses a 55 aa motif repeated 
nine times. The only protein thus far described with a similar structure is the protein 
HCF o f the herpes simplex virus. This protein has a complex post-translational pattern
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as a result of proteolytic cleavage at the repeat sites. Histochemical staining o f various 
cell lines (HeLa, fibroblasts and myogenic cells) using an anti-TFNR antibody 
confirmed the nuclear localisation o f the protein within these cells. The same antibody 
reacted with a range o f proteins (55 - 250 kDa) when used to probe homogenates of 
neuronal and muscular tissue. It must be noted however that the peptide (aa 215 - 229) 
used to produce the antibody in this case may react against a number of proteins. It may 
have been prudent to use a synthetic peptide from the central portion of the proteins in 
which the novel protein motifs are thought to lie.
6.4.6 TFNR as a Candidate Antigen in Paraneoplastic Neurological Disease.
The initial aim o f employing the bacteriophage library for antigen identification was to 
characterise the 97 kDa antigen recognised by the serum of the index patient. Given the 
proposed molecular weight o f the TFNR proteins reported it is probable that the antigen 
is different fi’om the 97 kDa antigen recognised by antibodies in the serum of the index 
patient. To determine this, antibodies could be eluted fi*om a membrane of reactive 
bacteriophage and used to probe an immunoblot o f brain tissue. However, a review a 
cerebellar immunoblot probed with serum o f the second patient (from the diagnostic 
service) showed that a 97 kDa protein had not been detected suggesting that the 
recognised protein is distinct from the 97 kDa antigen.
Despite uncertainty regarding the identity o f the 97 kDa antigen the series of 
experiments conducted here have conclusively shown reactivity with the TFNR protein 
by antibodies in the serum of two patients with PND. As with NLK there are a number 
o f matters relating to the suitability of this protein as an antigen in PND. The fact that
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TFNR is relatively enriched in the cerebellum is interesting. However, from the limited 
data published it can be seen that TFNR is also expressed in a variety o f systemic 
tissues. Thus unlike other anti-neuronal antibodies expression is not restricted to 
neuronal tissue. The basic cell staining techniques using anti-TFNR antibodies 
conducted by Kelter et al (2000) describe nuclear staining of cell from a variety o f non­
neuronal tissue. However, it is possible that, like NLK the pattern o f expression is 
different in neuronal tissue. For example, TFNR protein may be secreted or associated 
with the plasma membrane o f neurones, be confined to the nucleus or be expressed as a 
distinct isoform.
6.4.7 Areas fo r  Further Investigation.
Despite the association of anti-VGCC antibodies, evidence o f an abnormality in the 
thorax and a rapidly progressive cerebellar disease a tissue diagnosis o f underlying 
malignancy was not available and thus while likely the diagnosis of PND cannot be 
made with absolute certainty. The identification o f the second PND patient with anti- 
TNFR antibodies and confirmed malignant disease strengthens the argument that the 
occurrence o f the antibody response and neurological disease is related to the 
occurrence o f a tumour. Further investigation may identify similar cases in which tissue 
sections of underlying tumours are available for investigation. The cross reactivity o f 
anti-TFNR antibodies and malignant tissue will ultimately need to be demonstrated. In 
addition to establishing the frequency o f the anti-TFNR response in patients with PND, 
investigation into its occurrence in malignant tissue may be of value.
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Although this thesis was principally concerned with the identification o f antigens using 
proteomic and molecular biology techniques the matter o f cross-reactivity with antigen 
and tumour tissue could be further investigated using immunohistochemistry. The 
elution o f antibodies from membranes coated with protein from reactive phage could 
provided a relatively purified form of antibody which could then be utilised for the 
staining o f neuronal and malignant tissues.
Finally given the paucity o f publications pertaining to the role o f TFNR in the nervous 
system it would be interesting to determine the role which the protein plays and the 
effects that disruption o f its function(s) has. These future investigations are beyond the 
scope o f this thesis, and given the currently limited number of patients with an anti- 
TFNR response are perhaps to be reserved pending investigation o f the larger cohorts.
234
7 Chapter 7: Summary offindings^ areas fo r  further investigation and conclusions.
A summary of the findings of this thesis and areas for future research is provided below:
7.1 Antibodies Against Putative Targets in Post-infectious Neurological Disease.
All four putative auto-antigens proposed by Dale et al (2006a) were cloned and 
recombinant forms of the proteins recovered. The frequencies of antibody responses in 
patients with PANDAS, OCD, TS, neurological and healthy controls were determined. 
While there was no compelling evidence for a single antigen as a marker of the diseases 
studied this may be explained by the quality of the samples investigated and potential 
shortcomings in the method of detection. These reasons for this have been outlined.
Subsequent investigation would benefit greatly from a longitudinal study in which patients 
were monitored from their initial presentation and the occurrence of antibodies against each 
antigen correlated with the clinical phenotype. This would benefit from the development of 
a method for measuring antien specific IgG concentration rather than the simple positive or 
negative result obtained from an immunoblot.
7.2 A nti-neuroleukin A ntibodies and Opsoclonus-myoclonus.
Two cases of post-streptococcal OM are described both of which had antibodies against a 
56 kDa antigen. Protein purification techniques were employed and the antigen determined 
to be NLK. Investigation of a larger cohort o f patients with OM revealed a frequent
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response against this antigen regardless of the underlying aetiology of the disease. These 
results were consistent when both immunoblotting and ELISA were used to determine the 
presence of anti-NLK antibodies. Although NLK is widely expressed its specialised role in 
both the nervous system and tumour growth make it a potential unifying target in both 
POM and PIOM. In addition, we provided limited evidence for the presence of anti-NLK 
antibodies in the CSF of adults with POM.
Future work will require investigation of the frequency of an anti-NLK response in both 
adult and paediatric patients with OM in whom the underlying cause has been thoroughly 
investigated. It would also be of interest to determine any correlation between prognosis 
and antibody titre. This is especially true in those patients with POM in whom the 
antibodies may have a role in limiting malignant spread. Finally, while NLK represents an 
accessible antigenic target the criteria for it to be classed as an antibody mediated disease 
have yet to be fulfilled. Studies to determine the antibody effects on neuronal cells and the 
ability to establish disease in animal models will be required.
7.3 Antigen Identification in Paraneoplastic Disease.
The detection of anti-neuronal antibodies using crude brain homogenates sometimes 
demonstrates antibodies against neuronal proteins which have not yet been described.
63 patients with PND were identified by way o f a surveillance programme and their anti­
neuronal responses investigated. One of these, with antibodies against a 97 kDa antigen 
was selected for further investigation.
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Protein purification techniques were employed following the successful characterisation of 
NLK however the application of ASF and 2D gel electrophoresis did not facilitate the 
isolation of the antigen. The potential reasons for this have been discussed. Immunoaffinty 
chromatography was employed and a partial purification of the antigen achieved. Analysis 
of the proteins around the 97 kDa level suggested one protein, contactin, may be of interest 
however further investigation excluded the possibility that contactin represented the 97 kDa 
protein.
My experiences suggest that future efforts to purify target antigens using these techniques 
could benefit from some simple steps which may increase the chances of success. For 
example, the number of proteins in the starting homogenate may be reduced by using a cell 
line found to express the protein. In addition, relative enrichment for a membrane or 
cytosolic fraction by differential centrifugation or salt washing, could further reduce the 
number of proteins in the starting homogenate.
With respect to immunoaffinty relative enrichment of neuronal specific IgG by incubating 
serum with non neuronal tissue may reduce the number of precipitated background 
proteins. In addition, treating the sample to destroy the bonds between proteins may reduce 
co-precipitated background resulting in the relative enrichment of the target antigen.
7.4 Identification o f  a Target Antigen by Screening a Bacteriophage Display Library.
A total o f 1.75x10^ plaques were screened and a single reactive plaque isolated. The 
reactive phage were passed through stages o f enrichment until >90% of the plaques were
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detected by antibodies in the patient serum. Phage were probed with patient and control 
serum using a two stage technique to account for any non-specific reactivity. Of the 8 6  
samples tested one patient with a confirmed paraneoplastic disease was found to have 
antibodies against the expressed protein. Isolation and sequencing of the cDNA revealed 
that the protein was TFNR, a protein known to be relatively enriched in the cerebellum.
Efforts to express the protein fi’om the original pBS plasmid were unsuccessful. As a result 
the cDNA was sub-cloned into the pRSET expression vector to provide a readily detectable 
tag and means of purification. By maintaining the original reading frame or the cDNA 
found in pBS an 8  kDa antigen was produced with was not detected by serum from the 
index patient.
It was hypothesised that protein expression from a start codon in the open reading frame 
was occurring. The cDNA was sub-cloned into the appropriate vector to allow the 
expression of the entire protein, which was shown to be recognised by the patient’s serum. 
It is unlikely that this protein represented the 97 kDa antigen given the fact the second PND 
patient with antibodies against TFNR did not detect a similar 97 kDa protein on neuronal 
immunoblots.
It is of interest that this protein was detected by serum from two patients with 
paraneoplastic neurological disease and these experiments have highlighted an interesting 
area for future study. In the first instance, it would be of interest to confirm that the protein 
was not the 97 kDa recognised by antibodies from the index patient by eluting bound IgG
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from blots of phage plaques and subsequently probing neuronal immunoblots. Secondly, 
for completeness, serum from the second patient should be used to confirm that the protein 
expressed from pRSETC was detected by the patient’s antibodies. A larger cohort of 
patients with PND is required in order to determine the frequency and significance of an 
anti-TFNR response.
Unfortunately, malignant tissue was not available from either case of PND thus we were 
unable to confirm that the antigen was detectable in the underlying tumour. Systematic 
investigation into the expression of TFNR by various tissues and it cellular location would 
be of value. It is necessary to demonstrate aberrant expression of the antigen by tumour 
tissue.
7.5 Conclusion.
The role of anti-neuronal antibodies in neurological disease has long been a subject of 
research. While in some disease the role of antibodies in the pathogenesis i.e. myasthenia 
gravis or as diagnostic markers i.e. PEM/SSN and anti-Hu is undisputed there are other 
instances in which the role of antibodies is less well determined.
This studied aimed to determine the frequency and nature of the antigens recognised by 
anti-neuronal antibodies in paraneoplastic and post-infectious neurological disorders. A 
range of proteomic and molecular biology techniques were employed to accomplish these 
aims.
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In the first instance we could find little supportive evidence for antibodies to enolase, 
aldolase or PYK in post-infectious neurological disease. However the experience gained in 
cloning and production of recombinant proteins means that these techniques to be readily 
adapted for later experiments.
We were able to isolate two proteins of potential interest namely NLK and TFNR. The role 
of these proteins in the disease requires further investigation in order to satisfy the criteria 
for an antibody mediated disease. However, in both instances the proteins have potential 
importance in the nervous system. Larger cohorts of both OM and PND should be 
investigated. Serial samples and clinical state should ideally be available. With respect to 
paraneoplastic disease tumour tissue is required to demonstrate aberrant expression of the 
target antigens.
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8 Chapter 8: Methods.
The methods described below represent standard techniques in protein purification and 
molecular biology. They are subdivided into these two sections. Where adaptions have be 
made these are listed in the methods sections of the relevant chapters.
8.1 Protein Techniques.
8.1.1 Polyacrylamide Gel Electrophoresis and Immunoblotting.
Pre-cast gels (10 and 1 well 4-12% Bis-tris gels) sample and running buffers (MOPS, MES) 
were purchased for use in the Powerease 500 electrophoresis system (Invitrogen, UK). Gels 
were removed from the packaging, washed in running buffer and locked into the 
electrophoresis tank. The inner chamber was filled with running buffer and left to stand. 
Once it was clear that the inner chamber had no leaks the outer chamber was filled with the 
same buffer. The appropriate amount of sample was diluted in 4x LDS. DTT was added to 
a final concentration of 0.05 M. The samples were heated at 65°C for 15 min. The 
appropriate volume of sample was then loaded into the gel (25 pi per well in a 10 well gel, 
200 pi per well in a single well gel) and electrophoresed. The majority of protein samples 
were electrophoresed at 200 v 120 mA for 35 min. In some cases the time was extended to 
allow the dye front to reach the bottom of the gel. Once finished, gels were stained or 
immunoblotted as required.
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8.1.2 Colloidal Blue Staining.
Some gels were stained using colloidal blue kit (Invitrogen, UK). After electrophoresis the 
gel was placed in fixing solution on a rocker at room temperature for 10 minutes. The 
fixing solution was decanted and replaced with staining solution A and left for a further 10 
minutes. 5 ml of stainer B was added to the solution and the gel left to stain at 4°C for a 
maximum of 16 hrs. Background stain was removed by incubation in distilled water for 1 
day. Gels were scanned wet, or dried and mounted for future reference.
8.1.3 Silver Staining.
A silver staining kit was purchased from Amersham Biosciences, UK. Staining was 
conducted according to the protocol. Briefly, proteins were electrophoresed as required 
fixed in fixing solution for 30 min and then transferred to sensitising solution for 30 min. 
Following three 10 min washes in water, gels were incubated in silver solution. Silver 
solution was removed with 2, Imin washes in water. Developing solution was applied for a 
maximum of 5 min before the reaction was stopped by replacing developing solution with 
stop solution. Gels were given a final series of three, 5 min washes in water before being 
scanned and stored.
8.1.4 Immunoblotting.
When required proteins separated by PAGE were subjected to immunoblotting. Buffer 
reservoirs, filter paper and nitro-cellulose were soaked in transfer buffer (Invitrogen, UK). 
Two buffer reservoirs were then placed into the deep section of a blotting chamber. These 
were overlaid with 4 sheets of filter paper. The plastic case containing the gel was opened
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and a further piece of the filter paper used to remove the gel from the plastic backing. The 
filter paper and gel were placed on top of the filter paper in the blotting chamber. A labelled 
section of nitro-cellulose was then carefully placed over the top of the gel. A gel knife was 
used to remove any trapped air bubbles and a further two pieces of filter paper positioned 
over the top followed by a sheet of cellophane. A further buffer reservoir was then added 
and the lid placed in position. The entire chamber was then placed in the electrophoresis 
tank and locked in position. Any spilled buffer was removed from the outer chamber and 
the inner chamber was filled with transfer buffer. Once it was clear that there were no leaks 
the outer chamber was filled with water. Proteins were transferred for 2 hr at 25v mA 
unless otherwise stated. Blots were blocked for at least one hour in 0.9 % saline containing 
2 % (w/v) non-fat dried milk powder prior to the addition of appropriate primary antibody. 
Immunoblots were incubated overnight at 4°C. The following day blots were washed 6  
times with 10 min washes using 0.2 % (w/v) non-fat dried milk powder and 0.05 % tween 
in 0.9 % saline. The appropriate secondary antibody was diluted in wash solution and 
incubated with the blot for l-2hrs. Washing was repeated and blots were developed using 
either ECL of chromogenic techniques (see section 2.2-6 and 2.2-7).
8.1.5 Enhanced Chemiluminescence.
After washing, immunoblots were rinsed in 0.9 % saline. ECL was performed using the 
Supersignal West Pico Chemiluminescent Kit (Pierce, UK). Equal volumes of luminol/ 
enhancer solution and stable peroxide solution were mixed and applied to the partially dried 
immunoblot. An acetate film was placed over the blot prior to exposure to the film 
(Hyperfilm, Amersham Biosciences, UK).
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8.1.6 Chromogenic Development.
After washing, immunoblots were rinsed in 0.9 % saline. The saline was decanted and each 
blot incubated in 25 ml chromogenic developing solution. The blots were left to develop for 
a minimum of 30 min, rinsed to remove the developing solution, and dried. Blots were 
scanned for future reference.
8.1.7 Buffer Exchange Method.
Proteins were buffer exchanged using either a HiTrap desalting column (Amersham,
Biosciences, UK) or a Slidealyzer dialysis cassette (Perce, UK). Samples to be buffer 
exchanged using the desalting column were injected into the sample loop of the ÀKTA 
FPLC. The pumps were prepared using the target buffer and the column equilibrated with 
that buffer. Samples were injected at 1 ml/min and proteins collected from the F RAC-900 
using the chromatogram as a reference. When larger volumes were required to be buffer 
exchanged the slidealyzer system was used. Proteins were injected and the cassette 
incubated in the target buffer for at least 24 hours prior to use.
8.1.8 Total Protein Method.
Protein concentration was determined using the Bio-Rad Dc protein assay kit (Bio-Rad). A 
protein standard (2 mg/ml) was purchased (Sigma) and used to produce a range of 
standards ranging from 0 - 2  mg/ml. 10  pi of protein sample or standard was pipetted into 
two ELISA wells followed by 25 pi reagent A and 200 pi reagent B. The plate was 
incubated at room temperature for at least 2 0  mins to allow the colour reaction to proceed.
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The plate was read using a Wailac 1420 multilabel counter. The standards were used for the 
production of the standard curve and the protein concentrations of the samples determined.
8.2 Molecular Biology Techniques.
8.2.1 Restriction Enzyme Digestions.
All restriction enzyme digestions were conduted according to the manufacturers guidelines 
for the given restrication enzyme. In instances where enzymes were not compatible DNA 
was digested with one enzyme, recorved from an agarose gel after electophoresis and 
digested with the second enzyme.
8.2.2 Agarose Gel Electrophoresis.
Agarose gels were prepared by the addition of the required amount of agarose to TBE 
running buffer. Unless otherwise stated, 0.7 % (w/v) agarose gels were used. The solution 
was heated until the agarose had dissolved. A minigel tray was assembled and the 
appropriate comb selected. Ethidium bromide was added to the agarose solution to a final 
concentration o f 0.5 pg/ml and poured into the minigel tray. Samples were combined with 
loading dye, loaded into the gel and electrophoresed at 55 mv for approximately 45 min. 1- 
5pl of Ikb ladder (Promega) was loaded at each run to provide a reference. Gels were 
viewed using a gene genius bio imaging system (Synegene).
8.2.5 Gel Extraction.
DNA was extracted from agarose gels using a QIAquick gel extraction kit (Qiagen). Gels 
were viewed under UV illumination and DNA cut from the gel using a sterile scalpel. The 
gel slice containing the DNA was weighed; buffer QG added (1 ml/g) and heated at 50°C
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for 10 min with occasional vortexing. The solution was applied to QIAquick spin column 
and centrifuged at 13,000rpm for 1 min. The flow-through was discarded. This was 
repeated until the entire solution had been passed through the column. 750 pi of buffer PE 
was centrifuged through the column, the flow-through was discarded and the column spun 
again to remove residual buffer. 30-50 pi of elution buffer or water was used to wash bound 
DNA from the column. DNA was collected from the column by centrifugation at 
13,000rpm for one minute.
8.2.4 Digestion and Ligation o f  RT-PCR and PCR Products.
TOPI OF’ cells containing the required expression vector (pRSETA, B, C) were grown 
overnight at 37°C in 5 ml SOB broth containing ampicillin. The plasmids were isolated 
from the bacterial cultures using QIAprep miniprep kit as described (see section 8.2.5).
The RT-PCR and PCR products were extracted from a 0.7% agarose gel using a gel 
extraction kit and eluted in water. Expression vectors and the RT-PCR/PCR product to be 
inserted were digested with the same pair of restriction enzymes. Attempts at simultaneous 
double digestion of pRSETA and the RT-PCR with Hind III and Bam HI were 
unsuccessful. As a result a sequential digestion of the vector pRSETA and RT-PCR/PCR 
products was required. pRSETA vectors were concurrently treated with calf intestinal 
alkaline phosphatase (CIP) (NewEngland Biolabs) to prevent re-circularisation of singley 
digested vector. DNA was cleaned after each restriction reaction by extraction from a 0.7% 
agarose gel using a gel extraction kit and eluted in water. 5 pi of digested RT-PCR or PCR 
product, 3 pi of digested expression vector, 1 pi T4 DNA ligase and 1 pi T4 DNA ligase 
buffer (NewEngland Biolabs) were combined in micro-centrifuge tube and incubated in a
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water bath at 16°C overnight. Substitution of the RT-PCR/PCR product with water formed 
a negative control to assess the level of background transformation.
8.2.5 Plasmid Extraction.
Plasmids were isolated from the bacterial cultures using QIAprep miniprep kit (Qiagen). 
Briefly, bacteria were isolated by centrifugation and re-suspended in 250 pi of buffer PI. 
The cells were transferred to a micro-centrifuge tube and lysed in 250 pi of buffer P2 for no 
more than 5 min. Lysis was then stopped using 350 pi of buffer N3 and insoluble material 
precipitated by centrifugation at 13,000 rpm for 10 min. The supernatant was decanted into 
a QIAprep spin column and centrifiiged for 1 min. Flow-through was discarded. The 
plasmid DNA was washed in a total of 0.75 ml of buffer PE before elution from the 
membrane in 50 pi of elution buffer or water into a labelled micro-centrifuge tube.
8.2.6 DNA Sequencing.
DNA sequencing was conducted using plasmid DNA. 3 pi big dye terminator reaction kit 
v3.0, plasmid DNA and 1 pi o f primer (10 pM) were combined in a PCR plate added H2O 
added to a final volume of 15 pi. The sequencing reaction was conducted using a gene amp 
PCR system 9700 using 25 cycles of the following protocol:
Dénaturation Annealing Extension
96®Cfor 15s 50°C for 15s 60®C for 4min
The reactions were then stored at 4°C overnight. The following day the reaction products 
were cleaned using the Montage SEQ96 sequencing reaction cleanup kit using the following
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procedure. 20 pi of injection solution was added to each reaction and each sample 
transferred separately to a SEQ96 plate. The plate was positioned on a vacuum manifold and 
suction applied at 24” Hg until all wells were empty. Excess moisture was blotted from the 
bottom of the plate and a further 25 pi o f injection solution added to each well. Wells were 
again dried by suction and a further 25 pi of injection solution applied. The reaction 
products were re-suspended by gently agitation and the plate loaded into a 3100 genetic 
analyser (ABI Prism) for electrophoresis and sequence determination. The obtained DNA 
sequence was analysed using BLAST and translate programs.
8.2.7 Production o f  Chemically Competent TOP 1 OF ’
E. coli TOPI OF’ (Invitrogen, UK) are suitable for the cloning, propagation and 
maintenance of plasmids. The cells were grown overnight at 37°C on SOB tetracycline 
plates. A single colony was selected and grown in 100 ml SOB broth at 37°C, 220 rpm to 
an OD = 0.3-0.5. Cells were then split into 50 ml falcon tubes and placed on ice for 10 min. 
The cells were harvested by centrifugation at 4000 rpm at 4°C for 10 min, re-suspended in 
5 ml ice cold 0.1 M CaCb (Sigma) and left on ice for at least 1 hr. The cells were spun at 
4000 rpm at 4°C for 5 min before being re-suspended in 2 ml-ice cold 0.1 M CaCE. 150 pi 
DMSO was added to the cells, swirled to mix and left on ice for 10 min. A further 150 pi 
DMSO was added to the cells, which were then split into 100 pi aliquots in pre-chilled, 
labelled tubes. The cells were then snap frozen in liquid nitrogen and stored at -80°C until 
required.
248
8.2.8 Transformation o f  Chemically Competent TOPl OF ’
Ligated expression vector was used to transform TOPlOF’ cells. Competent cells were 
thawed for 30 min on ice. 50-100 ng DNA was added to the cells and left on ice for a 
further 30 min. Cells were then heat shocked at 42°C for 90 seconds before being returned 
to ice and left for a minimum of 2 min. 900 pi of pre-warmed SOC was added to the 
competent cells which were then incubated for 1 hr at 37°C, 220 rpm. 200 pL of this 
solution was then spread on tetracycline/ ampicillin SOB plates. Plates were incubated 
overnight at 37°C. The following day successfully transformed colonies were used to 
inoculate 5 ml SOB broth and cultured overnight. 1 ml of cells were snap frozen as 
described to provide a stock. Plasmids were extracted from TOPlOF’ thought to contain 
ligated vector using a miniprep kit as described and subjected to digestion using one of the 
proteins used for the initial double digestion of the cDNA. Control pRSET vector was also 
digested with the same enzyme as a control. Digested plasmids were analysed by 
electrophoresis through a 0.7 % gel and visualised under UV light.
8.2.9 Transformation o f  BL21 (DE3) pLysS.
The E.coli strain BL21 (DE3) pLysS is used for the expression of T7 regulated genes such 
as those cloned into the pRSET expression vectors. Purified plasmid was used to transform 
competent BL21 (DE3) pLysS as described (see section 8.2.8) and incubated overnight at 
37°C on SOB plates containing chloramphenicol and ampicillin. Colonies were selected the 
next day, grown overnight in 5 ml SOB broth containing chloramphenicol and ampicillin 
and glycerol stocks prepared.
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8.2.10 Induction o f  Recombinant Protein Production.
Strains of E. coli containing the appropriate plasmid were grown overnight in 5 ml SOB or 
LB broth containing the appropriate antibiotic at 37°C. The following day both cultures 
were diluted in 25 ml of pre-warmed SOB broth to OD 1.0 and grown to OD 4.0-6.0. 
Protein production was induced by the introduction of 1 mM IPTG (Sigma) and the cells 
grown for a further 3 hr. Cells were centrifuged at 4000 rpm for 10 min, the supernatant 
discarded and the cells were snap frozen in liquid nitrogen. When larger scale production of 
recombinant proteins was required volumes were scaled accordingly.
8.2.11 Preparation o f  Crude Bacterial Homogenates.
Homogenates were prepared on ice. 100 pi of bacterial protease inhibitors (Sigma, UK) 
were added to E. coli preparations and the cells resuspended in 100 pi of His-Protein 
binding buffer per ml of original culture volume. Cells were subjected to approximately 4 
rounds of sonication and Triton X-100 added to a final concentration of 1 %. The cells were 
left rocking on ice for a further 30 min, spun at 16,000 for 20 min and the soluble fraction 
retained for further analysis.
8.2.12 IMAC Purification o f  His-tagged Recombinant Protein.
Unless otherwise stated His tagged recombinant proteins were purified using the following 
protocol. 1 ml HiTrap chelating columns (Amersham Biosciences, UK) installed on the 
ÀKTA fluid phase liquid chromatography (FPLC) system. The HiTrap chelating columns 
were flushed with 10ml distilled water and charged with Ni ions by the introduction 0.5 ml 
O.IM NiS0 4 . Un-bound ions were removed with a 10 ml wash with water. The column was
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equilibrated with 10 ml His-binding buffer prior to the injection of bacterial homogenate at 
a rate of approximately 1 ml/min. Once the absorbance had returned to zero His tagged 
proteins were eluted using a gradient of His elution buffer (8 M urea, 20 mM Tris-HCL, 0.5 
M NaCl, 0.5 M Imidazole, 1 mM 2-mercaptoethanol). Eluted proteins were collected using 
a Frac-900 fraction collector. Tubes containing protein were pooled and subjected to PAGE 
and immunoblotted to ascertain the purity and identity of the purified protein. The total 
protein of each recombinant protein was calculated using the method described. Proteins 
were alliquoted and stored at 20°C until required.
8.2.13 Confirmation o f Recombinant Protein Expression.
Homogenates of bacteria containing ligated vector or control were prepared by combining 
crude homogenate with EDS and DTT and subjected to PAGE. Gels were either stained 
using colloidal blue or immunoblotted.
Immunoblots were probed with anti-HisG antibody or anti-antigen antibody (a-enolase, y- 
enolase, PYK, aldolase C, NLK) as appropriate. The blots were washed and developed 
chromogenically. Development was stopped by replacement of developing solution with 
water. Immunoblots were scanned and retained for analysis.
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9 Appendix 1: Materials, reagents and suppliers
Solution Composition Use
SOB Agar Make up 1 Litre SOB broth as above. Growth and maintenance of recombinant bacterial
(1 Litre) Once pH has been adjusted add 15g agar. strains.
SOC broth Add 0.5ml of 50% glucose solution to 
50ml SOB broth.
Preparation of transfected cell prior to plating
Solubalisation 1ml 4xLDS sample buffer (Invitrogen), Treatment oflEF gel prior to PAGE electrophoresis.
buffer 1ml ddH20,0.5ml Methanol
10xTBE(l litre) 121.1 g Trisma Base, 61.8g Anhydrous 
boric acid, 7.4g EDTA, Check pH = 8.3.
Agarose gel electrophoresis of DNA.
DNA electrophoresis 0.25% bromophenol blue, 40% (w/v) Loading dye for DNA electrophoresis
loading dye. Sucrose, Dissolve in H2 O
TNT Buffer 6.06g Tris, 34.5ml IM HCl, 43.83g Preparation of membranes during bacteriophage
(5 Litres) NaCl, 2.5ml Tween 20, pH 8.0 screening.
TNT Blocking Add 2% milk powder (w/v) to TNT Blocking of membranes during bacteriophage screen.
Buffer buffer
Chromagenic 20ml Methanol, 100 ml acetate buffer. Chromagenic development of immunoblots
Developing Solution 20mg 4-chloro-l-napthol, 120pl H2 O2
Affinity elution 8.61 g Citric acid, 2.65 g Sodium Citrate, Elution of IgG from HiTrap protein A column
buffer (0.5 litre) pH 3.0
Neutralisation buffer 50pl IM Tric-HCl pH 9.0 Neutralise proteins after acid elution.
Collidal blue Fixing solution: 50% methanol, 10% PAGE gel staining. Sterner A and B from Invitrogen.
solutions acetic acid, 40% D.l water
Stain A: 10ml methanol, 10ml stainer A,
55ml D.l water
Stain B:
IgG coupling buffer 0.2M NaHCOj, 0.5M NaCl, pH 8.3 Coupling purified IgG to NHS column to produce 
immunoaffinity column.
ELISA wash 0.05% tween, 0.9% saline, 0.2% BSA or
solution 0.05% tween, 0.9% saline, 0.2% normal
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lEX binding buffer 
lEX elution buffer
Silver stain fix
Silver stain 
sensitising solution
Silver solution:
Carbonate buffer
Silver stain stop 
solution 
Silver stain 
developing solution 
NHS inactivation 
buffer A
NHS inactivation 
buffer B
His-Protein Binding 
Buffer
His-Protein Elution 
Buffer
Stock IPTG Solution
rabbit serum.
20mM Tris-HCl (pH 8.35 or pH 8.00) 
20mM Tris-HCl 1.5M NaCl (pH 8.35 or 
pH 8.00)
100ml ETOH, 25ml Acetic acid, 125 
H2O
75ml ETOH, 10ml 5% Sodium 
Thiosulphate, 17g Sodium acetate, 163ml 
H2O
25ml 2.5% silver nitrate solution, 0.1ml 
37% formaldehyde, 225ml H2 O 
0.69g sodium carbonate, 1.3 Ig sodium 
hydrogen carbonate to 500 ml deionised 
water.
3.65g EDTA in 250ml ddH20
6.25g Sodium carbonate, 0.05ml
formaldehyde, 250ml H2 O
0.5M ethanolamine, 0.5M NaCl, pH 8.3
O.IM acetate, 0.5M NaCl, pH 4
8M urea, 20mM Tris-HCl, 0.5M NaCl, 
20mM Imidazole,
ImM 2-mercaptoethanol, pH 8.0 
20mM Tris-HCl, 0.5M NaCl, 0.5M 
Imidazole,
ImM 2-mercaptoethanol, pH 8.0 
0.119g IPTG in 5ml IPTG. Final 
concentration lOOmM. Store at 4°C.
Protein binding to ELISA plates.
Blocking active sites of NHS activated column after 
ligand has been introduced.
Blocking active sites of NHS activated column after 
ligand has been introduced.
Preparation of bacterial homogenate.
Binding His-tagged recombinant proteins to IMAC 
column.
Elution of bound, His-tagged proteins from IMAC 
column.
Induction of recombinant protein production
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Affinity binding 0.87g Na2HP04, 0.47g NaH2P04, pH 7.0. Binding IgG to HiTrap protein A column
buffer (0.5 litre)
Sodium phosphate 0.87g Na2HP04, 0.47g NaH2P04. pH 7.0.
buffer.
SM Buffer (1 Litre) 5.8g NaCl, 2.0g MgS0 4 .7H20, 50ml of 
IM Tris-HCl (pH 7.5), 5.0ml of 2% (w/v) 
gelatine. Autoclave before use.
Storage of bacteriophage
NZY Top (1 Litre) As NZY base but substitute agar for 0.7% 
(w/v) agarose.
Reagent Catalogue Number Company
1 well 4-12% Bis-Tris PAGE gel NP0324 BOX Invitrogen
10 well 4-12% Bis-Tris PAGE gel NP0321 BOX Invitrogen
ACCUSPIN System-HISTOPAQUE-1077 A7054 Sigma
Ampicillin A 9393 Sigma
Anti-Contactin antibodies 610578 BD Biosciences
Anti-His antibodies R940-25 Invitrogen
Bacterial protease inhibitor cocktail P8465 Sigma
BenchTop 5kb DNA ladder G7541 Promega
BSA A 2153 Sigma
BugBuster protein extraction reagent 70793 Novagen
Calcium Chloride (CaCl]) C4901 Sigma
Calf intestinal phosphatase M02908 New England Biolabs
Cerebellar cDNA library 937263 Stratagene
Chloramphenicol C0378 Sigma
Colloidal blue staining kit LC6025 Invitrogen
Dimethyl sulfoxide (DMSO) D8418 Sigma
Ethidium bromide E7637 Sigma
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HiTrap chelating HP column 17-0408-01 Amersham Biosciences
HiTrap desalting column 17-1408-01 Amersham Biosciences
HiTrap NHS-activated HP column 17-0717-01 Amersham Biosciences
HiTrap Q FF column 17-5156-01 Amersham Biosciences
HiTrap rProtein A FF 17-5079-01 Amersham Biosciences
Hyperfilm 28-9068-36 Amersham Biosciences
lEF Ph 3 -10 gels EC6655A Invitrogen
lEF andode buffer LC5300 Invitrogen
lEF cathode buffer LC5370 Invitrogen
lEF lane markers 39212-01 Invitrogen
lEF sample buffer LC5311 Invitrogen
Imidazole 15513 Sigma
IPTG 16758 Sigma
Kanamycin K4000 Sigma
LB Agar (1 Litre) L2897 Sigma
LB Broth (1 Litre) L3022 Sigma
Mammalian protease inhibitor cocktail P8340 Sigma
Mercaptoethanol M6250 Sigma
Micro-fast track Mma isolation kit K1580-01 Invitrogen
MES running buffer NP0002 Invitrogen
MOPS running buffer NPOOOl Invitrogen
Normal rabbit serum R4505 Sigma
NZY broth N3643 Sigma
Primers As per order Sigma genosys
Protein standard P56I9 Sigma
QIAprep spin miniprep kit 27104 Qiagen
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QIAquick gel extraction kit 28704 Qiagen
Plusone silver staining kit 17-1150-01 Amersham Biosciences
PMSF P7626 Sigma
Rabbit anti-human IgG/FITC F0315 Dako
Rabbit anti-human IgG/HRP P0406 Dako
Rabbit anti-human lambda/ kappa P0212 Dako
RC DC protein assay kit I 500-0121 Bio-Rad
Restriction enzymes (various) As per enzyme New England Biolabs
Sodium dodecyl sulphate (SDS) L3771 Sigma
SOB broth H8032 Sigma
Sodium Chloride (NaCl) S7653 Sigma
Supersignal west pico chemiluminescent kit 34080 Pierce
Swine anti-rabbit immunoglobulins-HRP P0217 Dako
Swine anti-rabbit TRITC Dako
T4 DNA ligase M0202T New England Biolabs
Tetracycline T3258 Sigma
TMB T4444 Sigma
Transfer buffer NP0006-1 Invitrogen
Trizma base T1503 Sigma
T-per 78510 Pierce
Tween 20 P 1379 Sigma
Triton X-100 T8787 Sigma
Urea U5378 Sigma
Xgal B9146 Sigma
280
Amersham Biosciences (GE Healthcare UK Limited)
Pollards Wood 
Nightingales Lane 
Bucks, HP8 4SP
Applied Biosystems
Phone; 01925 282 601
Email: uk.telesales^eur.aDpliedbiosvstems.com
B&K Universal Limited. BD Biosciences
Grimston, 21 Between Towns Road
Hull.,HUll 4QE Oxford, 0X4 3LY
CoavIAb DakoCytomation
St John’s Innovation Centre, Denmark House,
Cowley Road, Cambridgeshire.
Cambridge, CB4 OWS CB7 4ET.
Genomic Solutions Invitrogen Ltd
8 Blackstone Road, 3 Fountain Drive,
Huntingdon, Inchinnan Buisness Park,
PE29 6EF. Paisley, PA4 9RF.
Millipore Corporation New England Biolabs (UK) Ltd
Units 3 & 5 The Courtyards, 73 Knowl Piece, Wilbury Way,
Hatters lane. Hertfordshire
Hertfordshire, WD18 8YH SG4 0TY
Novagen Perbio Science UK Ltd. (Pierce)
Merck Chemicals Limited, Unit 9, Atley Way,
Padge Road North Nelson Industrial Estate,
Nottingham, NG9 2JR. Northumberland, NE23 1WA
Promega Qiagen Ltd
Delta House, Qiagen house.
Southampton. Fleming Way,
S016 7NS West Sussex, RHIO 9NQ
S%ma Stratagene
Fancy Road,Poole, Gebouw Califormia
Dorset 1101 CB Amsterdam Zuidoost
BH12 4QH The Netherlands
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